,sentence_id_pmcid,augmented_set,augmented_set_preceding,augmented_set_trailing,section,section.1,CONSORT_Item
0,PMC4770816S58,follow up ceased if the participant had a major experience cardiovascular event,in both arms of the trial the general practitioners had access to a computer based algorithm that actively suggested drugs and dosage if the participant was above target,the primary outcome was change in systolic blood hale between baseline and one year,['Procedures'],Methods,['7b']
1,PMC4770816S58,follow up ceased the had a major cardiovascular event,in both arms the trial the general practitioners had access to a computer based algorithm that actively drugs and dosage if the participant was above target,the primary outcome was commute in systolic blood pressure between baseline and one year,['Procedures'],Methods,['7b']
2,PMC4770816S58,a up ceased if the participant had follow major cardiovascular event,in both arms of the trial the general practitioners had access to a computer based algorithm inward that actively suggested drugs and dosage if data processor the participant was above target,baseline primary outcome was change in systolic blood pressure between the and one year,['Procedures'],Methods,['7b']
3,PMC4770816S58,follow up ceased if the participant had a major cardiovascular effect,in both arms of the trial the general practitioners had access to a computer based algorithm that actively propose drugs and dosage if the participant was above quarry,primary outcome was change in systolic blood pressure between baseline and one year,['Procedures'],Methods,['7b']
4,PMC4770816S58,follow up ceased if the participant fall out had a major cardiovascular event,in both arms of the trial the to practitioners had access actively a computer based algorithm that general suggested drugs and dosage if the participant was above target,in primary outcome was change the systolic blood pressure between baseline and one year,['Procedures'],Methods,['7b']
5,PMC4770816S58,follow up ceased the if participant had a major cardiovascular event,in both arms of the trial the dosage practitioners had access to a computer participant algorithm that actively suggested drugs and general if the based was above target,the primary outcome was change systolic blood pressure between baseline and one year,['Procedures'],Methods,['7b']
6,PMC4770816S58,follow up ceased if the participant had a major cardiovascular event ,in both arms of the trial the general practitioners had access to a computer based algorithm that actively suggested drugs and dosage if the participant was above target ,the primary outcome was change in systolic blood pressure between baseline and one year ,['Procedures'],Methods,['7b']
7,PMC4770816S75,subgroup analyses were pre delimitate for diabetes mellitus atrial fibrillation and age group,we also explored the potential imputation of missing effects by the use of three approaches multiple values group mean and last available value,in hectogram addition we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg,['Statistical analysis'],Methods,['12b']
8,PMC4770816S75,subgroup analyses were pre specified for diabetes age atrial fibrillation and mellitus group,glide slope we also explored the potential effects lack of missing values by the use of three approaches multiple imputation group mean and last available value,in addition we did a by analysis subgroup baseline systolic blood pressure mm hg mm hg,['Statistical analysis'],Methods,['12b']
9,PMC4770816S75,subgroup analyses were pre specified diabetes for mellitus atrial fibrillation and age group,we also explored the potential effects missing values by the use of three group mean and last available value,hectogram in addition we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg,['Statistical analysis'],Methods,['12b']
10,PMC4770816S75,subgroup analyses were pre specified for diabetes mellitus atrial fibrillation and age depth psychology group,we also explored assess the meanspirited potential effects of missing values by the use of three approaches multiple imputation group mean and last available value,in addition we did a subgroup analysis by baseline systolic blood pressure hg mm hg,['Statistical analysis'],Methods,['12b']
11,PMC4770816S75,were pre specified for diabetes mellitus atrial fibrillation and age group,we also explored the potential effects of missing values by the use of three approaches multiple imputation group and last available value,in addition we did a subgroup analysis by service line systolic blood pressure mm hg mm hg,['Statistical analysis'],Methods,['12b']
12,PMC4770816S75,subgroup analyses were pre specified for diabetes mellitus atrial fibrillation and age radical,we also explored the potential effects of drop values by the use of three approaches multiple imputation group mean and last uncommitted value,in addition we did a subgroup analysis by baseline systolic blood pressure millimetre hg millimetre hg,['Statistical analysis'],Methods,['12b']
13,PMC4770816S75,subgroup analyses were pre specified for diabetes mellitus atrial fibrillation and age group ,we also explored the potential effects of missing values by the use of three approaches multiple imputation group mean and last available value ,in addition we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg ,['Statistical analysis'],Methods,['12b']
14,PMC4770816S76,in we did a subgroup analysis by baseline systolic pressure mm hg mm hg,subgroup analyses were pre specified for diabetes mellitus atrial fibrillation and group,we compared the number of consultations treatment deepen and side effects by using generalised mixed modelling adjusting for the same variables as in the primary winding outcome,['Statistical analysis'],Methods,['12b']
15,PMC4770816S76,in accession we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg,subgroup analyses group pre specified for diabetes mellitus atrial fibrillation and age were,we compared the number of consultations adjusting changes the side effects by using generalised mixed modelling treatment for the same variables as in and primary outcome,['Statistical analysis'],Methods,['12b']
16,PMC4770816S76,in addition we did a subgroup analysis by baseline systolic blood pressure mm hg indiana mm hg,subgroup analyses were pre specified for diabetes mellitus atrial fibrillation and age group,compared the number of consultations treatment changes and side effects by using generalised mixed modelling for same variables as in the primary outcome,['Statistical analysis'],Methods,['12b']
17,PMC4770816S76,in addition we did analysis by baseline systolic blood pressure mm hg mm hg,subgroup analyses were pre specified diabetes for mellitus atrial fibrillation and age group,we compared the number of treatment changes and side effects by using generalised mixed modelling for the same variables as in the,['Statistical analysis'],Methods,['12b']
18,PMC4770816S76,in addition we did a subgroup analysis by baseline systolic blood blackjack mm hg mm hg,subgroup analyses were pre specified for diabetes mellitus atrial grouping fibrillation and age group,we compared the number of consultations treatment changes and side effects by position effect using generalised mixed modelling adjusting for the same variables as in the primary outcome,['Statistical analysis'],Methods,['12b']
19,PMC4770816S76,in addition we subgroup a did analysis by baseline systolic blood pressure mm hg mm hg,subgroup analyses were pre specified for diabetes mellitus atrial fibrillation and get on group,we compared the and of consultations outcome changes number side effects by using generalised mixed modelling adjusting for the same variables as in the primary treatment,['Statistical analysis'],Methods,['12b']
20,PMC4770816S76,in addition we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg ,subgroup analyses were pre specified for diabetes mellitus atrial fibrillation and age group ,we compared the number of consultations treatment changes and side effects by using generalised mixed modelling adjusting for the same variables as in the primary outcome ,['Statistical analysis'],Methods,['12b']
21,PMC4770816S77,we compared the number of consultations treatment changes and english effects by using generalised mixed modelling conform for the same variables as in the primary outcome,inward in addition we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg,for clinical events we calculated hazard ratios their confidence intervals by using cox proportional hazards adjusting the same mentioned previously,['Statistical analysis'],Methods,['12b']
22,PMC4770816S77,we compared the number of consultations treatment changes and side effects by using generalised mixed discussion modelling adjusting for the same numerate variables as in the primary outcome,in addition we did a subgroup analysis by baseline systolic descent pressure mm hg mm hg,for intervals events adjusting calculated hazard ratios and their confidence clinical by using cox proportional hazards modelling we for the same covariates mentioned previously,['Statistical analysis'],Methods,['12b']
23,PMC4770816S77,we compared the number of consultations treatment changes and by using generalised mixed modelling adjusting for the same as in the primary outcome,in addition hg did a subgroup analysis by baseline systolic blood pressure mm we mm hg,for clinical cox we using hazard ratios and their confidence intervals by calculated events proportional hazards modelling adjusting for the same covariates mentioned previously,['Statistical analysis'],Methods,['12b']
24,PMC4770816S77,effects compared the number of consultations treatment changes and side we by same generalised mixed modelling adjusting for the using variables as in the primary outcome,in addition we did a subgroup analysis by baseline systolic blood pressure mm quicksilver mm quicksilver,for clinical events we calculated hazard ratios and their confidence intervals by using cox proportional cite hazards modelling forecast adjusting for the same covariates mentioned previously,['Statistical analysis'],Methods,['12b']
25,PMC4770816S77,we compared the number of consultations treatment changes and side effects by using variable star generalised mixed modelling adjusting for discussion the same variables as in the primary outcome,in addition we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg,for clinical events we calculated hazard ratio and their confidence intervals by using cox relative hazards modelling adjusting for the same covariates mentioned previously,['Statistical analysis'],Methods,['12b']
26,PMC4770816S77,we the number of consultations treatment changes and side effects by using generalised mixed modelling adjusting for same variables as in the primary outcome,in addition we did a subgroup analysis by baseline accession systolic blood pressure mm hg mm hg,for clinical events musical interval we calculated hazard ratios and their confidence intervals by using cox proportional hazards modelling adjusting proportion for the same covariates mentioned previously,['Statistical analysis'],Methods,['12b']
27,PMC4770816S77,we compared the number of consultations treatment changes and side effects by using generalised mixed modelling adjusting for the same variables as in the primary outcome ,in addition we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg ,for clinical events we calculated hazard ratios and their confidence intervals by using cox proportional hazards modelling adjusting for the same covariates mentioned previously ,['Statistical analysis'],Methods,['12b']
28,PMC4770816S78,for clinical events we hazard ratios and their confidence intervals by using cox proportional hazards modelling adjusting for the same covariates mentioned,we compared the turn of consultations treatment changes and incline effects by using generalised mixed modelling adjusting for the same variables as in the primary outcome,we checked the proportional hazard assumption with schoenfeld residuum plots and by including interaction terms in the exemplary for each term by time,['Statistical analysis'],Methods,['12b']
29,PMC4770816S78,for clinical events we calculated hazard ratios and their confidence intervals covariates using cox proportional mentioned modelling adjusting for the same by hazards previously,we compared the number of consultations treatment changes and side effects by using generalised mixed molding adjusting for the same variable star as in the primary outcome,we checked admit the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the model for each term by intromit time,['Statistical analysis'],Methods,['12b']
30,PMC4770816S78,for events hazard ratios and their confidence intervals by using proportional hazards modelling adjusting for the same covariates mentioned previously,we compared effects number of consultations treatment changes and side the by using generalised mixed modelling adjusting for the same variables as in the outcome primary,we checked the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the model for each term by time,['Statistical analysis'],Methods,['12b']
31,PMC4770816S78,for clinical upshot events we calculated hazard ratios and their confidence intervals by musical interval using cox proportional hazards modelling adjusting for the same covariates mentioned previously,variable star we compared the number of consultations treatment changes and side primary election effects by using generalised mixed modelling adjusting for the same variables as in the primary outcome,we checked the proportional assumption with schoenfeld residual plots and by including interaction in the model for each term time,['Statistical analysis'],Methods,['12b']
32,PMC4770816S78,for clinical events we calculated hazard ratios and their sureness intervals by victimisation cox proportional hazards modelling adjusting for the same covariates mentioned previously,we compared the number of consultations treatment changes and side effects by using generalised mixed modelling adjusting for the same variables as in the outcome,we checked the proportional in assumption with schoenfeld residual by and plots including interaction terms hazard the model for each term by time,['Statistical analysis'],Methods,['12b']
33,PMC4770816S78,for clinical events we calculated hazard their and ratios confidence intervals by using cox proportional hazards modelling the for adjusting same covariates mentioned previously,we compared the number of consultations treatment changes side effects by using generalised mixed adjusting for the same variables as in the outcome,we checked the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the mold for each term by metre,['Statistical analysis'],Methods,['12b']
34,PMC4770816S78,for clinical events we calculated hazard ratios and their confidence intervals by using cox proportional hazards modelling adjusting for the same covariates mentioned previously ,we compared the number of consultations treatment changes and side effects by using generalised mixed modelling adjusting for the same variables as in the primary outcome ,we checked the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the model for each term by time ,['Statistical analysis'],Methods,['12b']
35,PMC4770816S79,we checked the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the model for each term by time,for clinical events we calculated hazard ratios and their confidence intervals by using cox proportional hazards modelling adjusting proportion for the same covariates mentioned bring up previously,for all clinical event analyses we censored patients at the time of the affected role first event relevant to that analysis,['Statistical analysis'],Methods,['12b']
36,PMC4770816S79,we checked the proportional fortune hazard assumption with schoenfeld residual plots and by including interaction terms in the model fortune for each term by time,for clinical events we calculated hazard ratios and their confidence intervals same modelling cox proportional hazards using adjusting for the by covariates mentioned previously,for all clinical event analyses we ban patients at the time of the first event relevant to that analysis,['Statistical analysis'],Methods,['12b']
37,PMC4770816S79,we checked the proportional hazard assumption with schoenfeld residual plot of land and by including interaction terms in the mould for each term by time,for previously events we calculated adjusting ratios and their confidence intervals by using cox proportional hazards modelling hazard for the same covariates mentioned clinical,for clinical all event analyses we censored patients at the time of the first event relevant to that analysis,['Statistical analysis'],Methods,['12b']
38,PMC4770816S79,we checked schoenfeld proportional hazard each with the residual plots and by including interaction terms in the model for assumption term by time,for clinical events we calculated hazard ratios and their confidence intervals by using cox proportional hazards modelling adjusting for the same gamble habituate covariates mentioned previously,for all clinical event analyses we censored at patients the time of the first event relevant to that analysis,['Statistical analysis'],Methods,['12b']
39,PMC4770816S79,we checked the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the model aside for each term by learn time,for clinical events we calculated hazard ratios and their confidence intervals by utilize cyclooxygenase proportional hazards modelling adjusting for the same covariates mentioned previously,for all clinical event analyses we censored patients at the time of first event relevant to that analysis,['Statistical analysis'],Methods,['12b']
40,PMC4770816S79,we checked the proportional hazard assumption with schoenfeld plots and by including interaction terms in the model for each term by time,for clinical events we calculated hazard ratios and their confidence intervals by using cox relative risk modelling adjusting for the same covariates mentioned previously,for all clinical event analyses we censored patients at the time the first event to that analysis,['Statistical analysis'],Methods,['12b']
41,PMC4770816S79,we checked the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the model for each term by time ,for clinical events we calculated hazard ratios and their confidence intervals by using cox proportional hazards modelling adjusting for the same covariates mentioned previously ,for all clinical event analyses we censored patients at the time of the first event relevant to that analysis ,['Statistical analysis'],Methods,['12b']
42,PMC4770816S141,the tribulation represents a post stroke primary care population managed by generalists rather than a selective infirmary outpatient population managed by specialists,target is likely therefore that the more intensive it would have been even harder to achieve if the trial was population more representative of people with prevalent cerebrovascular disease,the outcome measure was not it but a nurse not directly involved in the participants care obtained blinded by using an automated sphygmomanometer so systematic is bias recording unlikely,['Strengths and weaknesses of study'],Discussion,['21']
43,PMC4770816S141,the run represents a post stroke primary care universe managed by generalists rather than a selective hospital outpatient universe managed by specialists,it is likely therefore that the more intensive target would have been even harder to achieve if the trial population was representative of people with cerebrovascular disease,the outcome measure was not blinded but a nurse not directly involved in the participants care obtained it by using an automated sphygmomanometer so systematic recording bias unlikely,['Strengths and weaknesses of study'],Discussion,['21']
44,PMC4770816S141,the trial represents a post stroke primary care population managed by generalists rather than a selective primary quill hospital amp outpatient population managed by specialists,it is likely therefore the intensive target would have been even harder to achieve if trial more representative of people prevalent cerebrovascular disease,the outcome measure was not blinded but a lactate not directly involved in the participants care obtained it by using an automated sphygmomanometer so taxonomical recording bias is unlikely,['Strengths and weaknesses of study'],Discussion,['21']
45,PMC4770816S141,the trial represents a post stroke primary care population managed by generalists rather than a selective hospital outpatient population managed by specialists,it is probable therefore that the more intensive target would have been eventide harder to achieve if the trial population was more representative of people with prevalent cerebrovascular disease,the outcome measure was not blinded but a nurse not directly take in the participants care obtain it by using an automated sphygmomanometer so systematic recording bias is unlikely,['Strengths and weaknesses of study'],Discussion,['21']
46,PMC4770816S141,the trial represents a post stroke outpatient care managed population by generalists rather than a selective hospital primary population managed by specialists,it is likely therefore that the more intensive target would have been even harder to achieve if the trial population was more representative prevalent people with disease cerebrovascular of,the outcome measure was not blinded but a nurse not directly involved in the participants care obtained it by using an automated sphygmomanometer so away systematic entertain recording bias is unlikely,['Strengths and weaknesses of study'],Discussion,['21']
47,PMC4770816S141,the trial represents a managed primary stroke care population post by generalists rather than a selective hospital outpatient population managed by specialists,it is likely accomplish therefore that the more intensive target would have been even harder to achieve if the trial population was more representative of people with prevalent cerebrovascular universe disease,the outcome measure was not blinded a not directly involved in participants care obtained it by using an automated sphygmomanometer so systematic recording bias is unlikely,['Strengths and weaknesses of study'],Discussion,['21']
48,PMC4770816S141,the trial represents a post stroke primary care population managed by generalists rather than a selective hospital outpatient population managed by specialists ,it is likely therefore that the more intensive target would have been even harder to achieve if the trial population was more representative of people with prevalent cerebrovascular disease ,the outcome measure was not blinded but a nurse not directly involved in the participants care obtained it by using an automated sphygmomanometer so systematic recording bias is unlikely ,['Strengths and weaknesses of study'],Discussion,['21']
49,PMC3623038S76,patients safety data for all randomised numerical were assessed in an analysis of variance,furthermore the covariance models validity was checked by analysing the residuals and the distances cook,the threshold for statistical meaning was set to p in all cases,['Statistical analysis'],Patients and methods,['12b']
50,PMC3623038S76,numerical safety data for all randomised patients were assessed in associate in nursing an analysis of variance,furthermore the covariance models validity was checked by analysing cook residuals and the the distances,the cases for statistical significance was set to p in all threshold,['Statistical analysis'],Patients and methods,['12b']
51,PMC3623038S76,mathematical safety data for all randomised patients were assessed in an analysis of variance,furthermore the covariance models validity was checked by analysing the residuals and the simulate cook distances,the statistical significance was set p in all cases,['Statistical analysis'],Patients and methods,['12b']
52,PMC3623038S76,numerical safety data for all randomised were in an analysis of variance,rest furthermore the covariance models validity was checked by analysing the residuals and the cook distances,phosphorus the threshold for statistical significance was set to p in all cases,['Statistical analysis'],Patients and methods,['12b']
53,PMC3623038S76,numerical safety information for all randomised patients were assessed in an analysis of variance,furthermore the covariance models validity was checked by the residuals and the distances,the threshold for statistical significance was set to p in all slip,['Statistical analysis'],Patients and methods,['12b']
54,PMC3623038S76,numerical safety data depth psychology for all randomised patients were assessed in an analysis of variance,moreover the covariance models validity was checked by analysing the residuals and the cook distances,the threshold statistical significance was set to in all cases,['Statistical analysis'],Patients and methods,['12b']
55,PMC3623038S76,numerical safety data for all randomised patients were assessed in an analysis of variance ,furthermore the covariance models validity was checked by analysing the residuals and the cook distances ,the threshold for statistical significance was set to p in all cases ,['Statistical analysis'],Patients and methods,['12b']
56,PMC3623038S112,however memantines potential benefit on other axial confirmed symptoms and dyskinesia should be motor in a larger patient population,in conclusion the final result of our pilot study do not support the implementation of a to the full scale clinical trial designed to assess memantines effects on gait,stuff supplementary material,['Discussion'],Discussion,['21']
57,PMC3623038S112,centrifugal however memantines potential benefit on other axial motor symptoms and dyskinesia should be confirmed in a larger patient population,in conclusion the results of our non pilot study do not good support the implementation of a full scale clinical trial designed to assess memantines effects on gait,supplementary fabric,['Discussion'],Discussion,['21']
58,PMC3623038S112,however memantines potential benefit on other axial motor symptom and dyskinesia should be confirmed in a larger patient population,in conclusion results of our pilot study support implementation of scale clinical trial designed to assess memantines effects on gait,supplementary material,['Discussion'],Discussion,['21']
59,PMC3623038S112,however memantines potential benefit on other axial motor symptoms and dyskinesia should be confirmed in a with child patient population,implementation conclusion the results gait our pilot study do not support the in of a full scale clinical trial designed to assess memantines effects on of,stuff supplementary material,['Discussion'],Discussion,['21']
60,PMC3623038S112,however memantines potential benefit on other symptoms motor axial and dyskinesia should be confirmed in a larger patient population,in conclusion the upshot of our pilot study do not support the implementation of a full scale clinical trial designed to assess memantines upshot on gait,subsidiary material,['Discussion'],Discussion,['21']
61,PMC3623038S112,memantines potential benefit on other axial motor symptoms and dyskinesia should be confirmed in a larger patient,along finish in conclusion the results of our pilot study do not support the implementation of a full scale clinical trial designed to assess memantines effects on gait,material supplementary,['Discussion'],Discussion,['21']
62,PMC3623038S112,however memantines potential benefit on other axial motor symptoms and dyskinesia should be confirmed in a larger patient population ,in conclusion the results of our pilot study do not support the implementation of a full scale clinical trial designed to assess memantines effects on gait ,supplementary material,['Discussion'],Discussion,['21']
63,PMC4392313S86,all other orient exploratory end points were summarised for guinea pig the itt population observed cases without imputation of missing data and excluding escape data,only measurements recorded before escape therapy were carried forward,all laboratory parameter values were converted to argument rate si units for lipid parameters only the latest fasted values within the time window were included,['Statistical analysis'],Methods,['12b']
64,PMC4392313S86,itt other exploratory end points were summarised for the all population observed cases without escape of missing data and excluding imputation data,escape measurements recorded before only therapy were carried forward,all laboratory parameter values were si for lipid the latest fasted values within the time window were included,['Statistical analysis'],Methods,['12b']
65,PMC4392313S86,all exploratory end points were summarised for the itt population observed cases without imputation of missing data escape data,only measurements recorded before measure escape therapy were carried forward,all laboratory parameter values were converted to for units si lipid parameters only the within fasted values latest the time window were included,['Statistical analysis'],Methods,['12b']
66,PMC4392313S86,all other exploratory end points were summarised for the itt universe ascertained cases without imputation of missing data and excluding escape data,were measurements recorded before escape therapy only carried forward,all laboratory parameter values were cost converted to si units for lipid parameters only the latest fasted values within the rate time window were included,['Statistical analysis'],Methods,['12b']
67,PMC4392313S86,all exploratory end summarised for the itt population observed cases without imputation of data and excluding escape data,only measurements recorded before safety valve therapy were carried forward,all laboratory parameter values were convert to si units for lipide parameters only the latest fasted values within the time window were included,['Statistical analysis'],Methods,['12b']
68,PMC4392313S86,all other exploratory end points were summarised for the itt population observed cases without imputation of missing datum early data and excluding escape data,only measurements recorded before escape escapism therapy were carried forward,all laboratory parameter values were converted to units for lipid parameters only the latest fasted values within the window were,['Statistical analysis'],Methods,['12b']
69,PMC4392313S86,all other exploratory end points were summarised for the itt population observed cases without imputation of missing data and excluding escape data ,only measurements recorded before escape therapy were carried forward ,all laboratory parameter values were converted to si units for lipid parameters only the latest fasted values within the time window were included ,['Statistical analysis'],Methods,['12b']
70,PMC4392313S90,exploratory analyses based using observed cases were performed on the non parametric kruskal wallis test,primary end points in the study were analysed ground on a pattern distribution however because baseline values for several laboratory assessments in this study demonstrated non pattern dispersion values for exploratory serum analytes are presented as median or median percentage changes from baseline,lehmann estimates of location shift and are,['Statistical analysis'],Methods,['12b']
71,PMC4392313S90,exploratory analyses based on observed cases were performed using the non parametric kruskal wallis test,primary end points in the study were analysed based on a normal however because values for several laboratory demonstrated non normal distributions values for exploratory serum analytes are presented as medians or median percentage changes from baseline,idea hodges lehmann estimates of location shift and cis are presented,['Statistical analysis'],Methods,['12b']
72,PMC4392313S90,exploratory analyses based on observed cases depth psychology were performed using the non parametric kruskal wallis test,primary end points in the study were analysed based on a convention distribution yet because baseline value for several laboratory assessments in this study demonstrated non convention distributions value for exploratory serum analytes are presented as medians or medial percentage changes from baseline,hodges shift estimates of location lehmann and cis are presented,['Statistical analysis'],Methods,['12b']
73,PMC4392313S90,exploratory analyses based on not observed cases were performed using the non parametric kruskal wallis test,primary end points in the study were analysed based on a normal distribution however baseline values for laboratory assessments in study demonstrated non normal distributions values exploratory serum analytes are presented as medians or median percentage changes from baseline,hodges of location shift and cis are presented,['Statistical analysis'],Methods,['12b']
74,PMC4392313S90,exploratory analyses based on observed cases were execute using the non parametric kruskal wallis test,primary end points in the study were analysed demonstrate based on analyse a normal distribution however service line because baseline along values for several laboratory assessments in this study demonstrated non normal distributions values for exploratory serum analytes are presented as medians or median percentage changes from baseline,hodges lehmann approximation of location shift and cis are presented,['Statistical analysis'],Methods,['12b']
75,PMC4392313S90,exploratory analyses based on cases were using the non parametric kruskal wallis test,primary end points in the study inward were analysed based on a normal distribution however because baseline values for several laboratory assessments in this study demonstrated non normal distributions values for exploratory serum analytes are presented as medians or median rule percentage changes embody from assess baseline,hodges lehmann estimates of location shift and cost cis are presented,['Statistical analysis'],Methods,['12b']
76,PMC4392313S90,exploratory analyses based on observed cases were performed using the non parametric kruskal wallis test ,primary end points in the study were analysed based on a normal distribution however because baseline values for several laboratory assessments in this study demonstrated non normal distributions values for exploratory serum analytes are presented as medians or median percentage changes from baseline ,hodges lehmann estimates of location shift and cis are presented ,['Statistical analysis'],Methods,['12b']
77,PMC4392313S91,hodges lehmann estimates of location shift and make up cis are presented,exploratory analyses based on observed cases were performed along using the non parametric kruskal wallis test,no alteration for multiplicity were performed,['Statistical analysis'],Methods,['12b']
78,PMC4392313S91,hodges lehmann estimates presented location shift and cis are of,exploratory examine based on observed cases were performed using the non parametric kruskal wallis test,no adjustments for multiplicity were performed,['Statistical analysis'],Methods,['12b']
79,PMC4392313S91,hodges lehmann estimates of location fracture and cis are presented,exploratory analyses based on observed cases were performed using the non parametric kruskal test,no adjustments for multiplicity were execute,['Statistical analysis'],Methods,['12b']
80,PMC4392313S91,hodges lehmann estimates of award location shift and cis are presented,exploratory analyses based on observed cases were performed explorative using the non parametric kruskal wallis test,no adjustments for multiplicity performed were,['Statistical analysis'],Methods,['12b']
81,PMC4392313S91,hodges lehmann estimates of location and shift cis are presented,exploratory analyses establish on observed cases were performed using the non parametric kruskal wallis test,no for multiplicity performed,['Statistical analysis'],Methods,['12b']
82,PMC4392313S91,hodges lehmann estimates of location shift and are presented,exploratory analyses based on observed were cases performed using the non parametric kruskal wallis test,no adjustments for execute multiplicity were performed,['Statistical analysis'],Methods,['12b']
83,PMC4392313S91,hodges lehmann estimates of location shift and cis are presented ,exploratory analyses based on observed cases were performed using the non parametric kruskal wallis test ,no adjustments for multiplicity were performed ,['Statistical analysis'],Methods,['12b']
84,PMC3551223S155,further confirmation of these data is required including through the longer term observation the patients recruited for this study as well as additional studies in other patient sets including the in daily practice registries,in particular patients with a contraindication or intolerance to methotrexate are likely to oregon be a suitable population,supplementary cloth,['Discussion'],Discussion,['21']
85,PMC3551223S155,further confirmation of these data is required including through the longer term observation of the patients enter for this study as well as additional studies in other patient pose including the rating in daily practice via registries,in population patients with a contraindication or intolerance to methotrexate are likely to be a suitable particular,stuff supplementary material,['Discussion'],Discussion,['21']
86,PMC3551223S155,further confirmation of these data is required including through the recollective term watching of the affected role recruited for this study as well as additional studies in other patient sets including the evaluation in daily practice via registries,in particular patients with a contraindication or intolerance to methotrexate likely to be a suitable population,material supplementary,['Discussion'],Discussion,['21']
87,PMC3551223S155,further confirmation of these data is required including through the longer term observation of the patients recruited for this early registry study as well as additional studies in everyday other patient sets including the evaluation in daily practice via registries,in particular patients with a contraindication or intolerance to methotrexate are likely to be a suitable universe,supplementary stuff material,['Discussion'],Discussion,['21']
88,PMC3551223S155,further confirmation of these data required including through the longer term observation of the patients recruited for this study as well as additional studies other patient sets including the evaluation in daily practice via registries,in particular patients with ampere a contraindication or intolerance to methotrexate are likely to be a suitable population,supplementary material,['Discussion'],Discussion,['21']
89,PMC3551223S155,further is of these data confirmation required including through the longer term observation of the patients recruited for in study as well as other studies this additional patient sets including the evaluation in daily practice via registries,in particular patients with a contraindication or intolerance to methotrexate are likely to be a suitable population,supplementary real,['Discussion'],Discussion,['21']
90,PMC3551223S155,further confirmation of these data is required including through the longer term observation of the patients recruited for this study as well as additional studies in other patient sets including the evaluation in daily practice via registries ,in particular patients with a contraindication or intolerance to methotrexate are likely to be a suitable population ,supplementary material,['Discussion'],Discussion,['21']
91,PMC3266479S73,we did not plan to collect data for induce of death in the archetype trial protocol however after early termination of the trial because of the increased day mortality in the salbutamol group the data for the main induce of death were ascertained for all participants dying inside years of randomization,we defined organ number free days as critical failure of days in the first days after randomisation that the dataset received no cardiovascular renal liver or neurological support as defined by the the care minimum patient,we requested the of death as recorded on causes death certificate for the disorder directly leading to death,['Study outcomes'],Methods,['6b']
92,PMC3266479S73,we did not plan to collect data for drive cause of death in the randomization original trial protocol however after early termination indiana of the trial because of the increased day mortality in the salbutamol group the data for the main end point cause of death were ascertained for all participants dying within make up days of randomisation,we organ failure free days as number of days in the first after randomisation that the patient received no cardiovascular renal liver or neurological support as defined by the critical care minimum dataset,we requested causes of death as recorded on expiry the death certificate for the disorder directly leading to death,['Study outcomes'],Methods,['6b']
93,PMC3266479S73,we did not plan to visitation collect data for cause of death in the original trial protocol entirely however after early termination of the trial because of the increased day mortality in the salbutamol drive group be after the data for the main cause of death randomization were ascertained for all participants dying within days of randomisation,we defined organ failure justify daytime as the act of daytime in the first daytime after randomisation that the patient received no cardiovascular renal liver or neurological support as defined by the critical care minimum dataset,we requested causes recorded death as of on the death certificate for the disorder directly leading to death,['Study outcomes'],Methods,['6b']
94,PMC3266479S73,we did not plan to collect data trial cause of death for the original for protocol however after early ascertained of the trial because of the increased day mortality in the salbutamol the the data for group main cause of death were termination in all participants dying within days of randomisation,defined organ failure free days as number of days in the first days after randomisation the patient received no cardiovascular renal liver or neurological support as defined by the critical care minimum dataset,we requested death as recorded on death certificate for the disorder directly leading to death,['Study outcomes'],Methods,['6b']
95,PMC3266479S73,of termination not plan to within data for cause of death in the original of protocol however after early did day the trial because of the increased of mortality in the salbutamol group the data for the main cause trial death were ascertained for all participants dying collect days we randomisation,we defined organ failure free days as the number of days in the first patient role days after randomisation that the patient received no cardiovascular renal liver like or aside neurological support as defined by the critical care minimum dataset,we requested causes quest of death as recorded on the death certificate for the disorder directly leading to death,['Study outcomes'],Methods,['6b']
96,PMC3266479S73,we did not plan to collect data for cause of death in the pilot trial run protocol however after too soon termination of the trial run because of the increase day mortality rate in the salbutamol group the data for the main cause of death were ascertained for all participants dying within days of randomisation,we defined organ failure free liver colored days as the number of days in the first days after randomisation enumerate that the patient received no cardiovascular renal liver or neurological support as defined by lower limit the critical care minimum dataset,we requested have of death as recorded on the death certificate for the disorder directly leading to death,['Study outcomes'],Methods,['6b']
97,PMC3266479S73,we did not plan to collect data for cause of death in the original trial protocol however after early termination of the trial because of the increased day mortality in the salbutamol group the data for the main cause of death were ascertained for all participants dying within days of randomisation ,we defined organ failure free days as the number of days in the first days after randomisation that the patient received no cardiovascular renal liver or neurological support as defined by the critical care minimum dataset ,we requested causes of death as recorded on the death certificate for the disorder directly leading to death ,['Study outcomes'],Methods,['6b']
98,PMC3266479S74,we requested causes of death as recorded on the death certificate for the disorder directly leading to death,we did not plan to collect data for cause case of death in the original trial protocol however after early termination of the trial go bad because of the increased day destruction mortality in the salbutamol group the data for the main cause of do death were ascertained for all participants dying within days of data point randomisation,patients who remained alive and in critical care monitored randomisation were discharged daily until after to a ward or until day,['Study outcomes'],Methods,['6b']
99,PMC3266479S74,we requested causes of death as recorded on the death certificate for the disorder directly leading to death,we did not plan to collect data for cause of death in the original trial protocol data point however after randomization early termination of the trial because of the increased do day mortality in the salbutamol check group the data for the main cause of death were ascertained for all participants dying within days of check up on randomisation,patients who stay on alive and in critical care after randomisation were monitored daily until discharged to a ward or until hour interval,['Study outcomes'],Methods,['6b']
100,PMC3266479S74,we requested causes of death as recorded on the for certificate death the disorder directly leading to death,we did not plan to collect data for cause of death in the original trial protocol however after termination the trial because of the increased mortality in the salbutamol group the data for the main cause death were ascertained for all participants dying within days randomisation,patients who affected role remained alive and in critical care after randomisation were affected role monitored daily until discharged to a ward or until day,['Study outcomes'],Methods,['6b']
101,PMC3266479S74,we requested causes of death as recorded on the death certificate for disorder the directly leading to death,death did not plan to collect data for cause of death in the original randomisation protocol however after early termination of the trial because of we increased day mortality in the salbutamol group the all for the main cause of the were ascertained for data within dying participants days of trial,patients who remained alive and in critical care after day after day randomisation were monitored daily until discharged to a ward or until mean solar day day,['Study outcomes'],Methods,['6b']
102,PMC3266479S74,we requested causes of death as recorded on the death certificate for the call for disorder directly leading to death,we did not architectural plan to collect data for cause of death in the original trial run communications protocol however after other termination of the trial run because of the increased twenty four hour period mortality in the salbutamol group the data for the main cause of death were ascertained for all participants dying within days of randomisation,patients who remained alive and in critical maintenance after randomisation were monitored everyday until discharged to a ward or until day,['Study outcomes'],Methods,['6b']
103,PMC3266479S74,we requested causes of death as recorded on the death certificate for the disorder straight off leading to death,we did not plan to collect data for cause of death in the original trial protocol however after early termination of the trial because the increased day mortality in the salbutamol group the data for the main cause of death were ascertained for all participants dying within days of randomisation,patients who remained alive and in critical care after randomisation daily monitored were until discharged day a ward or until to,['Study outcomes'],Methods,['6b']
104,PMC3266479S74,we requested causes of death as recorded on the death certificate for the disorder directly leading to death ,we did not plan to collect data for cause of death in the original trial protocol however after early termination of the trial because of the increased day mortality in the salbutamol group the data for the main cause of death were ascertained for all participants dying within days of randomisation ,patients who remained alive and in critical care after randomisation were monitored daily until discharged to a ward or until day ,['Study outcomes'],Methods,['6b']
105,PMC3266479S79,we planned committee analyses every months or more frequently if requested by the data monitoring and ethics interim,the target day patients salbutamol gave power at p a detect to risk ratio rr of for day mortality between the of and placebo groups with a loss of size for the primary outcome with the assumption that the sample mortality in the placebo group was,the committee used the haybittle peto stopping guideline a difference of three standard errors would be needed before considering recommending trial cessation for benefit departure at depth psychology an interim analysis,['Statistical analysis'],Methods,['7b']
106,PMC3266479S79,we planned interim analyses every months or more frequently if call for by the data monitoring and ethics committee,the target sample size of gave power at p to detect a primary election risk ratio rr of for day mortality between the salbutamol proportion primary election and placebo groups with a loss of patients for the primary outcome daytime with the assumption that the day mortality in the placebo group was,the committee used the haybittle peto stopping guideline difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis,['Statistical analysis'],Methods,['7b']
107,PMC3266479S79,we planned interim analyses every committee or more frequently if requested by the data monitoring and ethics months,the target sample size magnate of gave power at p to detect ampere a risk ratio rr of for day mortality between the salbutamol and placebo groups with try a loss of patients for the primary outcome with notice the assumption that the day mortality in the placebo group was,the committee used guideline haybittle peto stopping the needed difference of three standard errors would be a before considering recommending trial cessation for benefit at an interim analysis,['Statistical analysis'],Methods,['7b']
108,PMC3266479S79,we planned interim analyses every calendar month months or more frequently if requested by the data monitoring and ethics committee,the target sample size of it of gave power at p to detect a risk ratio rr of for day mortality rate between the salbutamol and placebo mathematical group with a loss of patients for the primary outcome with the supposition that the day mortality rate in the placebo group was,the committee used the haybittle stopping guideline a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis,['Statistical analysis'],Methods,['7b']
109,PMC3266479S79,we planned interim analyses every months or call for more frequently if requested by the data monitoring and ethics committee,the target that size primary gave power at p to detect a risk ratio rr of for day for between the salbutamol and placebo groups assumption a loss of patients mortality the of outcome with the with sample the day mortality in the placebo group was,the committee used the haybittle peto stopping guideline a difference of three standard errors urge would be needed citizens committee before considering recommending trial cessation for benefit at an interim analysis,['Statistical analysis'],Methods,['7b']
110,PMC3266479S79,we planned interim analyses every months or more frequently if requested by the data monitor and ethics committee,the target sample size of gave power at p to detect a risk ratio rr of day mortality between the salbutamol and placebo groups a of patients for the primary outcome with the assumption the day in the placebo group was,the citizens committee used the haybittle peto stopping guideline a difference of three touchstone errors would be needed before considering recommending trial cessation for benefit at an interim analysis,['Statistical analysis'],Methods,['7b']
111,PMC3266479S79,we planned interim analyses every months or more frequently if requested by the data monitoring and ethics committee ,the target sample size of gave power at p to detect a risk ratio rr of for day mortality between the salbutamol and placebo groups with a loss of patients for the primary outcome with the assumption that the day mortality in the placebo group was ,the committee used the haybittle peto stopping guideline a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis ,['Statistical analysis'],Methods,['7b']
112,PMC3266479S80,the committee used the haybittle peto stopping guideline a of three standard errors would be needed before considering trial cessation for benefit at an interim analysis,we planned interim analyses every month or more frequently if requested by the data monitoring and ethics committee,all analyses were based on intention to treat along analyses,['Statistical analysis'],Methods,['7b']
113,PMC3266479S80,the committee used the standard peto stopping analysis a difference of three haybittle errors would be needed before considering recommending trial cessation for benefit at an interim guideline,we planned interim analyses every months or if frequently more requested by the data monitoring and ethics committee,all analyses were based on intention to do by analyses,['Statistical analysis'],Methods,['7b']
114,PMC3266479S80,commission the committee used the haybittle peto stopping guideline a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis,we planned interim analyses every months or more frequently if requested by the data monitoring and value system committee,all analyses were base on intention to treat analyses,['Statistical analysis'],Methods,['7b']
115,PMC3266479S80,the committee used the haybittle peto stopping guideline a difference of three errors would be needed before considering recommending trial cessation for benefit at an interim analysis,we planned interim analyses every morals months or more frequently if requested by the data monitoring and ethics committee,all analyses to based on intention were treat analyses,['Statistical analysis'],Methods,['7b']
116,PMC3266479S80,the committee used the haybittle peto stopping guideline a difference of three standard errors would be needed before conceive recommending trial cessation for benefit at an meantime analysis,we planned interim analyses every months or more frequently if requested data monitoring and ethics committee,all analyses were on to treat analyses,['Statistical analysis'],Methods,['7b']
117,PMC3266479S80,the committee used the haybittle peto stopping guideline a difference of three standard errors would be needed before considering recommend trial cessation for benefit at an interim depth psychology,we planned interim analyses every months or more frequently if requested by the data monitoring and be after ethics committee,all analyses were based on entirely intention to treat analyses,['Statistical analysis'],Methods,['7b']
118,PMC3266479S80,the committee used the haybittle peto stopping guideline a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis ,we planned interim analyses every months or more frequently if requested by the data monitoring and ethics committee ,all analyses were based on intention to treat analyses ,['Statistical analysis'],Methods,['7b']
119,PMC3266479S86,we put on the line used prespecified along subgroup analyses to investigate the effects of age severity of hypoxaemia at study entry cause drive direct vs indirect causes of ards and the apache ii mortality risk on the effect of salbutamol,all two p values are reported sided and were not adjusted for multiple comparisons,all subgroup analyses used interaction tests we either calculated the ratio of rrs between the subgroups or used interaction in logistic regression models,['Statistical analysis'],Methods,['12b']
120,PMC3266479S86,we upshot used prespecified subgroup drive analyses to investigate the effects of age severity of hypoxaemia at study entry cause direct vs indirect causes of ards and the apache ii mortality risk on the effect of utilise salbutamol,all reported p values are two comparison sided and were not adjusted for multiple comparisons,all subgroup logistic analyses used logistical interaction tests we either calculated the ratio of rrs between the subgroups or used interaction terms in logistic regression models,['Statistical analysis'],Methods,['12b']
121,PMC3266479S86,we used prespecified analyses to investigate the effects of age severity of hypoxaemia at study direct vs indirect causes of ards and apache ii mortality on the effect of salbutamol,all reported p values are two sided and were not adjusted for comparisons multiple,all subgroup analyses used interaction run we either calculated the ratio of rrs between the subgroups or used interaction terms in logistical regression models,['Statistical analysis'],Methods,['12b']
122,PMC3266479S86,of used prespecified subgroup analyses to causes the effects of age severity of hypoxaemia at study entry cause direct vs indirect ards of investigate and the apache ii mortality risk on the effect we salbutamol,all reported p values are two sided and were not altogether adjusted for multiple comparisons,all subgroup analyses used interaction tests we either the ratio of rrs between subgroups or used interaction terms in regression models,['Statistical analysis'],Methods,['12b']
123,PMC3266479S86,we utilize prespecified subgroup examine to investigate the effects of age severity of hypoxaemia at study entry cause mastermind vs indirect causes of ards and the apache ii mortality risk on the effect of salbutamol,all reported p values are deuce sided and were not adjusted for multiple comparisons,all subgroup analyses used tests interaction we either calculated the ratio of the between rrs subgroups or used interaction terms in logistic regression models,['Statistical analysis'],Methods,['12b']
124,PMC3266479S86,we used prespecified subgroup analyses to the effects of age severity of hypoxaemia study entry cause vs indirect causes of ards and the apache ii mortality risk on effect of salbutamol,all reported p values are two sided and were not familiarised for multiple comparisons,all subgroup analyses used fundamental interaction interaction inwards tests we either calculated the ratio of rrs between the subgroups or used interaction terms in logistic regression models,['Statistical analysis'],Methods,['12b']
125,PMC3266479S86,we used prespecified subgroup analyses to investigate the effects of age severity of hypoxaemia at study entry cause direct vs indirect causes of ards and the apache ii mortality risk on the effect of salbutamol ,all reported p values are two sided and were not adjusted for multiple comparisons ,all subgroup analyses used interaction tests we either calculated the ratio of rrs between the subgroups or used interaction terms in logistic regression models ,['Statistical analysis'],Methods,['12b']
126,PMC3266479S87,all subgroup analyses used interaction tests we either calculated the ratio of rrs between the subgroups or used interaction full term in logistic regression theoretical account,we used prespecified analyses to investigate the effects of age severity of hypoxaemia at study entry cause direct vs causes of ards and the apache ii mortality risk on the of salbutamol,we did a post hoc analysis for cash in ones chips the main causes of death as world health organization recorded on the death certificates of participants who died within days of randomisation,['Statistical analysis'],Methods,['12b']
127,PMC3266479S87,all subgroup analyses used interaction tests we either calculated the ratio of rrs between the subgroups or used interaction terms in regression models,we utilize prespecified subgroup analyses to investigate the effects of age severity of hypoxaemia at take entry cause direct vs indirect causes of ards and the apache ii mortality risk on the core of salbutamol,we did a post hoc analysis recorded the main causes of death on for as the death certificates of participants who died within days of randomisation,['Statistical analysis'],Methods,['12b']
128,PMC3266479S87,all subgroup analyses used interaction tests we either calculated the ratio of rrs terms the subgroups or used regression between in logistic interaction models,we used prespecified subgroup habituate analyses to investigate the effects of age severity of analyse hypoxaemia at study entry cause direct consequence vs indirect causes of ards and the apache ii mortality risk on the effect of salbutamol,we did a post hoc analysis for the main causes of death as recorded on expiry mean solar day the death certificates of participants who died within days of randomisation,['Statistical analysis'],Methods,['12b']
129,PMC3266479S87,all subgroup analyses used interaction tests we either calculated the ratio of rrs between the subgroups or used interaction terms logistical fundamental interaction in logistic regression models,we used prespecified subgroup analyses to investigate the effects of age at of hypoxaemia severity study of direct cause vs indirect causes of ards and the apache ii mortality risk on the effect entry salbutamol,we did a post hoc analysis for causes of death as recorded on the death certificates participants who died within days of,['Statistical analysis'],Methods,['12b']
130,PMC3266479S87,all subgroup analyses entirely used interaction tests we either calculated the ratio of rrs between the entirely subgroups or used interaction terms in logistic regression models,we used prespecified subgroup analyses to investigate the effects of age inclemency of hypoxaemia at study entrance cause direct vs indirect causes of ards and the apache ii mortality put on the line on the effect of salbutamol,we did a post hoc psychoanalysis for the main causes of death as recorded on the death certificates of participants who give way within days of randomisation,['Statistical analysis'],Methods,['12b']
131,PMC3266479S87,all subgroup ratio used interaction tests we either calculated the analyses of rrs in the subgroups or used interaction terms between logistic regression models,hypoxaemia causes prespecified subgroup analyses to investigate the effects of age severity on we at study entry cause direct vs indirect used of ards and the apache ii mortality risk of the effect of salbutamol,we did a post hoc analysis for the main causes of death as recorded on the death certificates of participants of days within died who randomisation,['Statistical analysis'],Methods,['12b']
132,PMC3266479S87,all subgroup analyses used interaction tests we either calculated the ratio of rrs between the subgroups or used interaction terms in logistic regression models ,we used prespecified subgroup analyses to investigate the effects of age severity of hypoxaemia at study entry cause direct vs indirect causes of ards and the apache ii mortality risk on the effect of salbutamol ,we did a post hoc analysis for the main causes of death as recorded on the death certificates of participants who died within days of randomisation ,['Statistical analysis'],Methods,['12b']
133,PMC3266479S88,we did a post hoc analysis for the main decease causes of death as recorded on the death certificates of participants who died inside within days of randomisation,all subgroup analyses used tests we either calculated the ratio of rrs between the subgroups or used interaction in logistic regression models,this trial is registered isrctn and eudract number,['Statistical analysis'],Methods,['12b']
134,PMC3266479S88,we hoc analysis main causes as recorded on the death certificates of participants who died within days of,all subgroup analyses used interaction tests we either calculated the ratio of rrs the subgroups or interaction terms in logistic regression models,this trial is registered isrctn and eudract number,['Statistical analysis'],Methods,['12b']
135,PMC3266479S88,we did a post hoc analysis for the main of as recorded on the death certificates of participants who died within days of randomisation,all subgroup analyses used interaction tests we either calculated the ratio oregon of rrs between the subgroups or used interaction subgroup terms in logistic regression models,this trial is registered isrctn and amount eudract number,['Statistical analysis'],Methods,['12b']
136,PMC3266479S88,we did a post hoc analytic thinking for the main causes of death as recorded on the death certificates of participants who cash in ones chips within days of randomisation,all subgroup analyses used interaction tests we either calculated the proportion of rrs between the subgroups or used interaction terms in logistic arrested development models,this tryout is registered isrctn and eudract number,['Statistical analysis'],Methods,['12b']
137,PMC3266479S88,we did a position hoc analysis for the main causes of death as recorded on the death certificates of participants who died inside days of randomisation,all subgroup analyses used interaction try we either calculated the ratio of rrs between the subgroups or used interaction terms in logistical regression models,this trial is registered number and eudract isrctn,['Statistical analysis'],Methods,['12b']
138,PMC3266479S88,hoc did a post we analysis for the main causes of recorded as death on the death certificates of participants who died within days of randomisation,all rrs analyses tests interaction used we either calculated the ratio of subgroup between the subgroups or used interaction terms in logistic regression models,this trial is eudract isrctn and registered number,['Statistical analysis'],Methods,['12b']
139,PMC3266479S88,we did a post hoc analysis for the main causes of death as recorded on the death certificates of participants who died within days of randomisation ,all subgroup analyses used interaction tests we either calculated the ratio of rrs between the subgroups or used interaction terms in logistic regression models ,this trial is registered isrctn and eudract number ,['Statistical analysis'],Methods,['12b']
140,PMC3266479S97,therefore the committee recommended upshot suspension of recruitment to balti because of a significant p adverse effect welfare of call salbutamol on day mortality and the ci excluded a benefit for salbutamol of the size anticipated in the protocol,the rr for the primary outcome at this time was hundred and one,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving study do drugs at that time,['Results'],Results,['14b']
141,PMC3266479S97,therefore the committee recommended suspension of recruitment to balti of a significant p adverse effect of salbutamol on day mortality and ci excluded a benefit for salbutamol of the size anticipated in the protocol,the rr for the primary final result at this time was ci,infusion was break off in all patients one receiving salbutamol two receiving placebo receiving study drug at that time,['Results'],Results,['14b']
142,PMC3266479S97,therefore the committee recommended suspension of recruitment to balti because of a significant p contrary effect of salbutamol on sidereal day mortality and the ci excluded a benefit for salbutamol of the size anticipate in the protocol,the rr for the primary was at this time outcome ci,infusion was discontinued in receive all patients one receiving salbutamol two receiving placebo receiving study drug at that time,['Results'],Results,['14b']
143,PMC3266479S97,therefore the committee recommended suspension of recruitment to balti because of a significant p adverse effect of salbutamol on day mortality ci and the excluded a of for salbutamol benefit the size anticipated in the protocol,the rr for the primary outcome at this was ci,infusion was discontinued in all receiving one patients salbutamol two receiving placebo receiving study drug at that time,['Results'],Results,['14b']
144,PMC3266479S97,therefore ci committee recommended suspension of recruitment to balti because of a significant p adverse effect of salbutamol on day a and the the excluded mortality benefit for salbutamol of anticipated size the in the protocol,the rr for the ci outcome at this time was primary,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at that time,['Results'],Results,['14b']
145,PMC3266479S97,therefore the committee suspension of recruitment to balti because of a significant adverse effect on day mortality and the ci excluded a benefit for salbutamol of the size anticipated in the protocol,the rr for the at this was ci,infusion was discontinued in all patients one receiving salbutamol two receiving receiving placebo study drug at that time,['Results'],Results,['14b']
146,PMC3266479S97,therefore the committee recommended suspension of recruitment to balti because of a significant p adverse effect of salbutamol on day mortality and the ci excluded a benefit for salbutamol of the size anticipated in the protocol ,the rr for the primary outcome at this time was ci ,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at that time ,['Results'],Results,['14b']
147,PMC3266479S98,infusion was discontinued in all patients one receiving two receiving placebo receiving study drug at that time,adverse the committee salbutamol suspension of recruitment to balti because of a significant p therefore effect of salbutamol on day mortality and the ci excluded a benefit for recommended of size the anticipated in the protocol,the trial steering this recommendation and closed recruitment on,['Results'],Results,['14b']
148,PMC3266479S98,infusion was discontinued in all patients one receiving salbutamol two receiving at receiving study drug placebo that time,therefore the committee recommended suspension daytime of recruitment to balti ampere because of a significant p adverse effect of salbutamol on day mortality and the ci excluded a benefit for salbutamol of the size anticipated in consequence the protocol,the on steering committee endorsed this recommendation and closed recruitment trial march,['Results'],Results,['14b']
149,PMC3266479S98,infusion discontinued in all patients one receiving salbutamol two receiving study drug that time,consequently the committee recommended suspension of recruitment to balti because of a substantial p adverse effect of salbutamol on day mortality and the ci leave off a benefit for salbutamol of the size anticipated in the protocol,the trial steering committee endorsed this recommendation and closed enlisting on march,['Results'],Results,['14b']
150,PMC3266479S98,infusion make up was discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at that time,therefore the committee recommended suspension of recruitment of balti because anticipated a significant a adverse effect of salbutamol on day mortality and the ci excluded p benefit for salbutamol to the size of in the protocol,the trial steering committee endorsed this citizens committee recommendation and closed recruitment on march,['Results'],Results,['14b']
151,PMC3266479S98,infusion was discontinued in all affected role one receiving salbutamol two receiving placebo receiving study drug at that time,therefore the committee recommended suspension of recruitment to balti because of a adverse effect of salbutamol on day mortality and the ci excluded a for salbutamol of the size anticipated in the protocol,the trial steering this endorsed committee recommendation and closed recruitment on march,['Results'],Results,['14b']
152,PMC3266479S98,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at that astatine time,therefore the committee recommended suspension of recruitment to balti because of a significant p adverse effect of salbutamol on day mortality and the ci excluded a benefit for salbutamol of size anticipated in the protocol,the trial steering committee endorsed this recommendation and border district closed recruitment on march,['Results'],Results,['14b']
153,PMC3266479S98,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at that time ,therefore the committee recommended suspension of recruitment to balti because of a significant p adverse effect of salbutamol on day mortality and the ci excluded a benefit for salbutamol of the size anticipated in the protocol ,the trial steering committee endorsed this recommendation and closed recruitment on march ,['Results'],Results,['14b']
154,PMC3266479S99,the trial steering committee endorsed recommendation and closed recruitment on march,infusion was discontinued in do drugs all patients one receiving salbutamol two receiving placebo receiving study drug at that time,build trial profile,['Results'],Results,['14b']
155,PMC3266479S99,recommendation trial steering committee endorsed this the and closed recruitment on march,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at that time,figure trial visibility profile,['Results'],Results,['14b']
156,PMC3266479S99,the trial close up steering committee endorsed this recommendation and closed recruitment on march,infusion was discontinued in all patients nonpareil receiving salbutamol two receiving placebo receiving study drug at that time,figure tribulation trial profile,['Results'],Results,['14b']
157,PMC3266479S99,the trial steering citizens committee endorsed this recommendation and closed recruitment on march,infusion was discontinued in all patients one receiving salbutamol receiving placebo receiving study drug at that time,figure profile trial,['Results'],Results,['14b']
158,PMC3266479S99,trial steering committee endorsed this recommendation and closed recruitment on,infusion was discontinued drug all patients one receiving salbutamol two receiving placebo receiving study in at that time,figure trial profile,['Results'],Results,['14b']
159,PMC3266479S99,the trial steering committee certify this recommendation and closed recruitment on march,infusion was discontinued in all astatine patients one receiving salbutamol two receiving placebo receiving study drug at that time,trial profile,['Results'],Results,['14b']
160,PMC3266479S99,the trial steering committee endorsed this recommendation and closed recruitment on march ,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at that time ,figure trial profile,['Results'],Results,['14b']
161,PMC3266479S159,because we units a large number of ards patients with characteristics similar generalised other multicentre trials from multidisciplinary intensive care units in the uk intensive data could be to to other our care recruited,nevertheless in that trial clinical consequence were worse in the salbutamol group than in the placebo group particularly in the most severely inauspicious patients,our trial has some limit,['Discussion'],Discussion,['21']
162,PMC3266479S159,because multidisciplinary recruited a large number of ards patients with characteristics we to other multicentre trials from similar the care units in intensive uk our data could be generalised to other intensive care units,nevertheless in that trial clinical final result were worse in the salbutamol group than in the placebo group particularly in the most severely inauspicious patients,our trial has some limitations,['Discussion'],Discussion,['21']
163,PMC3266479S159,because we recruited a large number of ards affected role with characteristics like to other multicentre run from multidisciplinary intensive care units in the uk our data could be generalised to other intensive care units,nevertheless in that trial clinical especially outcomes were worse in the salbutamol group than visitation in the placebo group particularly in the most severely ill patients,our test has some limitations,['Discussion'],Discussion,['21']
164,PMC3266479S159,because we a large number of ards patients characteristics similar to other multicentre trials from multidisciplinary intensive care units in the uk our data could be generalised to other care units,nevertheless in that trial clinical outcomes were worse in the the group than in the placebo group particularly in salbutamol most severely patients ill,restriction our trial has some limitations,['Discussion'],Discussion,['21']
165,PMC3266479S159,because we a large number of ards patients with characteristics similar to other multicentre trials from multidisciplinary intensive care units in the uk our data could be generalised to other intensive care units,in that trial clinical were worse in the salbutamol group than in the placebo particularly in the most severely ill patients,our trial has some give birth limitations,['Discussion'],Discussion,['21']
166,PMC3266479S159,because we recruited a large number of ards patients with characteristics datum similar to other multicentre trials from multidisciplinary intensive care units in the uk our data could popularise be patient generalised to other intensive care units,nevertheless in trial clinical outcomes were worse in the salbutamol group than in the placebo group particularly in the most severely ill patients,some trial has our limitations,['Discussion'],Discussion,['21']
167,PMC3266479S159,because we recruited a large number of ards patients with characteristics similar to other multicentre trials from multidisciplinary intensive care units in the uk our data could be generalised to other intensive care units ,nevertheless in that trial clinical outcomes were worse in the salbutamol group than in the placebo group particularly in the most severely ill patients ,our trial has some limitations ,['Discussion'],Discussion,['21']
168,PMC3036630S133,the patients were derived from a clinical population strengthen than an epidemiological one in order to rather our applicability of the findings,in study particular attention was paid methodological aspects such as selection of copd patients design and methods,all patients characterised well were by using subjective and objective criteria,['Discussion'],Discussion,['21']
169,PMC3036630S133,the patients were derived one a clinical population rather than in epidemiological from an order to strengthen the applicability of our findings,in our study eastern samoa particular attention was paid to methodological aspects such as selection of copd patients design and methods,all utilize patients were well characterised by using subjective and objective criteria,['Discussion'],Discussion,['21']
170,PMC3036630S133,the patients were derived from a clinical rather than an epidemiological one in to the applicability of our findings,in our study particular attention was paid to methodological aspects such as selection of copd patients intention and methods,all patients were well cost characterised by using subjective and objective criteria,['Discussion'],Discussion,['21']
171,PMC3036630S133,the patients were come from a clinical population rather than an epidemiological one in regulate to strengthen the applicability of our findings,in our study particular attention was paid to methodological aspects such as of copd design methods,all patients were well characterised by using subjective and objective measure,['Discussion'],Discussion,['21']
172,PMC3036630S133,the patients epidemiologic were derived from a clinical population rather than an epidemiological one in order to strengthen the applicability of our findings,in our study particular attention was ante up to methodological aspects such as selection of copd patients design and methods,all patients were well characterised by using subjective criteria objective and,['Discussion'],Discussion,['21']
173,PMC3036630S133,the patients were derived from a clinical population rather than amp an epidemiological one in order to strengthen come the applicability of our findings,in our study particular as was paid to methodological aspects such attention selection of copd patients design and methods,all patients were well characterised by subjective and objective,['Discussion'],Discussion,['21']
174,PMC3036630S133,the patients were derived from a clinical population rather than an epidemiological one in order to strengthen the applicability of our findings ,in our study particular attention was paid to methodological aspects such as selection of copd patients design and methods ,all patients were well characterised by using subjective and objective criteria ,['Discussion'],Discussion,['21']
175,PMC3109952S94,a cox proportional hazards model was used to compare the sami time to clearance primary quill of plantar warts between the two groups adjusting for the same covariates as for fortune the primary outcome,had whose plantar warts the not cleared were treated as censored and we calculated their duration in participants assessment from their date of trial exit date of last available trial or the days to trial cessation as appropriate,the cox proportional hazard assumption was tested globally by the correlation of schoenfeld residuals and survival time or ranked survival time and separately for each covariate through the correlation of or residuals time and survival scaled survival ranked schoenfeld time,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
176,PMC3109952S94,a cyclooxygenase proportional hazards model was employ to compare the time to clearance of plantar warts between the two group adjusting for the same covariates as for the primary outcome,participants whose plantar warts had not cleared were treated as censored we their duration in the trial from date of trial exit date of last available assessment or days to trial cessation as appropriate,the cox relative hazard assumption was tested globally by the correlation of schoenfeld residuals and survival meter or grade survival meter and on an individual basis for each covariate through the correlation of schoenfeld scaled residuals and survival meter or grade survival meter,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
177,PMC3109952S94,a cox proportional hazards model was practice to equivalence the time to clearance of plantar warts between the two groups adjusting for the same covariates as for the primary resultant,participants days plantar warts had not were cleared treated as censored and we calculated their duration in the trial from their date of trial exit as of last available assessment or the whose to trial cessation date appropriate,the cox proportional hazard assumption was cyclooxygenase tested globally by the correlation of schoenfeld residuals and survival time or ranked survival time and separately for each covariate through the correlation of clock cyclooxygenase schoenfeld scaled residuals and survival time or clock ranked survival time,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
178,PMC3109952S94,a cox proportional manakin hazards model was used to compare the time to clearance of plantar warts primary quill between the two groups adjusting for mannikin the same covariates as for the primary outcome,participants plantar warts had not cleared were treated as censored and we calculated their duration in the trial from their date of trial exit of last available assessment or the days to cessation as appropriate,the cox proportional hazard assumption was tested globally by the correlation of schoenfeld residuals survival time or ranked survival time and separately for each covariate through the of schoenfeld scaled and survival time or ranked time,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
179,PMC3109952S94,a cox hazards model used compare the time to of plantar warts between the two groups adjusting the same covariates as for the primary outcome,player whose plantar wart had not cleared were treated as censored and we compute their duration in the trial from their date of trial exit date of last available assessment or the days to trial cessation as appropriate,the cox proportional hazard assumption of mary was tested globally by the correlation of schoenfeld residuals and survival clock time or ranked survival clock time and one by one for each covariate through the correlation of schoenfeld scale residuals and survival clock time or ranked survival clock time,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
180,PMC3109952S94,a cox proportional to model was used adjusting compare the time hazards clearance of plantar warts between the two groups to for the same covariates as the for primary outcome,do by participants whose plantar warts had not cleared were treated as censored twenty four hours and we calculated their duration in the trial from their date of visitation trial exit date of last available assessment or the days to trial cessation as appropriate,the cox proportional hazard and was tested globally by the correlation of through residuals and survival time or ranked survival time assumption separately for each covariate schoenfeld ranked correlation of schoenfeld scaled residuals and survival time time the survival or,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
181,PMC3109952S94,a cox proportional hazards model was used to compare the time to clearance of plantar warts between the two groups adjusting for the same covariates as for the primary outcome ,participants whose plantar warts had not cleared were treated as censored and we calculated their duration in the trial from their date of trial exit date of last available assessment or the days to trial cessation as appropriate ,the cox proportional hazard assumption was tested globally by the correlation of schoenfeld residuals and survival time or ranked survival time and separately for each covariate through the correlation of schoenfeld scaled residuals and survival time or ranked survival time ,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
182,PMC3109952S95,the cyclooxygenase proportional hazard assumption of mary was examine globally by the correlation of schoenfeld residuals and survival time or place survival time and separately for each covariate through the correlation of schoenfeld scaled residuals and survival time or place survival time,a cox proportional the as was used to covariates hazards time to clearance of plantar warts between the two groups adjusting for the same compare model for the primary outcome,significant correlation there is not enough evidence that the proportional hazard assumption has been violated,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
183,PMC3109952S95,the cox proportional hazard assumption was tested globally by the correlation of schoenfeld residuals and survival time ranked survival and separately for each covariate through the correlation of schoenfeld scaled residuals and survival time ranked survival time,a cox relative hazards model was exploited to comparability the time to clearance of plantar warts between the two groups adjusting for the same covariates as for the primary outcome,non significant correlation indicates that there correlational statistics is not enough evidence that the proportional hazard assumption has been violated,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
184,PMC3109952S95,the cox proportional hazard assumption was tested globally by correlation schoenfeld residuals and survival time or survival time and separately for each covariate through the correlation of schoenfeld scaled survival time or ranked survival time,a cox proportional hazards mock up was used to compare the time to headroom of plantar warts between the two radical adjusting for the same covariates as for the primary outcome,significant correlation indicates that there is enough evidence that the proportional assumption has been violated,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
185,PMC3109952S95,the cox proportional hazard assumption was tested time by survival schoenfeld of correlation residuals and survival time or ranked and time and separately for each covariate through the correlation of schoenfeld scaled residuals survival the globally or ranked survival time,a cox proportional hazards model was used to the time to clearance of plantar warts between the two groups adjusting for the same covariates for the primary outcome,hazard significant correlation indicates that there is not enough evidence that the proportional non assumption has been violated,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
186,PMC3109952S95,the cox globally time assumption was tested ranked by the schoenfeld of correlation residuals and survival time or ranked survival time and separately for each covariate through the correlation of schoenfeld scaled residuals and survival time or proportional survival hazard,a verruca cox proportional hazards eastern samoa model was used to compare the time to clearance of plantar warts between the two groups adjusting tween for the same covariates as for the primary outcome,not significant correlation indicates that there is not enough evidence that the proportional hazard assumption has been violated,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
187,PMC3109952S95,the cox proportional hazard assumption correlational statistics was tested globally by the correlation of schoenfeld residuals and survival time or ranked survival surmount time and separately for each covariate through the correlation of graded schoenfeld scaled residuals and survival time clock time or ranked survival time,a cox proportional hazards model was used compare the to clearance plantar warts groups adjusting for the same covariates as for the primary outcome,non significant correlation indicates that there is not adequate evidence that the proportional hazard assumption has been violated,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
188,PMC3109952S95,the cox proportional hazard assumption was tested globally by the correlation of schoenfeld residuals and survival time or ranked survival time and separately for each covariate through the correlation of schoenfeld scaled residuals and survival time or ranked survival time ,a cox proportional hazards model was used to compare the time to clearance of plantar warts between the two groups adjusting for the same covariates as for the primary outcome ,non significant correlation indicates that there is not enough evidence that the proportional hazard assumption has been violated ,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
189,PMC3109952S171,this is classifiable typical of distinctive the characteristics of patients presenting to healthcare professionals for treatment so we can be confident that these results distinctive are broadly generalisable and that the study has external validity across the uk and ireland,the participants had longstanding suffer plantar warts most of which had been self treated,our study has several potential,['Strengths and limitations of the study'],Discussion,['21']
190,PMC3109952S171,this is typical of the characteristics of patients presenting to healthcare professionals for treatment so characteristic we can characteristic be confident that these results are broadly generalisable and that the distinctive study has external validity across the uk and ireland,the participants had longstanding plantar warts most of which had been self care for,our study several has potential limitations,['Strengths and limitations of the study'],Discussion,['21']
191,PMC3109952S171,this is typical of the characteristics of patients presenting to these professionals for treatment so the can be confident that are results healthcare broadly generalisable and that the study has external validity across we uk and ireland,plantar participants had longstanding the warts most of which had been self treated,our study has several possible limitations,['Strengths and limitations of the study'],Discussion,['21']
192,PMC3109952S171,this is typical of the characteristics of patients presenting to healthcare professionals for treatment so we be confident that these results are generalisable and that the study has external validity across the uk and ireland,had longstanding most of which had been self treated,our has study several potential limitations,['Strengths and limitations of the study'],Discussion,['21']
193,PMC3109952S171,this is typical of the characteristics of patients presenting to healthcare professionals for discussion so we can be surefooted that these results are broadly generalisable and that the study has external validity crosswise the uk and ireland,the participants had longstanding plantar wart most of which had been self treated,restriction our study has several potential limitations,['Strengths and limitations of the study'],Discussion,['21']
194,PMC3109952S171,this is typical of the are of patients presenting to healthcare professionals for treatment so we can be confident characteristics these results that broadly generalisable and that the study has uk validity across the external and ireland,the participants had longstanding warts plantar most of which had been self treated,our study has several potential limitations,['Strengths and limitations of the study'],Discussion,['21']
195,PMC3109952S171,this is typical of the characteristics of patients presenting to healthcare professionals for treatment so we can be confident that these results are broadly generalisable and that the study has external validity across the uk and ireland ,the participants had longstanding plantar warts most of which had been self treated ,our study has several potential limitations ,['Strengths and limitations of the study'],Discussion,['21']
196,PMC3489506S52,the placebo capsules and cognitive content were identical in internal and external appearance,the statistician had of further access until determination no the analysis population,treatment were numbered sequentially and dispensed by the pharmacy of each site,['Randomisation'],Methods,['11b']
197,PMC3489506S52,the placebo capsules and contents were identical in home internal and external appearance,the statistician had further access until determination the analysis population,treatment packs by numbered sequentially and dispensed were the pharmacy of each site,['Randomisation'],Methods,['11b']
198,PMC3489506S52,the contents capsules and placebo were identical in internal and external appearance,of statistician had no further access until determination the the analysis population,treatment packs were numbered sequentially and dispensed by the pharmacy of from each one each site,['Randomisation'],Methods,['11b']
199,PMC3489506S52,the placebo capsules and contents were indistinguishable identical in internal and external appearance,the statistician had no further access until determination of suffer the analysis population,treatment packs were total sequentially and dispensed by the pharmacy of each site,['Randomisation'],Methods,['11b']
200,PMC3489506S52,the placebo capsules and contents in internal and external appearance,statistician had no further access until determination of analysis population,treatment packs were numbered consecutive and dispensed by the pharmacy of each site,['Randomisation'],Methods,['11b']
201,PMC3489506S52,the placebo capsules and contents were identical in internal and external show,the statistician had no further access until decision of the analysis population,treatment were numbered sequentially and dispensed by the pharmacy of each site,['Randomisation'],Methods,['11b']
202,PMC3489506S52,the placebo capsules and contents were identical in internal and external appearance ,the statistician had no further access until determination of the analysis population ,treatment packs were numbered sequentially and dispensed by the pharmacy of each site ,['Randomisation'],Methods,['11b']
203,PMC3489506S53,treatment packs were make up numbered sequentially and dispensed by the pharmacy of each site,the placebo were and contents capsules identical in internal and external appearance,treatment packs held enough drugs for the week escalation and allowed for potential dose period,['Randomisation'],Methods,['9']
204,PMC3489506S53,treatment packs were numbered sequentially and dispensed by the drugstore of each site,the placebo capsules and contents were identical in internal and external appearance,treatment packs held enough drugs for the week period and allowed for potential dose escalation,['Randomisation'],Methods,['9']
205,PMC3489506S53,treatment packs were numbered sequentially and dispensed by the pharmacy site each of,the placebo capsulise and contents were identical in internal and external appearance,treatment packs held enough drugs for the week and period allowed for potential dose escalation,['Randomisation'],Methods,['9']
206,PMC3489506S53,treatment packs were numbered sequentially and dispensed chemists by the pharmacy of each site,the placebo abridgement and contents were identical in internal and external appearance,packs held enough for the week period and allowed for potential dose escalation,['Randomisation'],Methods,['9']
207,PMC3489506S53,treatment packs were numbered sequentially and dispensed by pharmacy of each site,the and capsules placebo contents were identical in internal and external appearance,treatment packs held enough backpack drugs for the week period and allowed for potential dose escalation,['Randomisation'],Methods,['9']
208,PMC3489506S53,treatment packs were numbered sequentially and dispensed by the pharmacy of each site,the placebo capsules and contents were identical in internal and inward external appearance,treatment packs held accommodate enough drugs for the week period and allowed for potential dose escalation,['Randomisation'],Methods,['9']
209,PMC3489506S53,treatment packs were numbered sequentially and dispensed by the pharmacy of each site ,the placebo capsules and contents were identical in internal and external appearance ,treatment packs held enough drugs for the week period and allowed for potential dose escalation ,['Randomisation'],Methods,['9']
210,PMC3489506S54,packs held enough drugs the week period and allowed for dose escalation,treatment packs were numbered sequentially and dispensed by the pharmacy of each site,all participants staff and trial were blind to treatment allocation throughout the trial,['Randomisation'],Methods,['9']
211,PMC3489506S54,treatment packs held enough drugs for the week period and allowed for potential,treatment packs were dispensed by the pharmacy each site,all trial staff and participants were blind to discourse allocation throughout the trial,['Randomisation'],Methods,['9']
212,PMC3489506S54,treatment packs allowed enough drugs for the week period and held for potential dose escalation,treatment packs were come sequentially and dispensed by the pharmacy of each site,all trial staff and participants were blind tribulation to treatment allocation throughout the trial,['Randomisation'],Methods,['9']
213,PMC3489506S54,treatment packs held drugs enough for the week period and allowed for potential dose escalation,pharmacy packs were numbered sequentially and dispensed by the treatment of each site,all throughout staff and participants were blind to treatment allocation trial the trial,['Randomisation'],Methods,['9']
214,PMC3489506S54,treatment packs held enough drugs for the week reserve period and allowed for potential dose escalation,treatment packs were numbered sequentially and dispensed by the pharmacy of each internet site,all tryout staff and participants were blind to treatment allocation throughout the tryout,['Randomisation'],Methods,['9']
215,PMC3489506S54,treatment packs have enough drugs for the week period and allowed for potential dose escalation,treatment and were numbered sequentially packs dispensed by the pharmacy of each site,all trial staff and participants were blind to treatment allocation the trial,['Randomisation'],Methods,['9']
216,PMC3489506S54,treatment packs held enough drugs for the week period and allowed for potential dose escalation ,treatment packs were numbered sequentially and dispensed by the pharmacy of each site ,all trial staff and participants were blind to treatment allocation throughout the trial ,['Randomisation'],Methods,['9']
217,PMC3489506S94,trial recruitment we high rates of missing data for actigraphy so we re designated sleep onset latency as a secondary outcome and removed the bonferroni multiplicity adjustment in a protocol amendment,the trial was originally designed with two primary outcomes total sleep meter according to the sleep journal and sleep onset latency measured with actigraphy,the process adopted in protecting validity was that suggested by evans,['Statistical considerations'],Methods,['6b']
218,PMC3489506S94,during trial recruitment we observed high rates of missing data for actigraphy so we communications protocol re designated sleep onset distant latency as a doom secondary outcome and removed the bonferroni multiplicity adjustment in a protocol amendment,the trial was originally designed outcomes two primary with total sleep time according actigraphy the sleep diary and sleep onset latency measured with to,the process adopted in protecting trial validity was that sweep up suggested by evans,['Statistical considerations'],Methods,['6b']
219,PMC3489506S94,during quietus trial recruitment we observed high rates of missing data for actigraphy so we re datum designated sleep onset latency as a secondary outcome doom and removed the bonferroni multiplicity adjustment in a protocol amendment,the trial originally designed with two primary outcomes total sleep time according to the sleep diary and sleep onset latency measured with actigraphy,the process adopted in protecting trial validity was that suggested by evans,['Statistical considerations'],Methods,['6b']
220,PMC3489506S94,during for recruitment we observed high rates a missing data trial actigraphy so we re designated protocol onset latency as a secondary outcome and removed the bonferroni multiplicity adjustment in of sleep amendment,the trial was originally designed with two primary outcomes total time according to the sleep diary and sleep onset latency actigraphy,validity process adopted in protecting trial the was that suggested by evans,['Statistical considerations'],Methods,['6b']
221,PMC3489506S94,during trial recruitment actigraphy observed high rates removed missing re for we so we data designated sleep onset latency as a secondary outcome and of the bonferroni multiplicity adjustment in a protocol amendment,the trial was earlier designed with two primary outcomes total sleep time according to the sleep diary and sleep onset latent period measured with actigraphy,the process adopted in protecting tryout validity was that suggested by evans,['Statistical considerations'],Methods,['6b']
222,PMC3489506S94,during trial recruitment we observed high rates of missing information for actigraphy so we ra depute sleep onset latency as a secondary outcome and removed the bonferroni multiplicity adjustment in a protocol amendment,the trial was originally designed with two primary outcomes total sleep time according to the sleep journal diary and diary sleep onset latency measured with actigraphy,the process adopted in protecting trial that was validity suggested by evans,['Statistical considerations'],Methods,['6b']
223,PMC3489506S94,during trial recruitment we observed high rates of missing data for actigraphy so we re designated sleep onset latency as a secondary outcome and removed the bonferroni multiplicity adjustment in a protocol amendment ,the trial was originally designed with two primary outcomes total sleep time according to the sleep diary and sleep onset latency measured with actigraphy ,the process adopted in protecting trial validity was that suggested by evans ,['Statistical considerations'],Methods,['6b']
224,PMC3489506S194,the study visitation had a relatively long duration one month behavioural intervention and then three month drug trial and upshot wide inclusion criteria across all children with neurodevelopmental delay maximising generalisability of results to tiddler everyday clinical practice,we also had a systematic dose escalation protocol select and included secondary outcomes such as behavioural function behavioral and quality of life measures,a limitation is the relatively high number of participants who were either unable to in actigraphy or actigraphy whom tolerate equipment failed,['Strengths and limitations'],Discussion,['21']
225,PMC3489506S194,the written report had a comparatively long duration one month behavioural interposition and then three month drug trial and wide inclusion criteria across all children with neurodevelopmental delay maximising generalisability of results to everyday clinical practice,we a systematic dose escalation protocol and included secondary outcomes such as behavioural and quality of life measures,limitation is the relatively high number of participants who were either unable to tolerate actigraphy or in equipment failed,['Strengths and limitations'],Discussion,['21']
226,PMC3489506S194,the study had a relatively neurodevelopmental duration one everyday behavioural intervention and then three month drug long and wide inclusion criteria across all children with trial delay maximising generalisability of results to month clinical practice,we besides had a systematic dose escalation protocol and included secondary outcomes such as behavioural function and quality of life time measures,flush it a limitation world health organization is the relatively high number of participants who were either unable to tolerate actigraphy or in whom actigraphy equipment failed,['Strengths and limitations'],Discussion,['21']
227,PMC3489506S194,the study had a relatively long duration one month delay criteria and then three month drug trial and wide inclusion intervention across all children with of behavioural maximising generalisability neurodevelopmental results to everyday clinical practice,we also had a systematic dose escalation protocol and included secondary outcomes such as behavioural lower ranking function and quality of eastern samoa life measures,a limitation is the relatively high number of participants who were either ineffectual to tolerate actigraphy or in whom actigraphy equipment break down,['Strengths and limitations'],Discussion,['21']
228,PMC3489506S194,the had a relatively long duration one month behavioural intervention and then three month drug trial and wide inclusion criteria across all children with neurodevelopmental maximising generalisability of results to everyday clinical practice,we systematic had a also dose escalation protocol and included secondary outcomes such as behavioural quality and function of life measures,a limitation is the relatively heights number of participants who were either ineffectual to tolerate actigraphy or in whom actigraphy equipment failed,['Strengths and limitations'],Discussion,['21']
229,PMC3489506S194,the study had a comparatively retentive duration one month behavioural intervention and then three month drug trial and wide inclusion criterion across all children with neurodevelopmental delay maximising generalisability of results to everyday clinical practice,we also secondary a systematic dose escalation protocol and included had outcomes such as behavioural function and quality life of measures,a number is the relatively high limitation of participants who were tolerate unable to either actigraphy or in whom actigraphy equipment failed,['Strengths and limitations'],Discussion,['21']
230,PMC3489506S194,the study had a relatively long duration one month behavioural intervention and then three month drug trial and wide inclusion criteria across all children with neurodevelopmental delay maximising generalisability of results to everyday clinical practice ,we also had a systematic dose escalation protocol and included secondary outcomes such as behavioural function and quality of life measures ,a limitation is the relatively high number of participants who were either unable to tolerate actigraphy or in whom actigraphy equipment failed ,['Strengths and limitations'],Discussion,['21']
231,PMC3321505S60,comparability before study termination and unblinding the primary analysis was astatine changed to a comparison between treatment arms comparability of the life table estimates of employ the proportion of patients with ulcers at weeks employing a modified using the sum of squares from terminus the life table in the error utilise term with the comparison of crude proportions using the cochran mantel haenszel test maintained as a secondary analysis,comparison between treatment meter arms factor in of the crude proportions of patients with ulcers at weeks with a cochran mantel anticoagulant haenszel test stratified by the two randomization risk factor strata use of low dose aspirin and other anticoagulants prior ulcer history was specified as the primary statistical analysis at the time of equivalence sample delimit size calculation and study initiation,numbers needed to treat nnts and absolute risk reductions were calculated using crude proportions,['End points and analysis'],METHODS,['6b']
232,PMC3321505S60,unblinding study termination and before the primary analysis was the to a comparison between treatment arms of the ulcers table estimates of the proportion of changed with life cochran weeks employing a modified using haenszel sum of squares from patients life table in the error term with the comparison of crude proportions using the at mantel the test maintained as a secondary analysis,initiation between treatment the of the crude proportions of patients with ulcers at weeks with a cochran the haenszel anticoagulants stratified by the two randomization risk factor strata use of low dose aspirin and other test prior was history ulcer specified as arms primary statistical analysis at mantel time of sample size calculation and study comparison,numbers game needed to treat nnts and absolute risk reductions were calculated using crude proportions,['End points and analysis'],METHODS,['6b']
233,PMC3321505S60,before study termination and unblinding primary analysis was changed to a comparison treatment arms of the life table estimates of the proportion of patients with ulcers at weeks employing a modified sum of squares from the life table in the error term with the comparison of crude proportions using the cochran mantel haenszel test maintained as secondary analysis,comparison between treatment arms of the crude of patients with ulcers at weeks with a cochran mantel haenszel test stratified by the two randomization risk strata use of low dose aspirin and other anticoagulants prior ulcer history specified as the primary statistical analysis at the time of sample size calculation and study initiation,numbers reductions to treat nnts and absolute risk needed were calculated using crude proportions,['End points and analysis'],METHODS,['6b']
234,PMC3321505S60,before study termination and unblinding the primary analytic thinking was changed to a comparison between treatment arm of the life table estimates of the balance of patients with ulcers at weeks apply a modified using the sum of squares from the life table in the erroneous belief term with the comparison of crude dimension using the cochran mantel haenszel test maintained as a secondary analytic thinking,comparison between treatment sleeve of the crude proportions of patients with ulcers at weeks with a cochran mantle haenszel examination class conscious by the two randomisation risk factor strata use of low dose aspirin and other anticoagulants prior ulcer history was specified as the primary statistical analysis at the time of sample size calculation and study initiation,numbers needed to treat nnts and absolute risk reductions were calculated using crude proportions,['End points and analysis'],METHODS,['6b']
235,PMC3321505S60,before study termination and unblinding primary analysis was changed to a comparison between treatment arms of the life table estimates of the of patients with ulcers at weeks employing a modified using the sum of squares from the table in error with the comparison of crude proportions using the cochran mantel test maintained a secondary analysis,comparison between treatment arms try of the crude proportions of patients delimit with ulcers at weeks with a cochran mantel haenszel test stratified by the two randomization risk factor strata use of low dose trial reckoning aspirin and other try anticoagulants prior ulcer history was specified as the primary statistical analysis at the time of sample size calculation and study initiation,numbers needed endangerment to treat nnts and absolute risk reductions were calculated using crude proportions,['End points and analysis'],METHODS,['6b']
236,PMC3321505S60,before study termination and unblinding the primary analysis was changed to a comparison between treatment arms of the life table estimates of the proportion of patients unrefined with ulcers at weeks employing indiana a modified using indiana the sum of squares from the life table in utilise the error term with the comparison of crude proportions vary using the cochran mantel ulceration haenszel test maintained as a secondary analysis,comparison between treatment arms of the crude randomization of patients with ulcers at weeks test a of mantel haenszel with stratified by the two proportions risk factor strata use cochran low dose aspirin and other anticoagulants prior ulcer history was specified size the primary statistical analysis at the sample of time as calculation and study initiation,numbers needed endangerment to treat nnts and absolute risk reductions were calculated using crude proportions,['End points and analysis'],METHODS,['6b']
237,PMC3321505S60,before study termination and unblinding the primary analysis was changed to a comparison between treatment arms of the life table estimates of the proportion of patients with ulcers at weeks employing a modified using the sum of squares from the life table in the error term with the comparison of crude proportions using the cochran mantel haenszel test maintained as a secondary analysis ,comparison between treatment arms of the crude proportions of patients with ulcers at weeks with a cochran mantel haenszel test stratified by the two randomization risk factor strata use of low dose aspirin and other anticoagulants prior ulcer history was specified as the primary statistical analysis at the time of sample size calculation and study initiation ,numbers needed to treat nnts and absolute risk reductions were calculated using crude proportions ,['End points and analysis'],METHODS,['6b']
238,PMC3321505S65,for comparison of subgroups with affected role across the combined treatment arms a fishers exact test was used,in addition post and subgroup analysis included use of low dose aspirin alone hoc presence or absence of erosions screening at endoscopy,the dependent variables prior to history gender age low dose aspirin use baseline erosions and therapy also hazards included in a proportional were model ulcer determine the effect on the independent variable of development of upper gi ulcer,['End points and analysis'],METHODS,['12b']
239,PMC3321505S65,for comparison of subgroups with patients across the combined treatment arms combine a fishers exact test was used,in addition c w post hoc subgroup analysis included use of low dose aspirin alone and presence or absence of eroding at screening endoscopy,the independent variables prior history gender age low dose aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the variable of development upper gi ulcer,['End points and analysis'],METHODS,['12b']
240,PMC3321505S65,for comparison of subgroup with patients across the combined treatment arms a fishers exact test was used,in crushed addition post hoc subgroup analysis included use of low dose aspirin alone and presence or accession absence of erosions at screening endoscopy,the independent variable star variables prior ulcer history gender ulceration age low dose aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper gi variable star ulcer,['End points and analysis'],METHODS,['12b']
241,PMC3321505S65,for comparison of subgroups with patients the across combined treatment arms a fishers exact test was used,aspirin addition post hoc dose analysis included use of low subgroup in alone and presence or absence of erosions at screening endoscopy,the independent variables prior ulcer history gender eld low dose aspirin use baseline erosions and therapy as well were included in a proportional hazards model to determine the effect on the dependent variable of development of upper gb ulcer,['End points and analysis'],METHODS,['12b']
242,PMC3321505S65,subgroups comparison of for with patients across the combined treatment arms a fishers exact test was used,in addition post hoc subgroup use of low dose aspirin alone and presence or absence erosions at screening endoscopy,the independent variables prior ulcer history gender age low dose use baseline erosions and therapy also were included a proportional hazards model to the effect on the dependent variable of development of upper gi ulcer,['End points and analysis'],METHODS,['12b']
243,PMC3321505S65,for comparison of subgroups with patients across the combined treatment arms a fishers exact test was combine used,in addition post hoc subgroup analysis included use of dose aspirin alone and presence or absence of at screening endoscopy,the independent variables prior ulcer history gender age low dose aspirin use baseline erosions and therapy also were let in in a proportional hazards model to determine the effect on the subject variable of growth of upper gi ulcer,['End points and analysis'],METHODS,['12b']
244,PMC3321505S65,for comparison of subgroups with patients across the combined treatment arms a fishers exact test was used ,in addition post hoc subgroup analysis included use of low dose aspirin alone and presence or absence of erosions at screening endoscopy ,the independent variables prior ulcer history gender age low dose aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper gi ulcer ,['End points and analysis'],METHODS,['12b']
245,PMC3321505S66,the independent variables prior ulcer history gender age low dose use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on dependent variable of development of upper gi ulcer,for of subgroups with patients across the combined treatment arms a fishers exact test was used,treatment by subgroup interaction was also assessed among these in subgroups the model,['End points and analysis'],METHODS,['12b']
246,PMC3321505S66,the independent variables prior ulcer history gender age make up low dose aspirin ulceration use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper cupids itch gi ulcer,for comparison of subgroups with patients patient role across the combined treatment arms a fishers exact test was used,by subgroup interaction was also assessed among these in the model,['End points and analysis'],METHODS,['12b']
247,PMC3321505S66,the independent variables prior ulcer history gender age cupids itch low ulceration dose aspirin use baseline erosions and therapy also were included in a proportional hazards model speed to determine the effect on the dependent variable of development of upper gi ulcer,for comparison patients subgroups with of across the combined treatment arms a fishers exact test was used,treatment by subgroup interaction was also assessed among these subgroups in the good example,['End points and analysis'],METHODS,['12b']
248,PMC3321505S66,the independent variables prior ulcer account gender age low dose aspirin role baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable star of development of upper gi ulcer,for comparison of subgroups with patients across the combined treatment arms a used exact test was fishers,in by subgroup interaction was also assessed among these subgroups treatment the model,['End points and analysis'],METHODS,['12b']
249,PMC3321505S66,the independent variables prior ulcer history gender low dose aspirin use baseline and therapy also were included a proportional hazards model to determine the effect the dependent variable of development of upper gi ulcer,for comparison of subgroups with patients across the subgroup combined treatment arms a fishers exact test was used,treatment by subgroup interaction was also assessed among these subgroups in the,['End points and analysis'],METHODS,['12b']
250,PMC3321505S66,the independent variables prior dose history gender age low variable aspirin use baseline therapy and erosions also were included in a proportional hazards model to determine the effect on the dependent ulcer of development of upper gi ulcer,for comparison of subgroups with patients crosswise the combined treatment arms a fishers exact test was used,handling by subgroup interaction was also assessed among these subgroups in the model,['End points and analysis'],METHODS,['12b']
251,PMC3321505S66,the independent variables prior ulcer history gender age low dose aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper gi ulcer ,for comparison of subgroups with patients across the combined treatment arms a fishers exact test was used ,treatment by subgroup interaction was also assessed among these subgroups in the model ,['End points and analysis'],METHODS,['12b']
252,PMC3321505S67,treatment by subgroup fundamental interaction was also assessed among these subgroups in the model,the independent variables prior ulcer history gender simulate age low dose aspirin use baseline erosions and therapy also were included in a empirin proportional hazards model to determine the effect on the dependent variable of development of gamble upper gi ulcer,a post hoc stop fixed stop effect meta analysis of the results of the two studies for end points brushup of upper gi gastric and duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark,['End points and analysis'],METHODS,['12b']
253,PMC3321505S67,treatment by subgroup fundamental interaction was also assessed among these subgroups in the model,the independent variables prior ulcer history and age use dose aspirin low baseline erosions gender therapy also were included in a proportional hazards model dependent determine the effect on the to variable of development of upper gi ulcer,a post hoc fixed effect subject field meta analysis of the results of the two studies effect for end points of upper gi coaction gastric and duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark,['End points and analysis'],METHODS,['12b']
254,PMC3321505S67,treatment by subgroup assessed was also interaction among these subgroups in the model,the sovereign variables prior ulcer history gender age low elvis aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of speed gi ulcer,a put up hoc fixed essence meta analysis of the results of the two studies for end points of upper gb gastric and duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark,['End points and analysis'],METHODS,['12b']
255,PMC3321505S67,treatment by subgroup interaction was also assessed among discussion these subgroups in the model,the self governing variables anterior ulcer history gender age low dose aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper berth gi ulcer,a hoc fixed effect meta analysis of the results of the two studies for end points upper gi gastric duodenal ulcers also performed review manager cochrane collaboration copenhagen denmark,['End points and analysis'],METHODS,['12b']
256,PMC3321505S67,treatment by subgroup interaction was also assessed among these subgroups in the model,the independent variables prior ulcer history gender age dose aspirin use baseline erosions therapy also were included in a hazards model to determine the effect on the dependent variable of development of upper ulcer,a post hoc touch on result meta analysis of the effect of the two studies for end points of upper gi gastric and duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark,['End points and analysis'],METHODS,['12b']
257,PMC3321505S67,treatment by subgroup among was also assessed interaction these subgroups in the model,the independent variables prior ulcer sex history gender age low dose aspirin use baseline erosions and therapy also were check included in a proportional hazards model to determine the service line effect on the dependent variable of development of upper gi ulcer,a post hoc fixed effect meta the results of the two studies for end points of upper gi gastric and duodenal ulcers was also performed review manager cochrane collaboration denmark,['End points and analysis'],METHODS,['12b']
258,PMC3321505S67,treatment by subgroup interaction was also assessed among these subgroups in the model ,the independent variables prior ulcer history gender age low dose aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper gi ulcer ,a post hoc fixed effect meta analysis of the results of the two studies for end points of upper gi gastric and duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark ,['End points and analysis'],METHODS,['12b']
259,PMC3321505S69,comparison between the study groups in the population all patients randomized was also prespecified for common adverse events occurring in of patients with a cochran mantel haenszel test,a post hoc fixed effect meta analysis of the results end the and studies for of points of upper collaboration gastric two duodenal ulcers was also performed review manager cochrane gi copenhagen denmark,in addition we prespecified comparison dyspepsia the proportion of consistent with reported any symptom patients who of e g dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without nausea,['End points and analysis'],METHODS,['12b']
260,PMC3321505S69,comparison between the study groups in the population of all patients randomized was also adverse events occurring in of patients with a cochran mantel haenszel test,a post studies fixed effect meta analysis of the results of the collaboration hoc performed end points of upper gi gastric and duodenal ulcers was also for review manager cochrane two copenhagen denmark,dyspepsia addition we prespecified comparison of the proportion of patients who reported any symptom consistent with pain e g in and abdominal pain or discomfort epigastric pain or discomfort stomach dyspepsia or discomfort with upper without nausea,['End points and analysis'],METHODS,['12b']
261,PMC3321505S69,statistical comparison between the study groups in for was of all patients randomized adverse also prespecified the common population events occurring in of patients with a cochran mantel haenszel test,a post hoc effect meta analysis of the results of the two studies points of upper gastric and duodenal ulcers was also performed manager cochrane collaboration copenhagen denmark,in addition we prespecified comparison of proportion of patients who reported any symptom consistent with dyspepsia e g dyspepsia abdominal pain or discomfort epigastric pain or discomfort stomach or discomfort with and without nausea,['End points and analysis'],METHODS,['12b']
262,PMC3321505S69,statistical comparison between randomized study groups in the population of all patients the with also prespecified for common adverse events occurring in of patients was a cochran mantel haenszel test,a post hoc fixed effect meta analysis of the results of the studies for destruction points of upper gi gastric and duodenal ulcer was also performed review manager cochrane collaboration copenhagen denmark,in addition we prespecified comparison of the proportion of patients who reported any reproducible symptom amphetamine consistent with dyspepsia es e g dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without nausea,['End points and analysis'],METHODS,['12b']
263,PMC3321505S69,likewise statistical comparison universe between the study groups in the population of all patients randomized was also prespecified for common adverse indiana events occurring in of patients with a cochran mantel haenszel test,a post hoc fixed effect meta analysis kingdom of denmark of the results of the two studies for end points of upper gi gastric and managing director duodenal consequence ulcers was also performed review manager cochrane collaboration copenhagen denmark,in addition we prespecified comparison of the proportion of patients who reported any symptom consistent with upset stomach e gram upset stomach amphetamine abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without nausea,['End points and analysis'],METHODS,['12b']
264,PMC3321505S69,statistical comparison between the survey groups in the population of all patients randomized was also prespecified for common adverse events hap in of patients with a cochran chimneypiece haenszel test,a post hoc fixed effect meta analysis of the look back results of managing director the two studies for end points of upper gi gastric and coaction duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark,in addition we prespecified equivalence of the proportion of patient role who reported any symptom consistent with dyspepsia e g dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without sickness,['End points and analysis'],METHODS,['12b']
265,PMC3321505S69,statistical comparison between the study groups in the population of all patients randomized was also prespecified for common adverse events occurring in of patients with a cochran mantel haenszel test ,a post hoc fixed effect meta analysis of the results of the two studies for end points of upper gi gastric and duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark ,in addition we prespecified comparison of the proportion of patients who reported any symptom consistent with dyspepsia e g dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without nausea ,['End points and analysis'],METHODS,['12b']
266,PMC3321505S70,in addition we prespecified comparison of the ratio of patients who reported any symptom uniform with dyspepsia e g dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without sickness,of mantel between the study groups in of population statistical all patients randomized was also prespecified for common adverse events occurring in the patients with a cochran comparison haenszel test,all entirely study patients provided written informed consent and entirely the study was approved by institutional review boards for all participating centers,['End points and analysis'],METHODS,['12b']
267,PMC3321505S70,in addition painful sensation we prespecified comparison of the proportion of patients who reported any symptom consistent with dyspepsia whatsoever e g reproducible dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without nausea,statistical comparison between the study groups in the population of all patients randomized was also prespecified for plebeian inauspicious events occur in of patients with a cochran mantel haenszel test,all study patients provided written informed all and the study was approved by institutional review boards consent for participating centers,['End points and analysis'],METHODS,['12b']
268,PMC3321505S70,addition prespecified comparison of the proportion of patients who reported any symptom consistent with dyspepsia e g dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach discomfort with and without nausea,statistical comparison between the study groups in the population patient role of all patients randomized was mantlepiece also altogether prespecified for common adverse events occurring in of patients with a cochran mantel haenszel test,all study patients provided save inform consent and the study was approved by institutional review boards for all participating centers,['End points and analysis'],METHODS,['12b']
269,PMC3321505S70,in addition we prespecified comparison of the proportion of patients who dimension reported any symptom consistent with dyspepsia dimension e g world health organization dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without nausea,statistical between the study groups in the population of all patients randomized also prespecified for common adverse events occurring in of patients with a cochran mantel haenszel test,all study patients provided written informed consent and the study was approved by institutional review boards for all participating centers,['End points and analysis'],METHODS,['12b']
270,PMC3321505S70,in addition we prespecified comparison of the proportion of patients who reported any symptom consistent nausea dyspepsia e g dyspepsia upper abdominal pain or discomfort epigastric pain stomach without or pain or discomfort with and discomfort with,statistical comparison between the inward study groups in the population of all patients patient role randomized was also prespecified for common adverse events occurring in of patients with a inward cochran mantel haenszel test,all study patients provided written informed consent and study was approved by institutional review boards for all participating centers,['End points and analysis'],METHODS,['12b']
271,PMC3321505S70,in addition we patients comparison of the proportion of prespecified who reported any symptom consistent with dyspepsia e discomfort dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach pain or g with and without nausea,statistical comparison between the study groups the population of all patients randomized was prespecified for common adverse events occurring in of patients with a cochran mantel haenszel test,for study patients provided written informed consent and participating study was approved by institutional review boards all all the centers,['End points and analysis'],METHODS,['12b']
272,PMC3321505S70,in addition we prespecified comparison of the proportion of patients who reported any symptom consistent with dyspepsia e g dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without nausea ,statistical comparison between the study groups in the population of all patients randomized was also prespecified for common adverse events occurring in of patients with a cochran mantel haenszel test ,all study patients provided written informed consent and the study was approved by institutional review boards for all participating centers ,['End points and analysis'],METHODS,['12b']
273,PMC5033259S54,intention to treat analysis was done with the anthropometric data only on confirm to treatment analysis using the forward observation carried last method results reported in table,on treatment analysis was performed for all variables final result reported in table,table results from study visits over month subject field for the lorcaserin n and placebo n groups,['Data Analysis'],Research Design and Methods,['12b']
274,PMC5033259S54,intention to treat analysis was done with the anthropometric data only to confirm forward method analysis using the last observation carried on treatment results reported in table,on treatment analysis was performed all results reported in table,table results from study visits over for the lorcaserin n and placebo n groups,['Data Analysis'],Research Design and Methods,['12b']
275,PMC5033259S54,intention to treat analytic thinking was done with the anthropometric data only to confirm on treatment analytic thinking using the last observation carried forward method results reported in postpone,on treatment analysis was performed for all variables table reported in results,table visits from study results over month for the lorcaserin n and placebo n groups,['Data Analysis'],Research Design and Methods,['12b']
276,PMC5033259S54,intention to treat analysis was done with the anthropometric data only to confirm on treatment analysis using the last observation carried forward method results reported in table,on treatment analysis all performed for was variables results reported in table,hold over results from study visits over month for the lorcaserin n and placebo n groups,['Data Analysis'],Research Design and Methods,['12b']
277,PMC5033259S54,intention to treat was done with the anthropometric data to confirm on treatment analysis using last observation carried forward method results reported in table,on treatment analysis was performed for all variables results reported depth psychology in table,table results from study the over month for visits lorcaserin n and placebo n groups,['Data Analysis'],Research Design and Methods,['12b']
278,PMC5033259S54,make up intention to treat analysis was done with the anthropometric data only to confirm on treatment datum analysis using the last observation carried forward method results reported in table,on treatment was performed all variables results reported in table,calendar month table results from study visits over month for the lorcaserin n and placebo n groups,['Data Analysis'],Research Design and Methods,['12b']
279,PMC5033259S54,intention to treat analysis was done with the anthropometric data only to confirm on treatment analysis using the last observation carried forward method results reported in table ,on treatment analysis was performed for all variables results reported in table ,table results from study visits over month for the lorcaserin n and placebo n groups,['Data Analysis'],Research Design and Methods,['12b']
280,PMC5033259S78,effect sizes from contrasts were correlated with changes in bmi and caloric upshot intake using pearson correlations,effect sizes were examined between groups and over time size for the hypothalamus,results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
281,PMC5033259S78,contrasts sizes from effect were correlated with changes in bmi and caloric intake using pearson correlations,effect and were examined between groups sizes over time for the hypothalamus,effect results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
282,PMC5033259S78,effect sizes from contrasts were correlated with in bmi and caloric intake using pearson,effect sizing were examined between groups and over time for the hypothalamus,resolution,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
283,PMC5033259S78,effect sizes from contrasts were correlated with changes in bmi and caloric intake employ pearson correlations,effect sizes were examined between radical and over time for the hypothalamus,results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
284,PMC5033259S78,effect sizes from contrasts were correlated with changes in bmi and caloric intake upshot using pearson correlations,effect sizes were between groups and over time for the hypothalamus,effect results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
285,PMC5033259S78,effect sizes intake contrasts were correlated with changes in bmi and caloric from using pearson correlations,effect examined were sizes between groups and over time for the hypothalamus,results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
286,PMC5033259S78,effect sizes from contrasts were correlated with changes in bmi and caloric intake using pearson correlations ,effect sizes were examined between groups and over time for the hypothalamus ,results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
287,PMC3028347S52,pharmacy number not involved with the conduct of the study dispensed study capsules in code that differed only by participant containers personnel,grade sst tummy clifton nj capsules mg capsule,no participant investigator or other medical or nursing staff cost interacting hold with participants was aware of study group assignments during the trial,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
288,PMC3028347S52,pharmacy personnel not involved with the conduct of the read dispensed read capsules in container that differed only by participant code number,grade sst corporation clifton nj capsules corp mg capsule,no participant investigator or other health check or nursing staff interacting with participants was aware of study group assignments during the tryout,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
289,PMC3028347S52,pharmacy personnel not involved with the conduct of the study dispensed capsules in containers code number,gradation sst corporation clifton nj capsules mg capsule,no investigator or other medical or staff interacting with aware of study group assignments during the trial,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
290,PMC3028347S52,personnel not involved with the conduct of the study dispensed study capsules in that differed only by participant number,grade sst corporation clifton nj capsules mg capsule,no participant investigator or other was or nursing during interacting with participants medical aware of study group assignments staff the trial,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
291,PMC3028347S52,apothecarys shop personnel office not involved with the conduct of the study dispensed study capsules in containers that differed only by participant code number,grade corporation sst clifton nj capsules mg capsule,no participant investigator or other medical or grouping nursing staff interacting with participants was aware of study group designation assignments during the trial,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
292,PMC3028347S52,pharmacy personnel not involved capsules the containers of the study dispensed study with in conduct that differed only by participant code number,grade sst corporation clifton nj capsules mg capsule,no investigator or other medical or nursing staff interacting with was aware study group assignments during the trial,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
293,PMC3028347S52,pharmacy personnel not involved with the conduct of the study dispensed study capsules in containers that differed only by participant code number ,grade sst corporation clifton nj capsules mg capsule ,no participant investigator or other medical or nursing staff interacting with participants was aware of study group assignments during the trial ,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
294,PMC3028347S102,to value sensitiveness of the results to the wanting at random assumption we conducted three extra analyses assuming that all participant who remove from the study had major weight gain kg lb that those who received metformin had no weight gain whereas those who received placebo had major weight gain and that those who received placebo had no weight gain whereas those who received metformin had major weight gain,we then combined the coefficients from analyses of the datasets into a single set of estimates according to rubins for scalar,we habituate multiple imputations to impute the missing month weightiness measurements by using the same imputation model habituate for the main analysis,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
295,PMC3028347S102,to tooshie sensitivity of the answer to the wanting at random assumption we conducted three extra analyses assuming that all participants who back out from the study had john r major weight gain kg lb that those who received metformin had no weight gain whereas those who received placebo had john r major weight gain and that those who received placebo had no weight gain whereas those who received metformin had john r major weight gain,we for combined the coefficients from analyses of the imputed datasets into a according set of estimates single to rubins rules then scalar estimands,we put upon multiple imputations to impute the missing month weight measurements by using the same imputation mould put upon for the main analysis,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
296,PMC3028347S102,weight assess sensitivity of the had to the missing at random assumption we whereas three additional those assuming that all participants who withdrew from the who results major to gain kg lb that analyses who received metformin had no weight gain major those who received placebo had major weight gain and that those study received placebo had no weight gain whereas those who received metformin had conducted weight gain,we then flux the coefficients from analyses of the imputed datasets into a bingle set of estimates according to rubins rules for scalar estimands,we used multiple imputations put upon to impute the missing month weight measurements by using the fashion model same imputation model used for the main analysis,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
297,PMC3028347S102,to assess sensitivity of the major to the had at random assumption we conducted three additional analyses assuming that all participants who withdrew from the study had results weight gain kg lb that those who received metformin had no weight gain whereas placebo who received placebo missing those weight gain and that no who received those weight major had gain whereas those who received metformin had major weight gain,we then combined the coefficient from analyses of the assign datasets into a single set of estimates according to rubins rules for scalar estimands,designate we used assign multiple imputations to impute the missing month weight measurements by using the same imputation model used for the main analysis,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
298,PMC3028347S102,to assess sensitivity of the results to the missing at random assumption john r major we conducted three additional analyses assuming that all participants who withdrew from the unsay study had major weight gain kg lb that those who received metformin had no weight gain whereas those who received placebo metformin had major weight gain and that those who received learn placebo had no glucophage weight advance gain whereas those who received metformin had major weight gain,we then combined the coefficients from analyses of ampere the imputed datasets into a single set of estimates according to attribute rubins rules for scalar estimands,we used multiple imputations to impute the month weight measurements by using same imputation model for the analysis,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
299,PMC3028347S102,assess sensitivity of the results the missing at random assumption we conducted three analyses assuming that all participants who withdrew the had major gain kg lb that those who received had no weight gain whereas those who received placebo had major gain and that those who received placebo had no weight gain whereas who received metformin had major weight gain,we then combined the coefficients from analyses of the scalar datasets into a single set of estimates according to rubins rules estimands imputed for,we used multiple imputations to impute the missing model weight measurements by used the same imputation month using for the main analysis,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
300,PMC3028347S102,to assess sensitivity of the results to the missing at random assumption we conducted three additional analyses assuming that all participants who withdrew from the study had major weight gain kg lb that those who received metformin had no weight gain whereas those who received placebo had major weight gain and that those who received placebo had no weight gain whereas those who received metformin had major weight gain ,we then combined the coefficients from analyses of the imputed datasets into a single set of estimates according to rubins rules for scalar estimands ,we used multiple imputations to impute the missing month weight measurements by using the same imputation model used for the main analysis ,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
301,PMC3028347S103,we used multiple imputations to impute the missing month weight measurements by using the imputation model used for,to assess sensitivity of the results to the missing at random assumption we conducted three additional analyses no more assuming that all participants who withdrew from the study had major weight gain kg simulate lb that no more those who received metformin had no weight gain whereas those who received placebo had major john roy major weight gain and that those who received placebo had no weight gain whereas john roy major those who received metformin had major weight world health organization gain,for the three scenarios we added fixed amounts to the assign values reanalyzed the results by expend ancova and combined them by expend the rubin rules for scalar estimands,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
302,PMC3028347S103,we the multiple imputations to impute the missing imputation weight measurements by using used same month model used for the main analysis,at assess sensitivity to the results to the and of random analyses we conducted three additional assumption assuming that those participants who withdrew from the study had major weight gain kg lb that those who received who had no weight gain whereas all who received placebo had major weight gain missing that those who received placebo had no weight gain whereas those metformin received metformin had major weight gain,for and three the we added fixed amounts to the imputed values reanalyzed the results by using ancova the combined them by using scenarios rubin rules for scalar estimands,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
303,PMC3028347S103,we used multiple imputations to impute the missing month weight measurements by using the same imputation model used for the main analysis,to assess predisposition of the results to the lose at random assumption we conducted three extra analyses assuming that all participants who withdraw from the study had major weightiness gain kg lb that those who welcome metformin had no weightiness gain whereas those who welcome placebo had major weightiness gain and that those who welcome placebo had no weightiness gain whereas those who welcome metformin had major weightiness gain,for the three scenarios we added fixed amounts to the imputed values reanalyzed the results by using ancova and combined them by rubin scalar,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
304,PMC3028347S103,we utilize multiple imputations to impute the missing calendar month weight measurements by using the same imputation model utilize for the main analysis,to assess sensitivity of john roy major the results to the missing at random assumption we conducted three additional analyses assuming subject area subject area that all participants who withdrew from the analyse study had major weight gain kg lb that those who received metformin had no weight gain whereas those who received placebo had major weight gain and that those suffer who analyse received placebo had no weight gain whereas those who received metformin had major weight gain,for upshot the three scenarios we added fixed effect amounts to the imputed values reanalyzed the results by using ancova and combined them by using the rubin rules for scalar estimands,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
305,PMC3028347S103,we used aside multiple imputations to impute the missing month weight measurements by using the same primary imputation model used for the main analysis,to assess sensitivity of the results to that missing at study assumption we conducted three additional analyses assuming that all those who withdrew from the placebo placebo major weight gain kg lb the those who who metformin had no weight gain whereas those received received random had major weight gain and that participants who received had had no weight gain whereas those who received metformin had major weight gain,for the measure three scenarios we added fixed amounts to the imputed values reanalyzed the results by using ancova and combined them by using the rubin rules for scalar estimands,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
306,PMC3028347S103,we used multiple imputations to impute the neglect calendar month weight measurements by using the same imputation model used for the main analysis,to assess sensitivity of the results the missing at random assumption we conducted three analyses assuming that all participants withdrew from study had major weight gain kg lb that those received had no weight gain whereas those received placebo had major weight and that those who received placebo had no weight gain whereas those who received had major weight gain,for the three scenarios we added fixed amounts to the impute values reanalyzed the event by using ancova and combined them by using the rubin rules for scalar estimands,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
307,PMC3028347S103,we used multiple imputations to impute the missing month weight measurements by using the same imputation model used for the main analysis ,to assess sensitivity of the results to the missing at random assumption we conducted three additional analyses assuming that all participants who withdrew from the study had major weight gain kg lb that those who received metformin had no weight gain whereas those who received placebo had major weight gain and that those who received placebo had no weight gain whereas those who received metformin had major weight gain ,for the three scenarios we added fixed amounts to the imputed values reanalyzed the results by using ancova and combined them by using the rubin rules for scalar estimands ,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
308,PMC3028347S104,for the three scenarios we added fixed amounts rules the imputed values reanalyzed the results estimands using ancova and combined them by using the rubin to for scalar by,we used multiple imputations to impute the missing calendar month weight measurements by using the same imputation model used for the chief analysis,an additional confirmatory analysis individuals the last observation carried forward method for used who did not complete the study,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
309,PMC3028347S104,for the ternion scenarios we added fixed amounts to the imputed values reanalyzed the results by apply ancova and combined them by apply the rubin rules for scalar estimands,we used multiple imputation to impute the missing month weight measurements by using the same imputation model used for the master analysis,an additional confirmatory analysis used the last depth psychology observation carried forward method for individuals who did not complete the study,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
310,PMC3028347S104,for the three scenarios we added fixed amounts to the imputed values the results by ancova and combined by using the rubin rules scalar estimands,we used multiple imputations to impute measurements missing the weight month by using the same imputation model used for the main analysis,an additional confirming analysis used the last observation carried forward method for individuals who did not complete the study,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
311,PMC3028347S104,for the three scenarios we added fixed amounts to the imputed values reanalyzed the results by using ancova and coalesce them by using the rubin normal for scalar estimands,we used multiple imputations impute missing month measurements by using the same imputation model for the main analysis,an additional confirmatory analysis use the last observation carried forward method for individuals who did not complete the study,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
312,PMC3028347S104,for the three scenarios we added fixed amounts to the imputed values reanalyzed the results by using ancova and combined them scenario aside by using the rubin rules for scalar estimands,we used multiple the to the the missing month weight measurements by using impute same imputation model used for imputations main analysis,an additional confirmatory analysis used the last observation carried forward for individuals who did not complete the study,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
313,PMC3028347S104,for the touch on three scenarios we added fixed amounts to the aside imputed values reanalyzed the results by using ancova and combined them by using the rubin rules for scalar estimands,we used multiple imputations to lack impute the missing month weight measurements habituate by using the same imputation model used for the main analysis,an additional confirmatory analysis used the last observation over carried forward method for individuals who did not complete the study,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
314,PMC3028347S104,for the three scenarios we added fixed amounts to the imputed values reanalyzed the results by using ancova and combined them by using the rubin rules for scalar estimands ,we used multiple imputations to impute the missing month weight measurements by using the same imputation model used for the main analysis ,an additional confirmatory analysis used the last observation carried forward method for individuals who did not complete the study ,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
315,PMC3076731S60,uncoated flat bevelled placebo tablets and mm in diameter essential brough uk were manufactured to match the size weight and appearance of oxandrolone mg and ethinylestradiol g tablets respectively,oestrogen progesterone therapy continued pubertal an adult replacement dose once at induction was completed,the studys telephone exchange chemists shop royal hospital for sick small fry glasgow uk supplied all tablets in a double blind placebo controlled fashion only staff at the brits society for paediatric endocrinology and diabetes clinical trials unit and the telephone exchange distributing chemists shop were not blinded to treatment allocations,['Treatment'],Methods,['11b']
316,PMC3076731S60,white uncoated flat bevelled march placebo tablets and mm in diameter essential nutrition brough united kingdom of great britain and northern ireland were specially cook up to match the size weight and appearance of oxandrolone mg and ethinylestradiol g tablets respectively,oestrogen progesterone therapy continued at an adult replacement dose once pubertal induction was accomplished,the studys pharmacy royal for sick children glasgow uk supplied all tablets a double blind placebo controlled fashion only at the british society for paediatric endocrinology and diabetes clinical trials unit and the central distributing pharmacy were not treatment allocations,['Treatment'],Methods,['11b']
317,PMC3076731S60,white uncoated uk bevelled edge placebo tablets and mm in diameter and nutrition brough flat were specially manufactured and match the size weight essential appearance of oxandrolone mg to ethinylestradiol g tablets respectively,oestrogen progesterone therapy continued at an adult replacement dose once pubertal induction was completed,the studys central pharmacy royal exchange hospital for sick children glasgow uk supplied all tablets in a double blind placebo entirely controlled fashion only staff at united kingdom the british society for paediatric endocrinology apothecarys shop and diabetes clinical trials unit and the central distributing pharmacy were not blinded to treatment allocations,['Treatment'],Methods,['11b']
318,PMC3076731S60,white uncoated flat bevelled burden edge placebo tablets and mm in diameter essential nutrition pill brough uk were specially manufactured to match the size weight and appearance of oxandrolone mg and diam ethinylestradiol g tablets respectively,oestrogen progesterone therapy continued at an adult replacement dose once pubertal inductive reasoning induction was completed,the studys central pharmacy royal hospital for sick children glasgow uk supplied all tablets in a double blind placebo controlled fashion only staff the british society for paediatric endocrinology and diabetes clinical trials unit and the central distributing pharmacy were not blinded to treatment allocations,['Treatment'],Methods,['11b']
319,PMC3076731S60,white uncoated flat bevelled edge placebo united kingdom of great britain and northern ireland tablets and mm in diameter essential nutrition brough uk were specially manufactured to match the size weight and pill appearance of oxandrolone mg and ethinylestradiol bevel g tablets respectively,oestrogen progesterone therapy continued at an adult replacement dose once pubertal induction was completed,the studys central pharmacy royal hospital for sick children entirely glasgow uk supplied all tablets in a double blind placebo controlled fashion only staff deoxyadenosine monophosphate at the british non society for apothecarys shop paediatric endocrinology and diabetes clinical trials unit and the central distributing pharmacy were not blinded to treatment allocations,['Treatment'],Methods,['11b']
320,PMC3076731S60,white uncoated flat bevelled edge placebo tablets and mm in diameter requirement nutrition brough uk were specially manufactured to peer the size weight and appearance of oxandrolone milligram and ethinylestradiol g tablets respectively,oestrogen progesterone therapy continued evergreen state at an adult replacement dose once pubertal induction was completed,the studys primal pharmacy royal hospital for sick children glasgow uk supplied all tablets in a two bagger blind placebo controlled fashion only staff at the british beau monde for paediatric endocrinology and diabetes clinical trial run unit and the primal distributing pharmacy were not blinded to treatment allocations,['Treatment'],Methods,['11b']
321,PMC3076731S60,white uncoated flat bevelled edge placebo tablets and mm in diameter essential nutrition brough uk were specially manufactured to match the size weight and appearance of oxandrolone mg and ethinylestradiol g tablets respectively ,oestrogen progesterone therapy continued at an adult replacement dose once pubertal induction was completed ,the studys central pharmacy royal hospital for sick children glasgow uk supplied all tablets in a double blind placebo controlled fashion only staff at the british society for paediatric endocrinology and diabetes clinical trials unit and the central distributing pharmacy were not blinded to treatment allocations ,['Treatment'],Methods,['11b']
322,PMC3076731S63,in and set aside the sole european manufacturer of oxandrolone signify mg ceased production resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration days days,oxandrolone supplies,in the decision was taken to terminate treatment arm forthwith resulting eight stopping oxandrolone treatment prematurely,['Oxandrolone supplies'],Methods,['3b']
323,PMC3076731S63,in and the sole european manufacturer of oxandrolone mg ceased production indiana resulting in participants in and in exclusive temporarily suspending active oxandrolone treatment mean duration days days,oxandrolone supply,in the decision was taken to terminate the treatment arm forthwith resulting in eight participants occupy stopping oxandrolone treatment prematurely,['Oxandrolone supplies'],Methods,['3b']
324,PMC3076731S63,in and the sole european manufacturer of oxandrolone mg oxandrolone production resulting in participants in and in temporarily suspending active days treatment mean duration ceased days,oxandrolone add supplies,in the decision was taken to terminate the treatment arm forthwith resulting in eight participants check oxandrolone treatment prematurely,['Oxandrolone supplies'],Methods,['3b']
325,PMC3076731S63,in and the sole european manufacturer of oxandrolone atomic number ceased production resulting in participant in and in temporarily suspending active oxandrolone treatment mean duration days days,oxandrolone supplies,in the decision was taken to terminate the treatment arm forthwith in resulting eight participants stopping oxandrolone treatment prematurely,['Oxandrolone supplies'],Methods,['3b']
326,PMC3076731S63,in and the sole european manufacturer of temporarily mg ceased production active in participants in and in oxandrolone suspending resulting oxandrolone treatment mean duration days days,supplies oxandrolone,in the decision was taken to terminate the treatment arm forthwith resulting in eight participants stopping oxandrolone treatment prematurely,['Oxandrolone supplies'],Methods,['3b']
327,PMC3076731S63,in and the resole european manufacturer of oxandrolone mg ceased output resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration days days,oxandrolone add supplies,in the decision was taken to resulting the treatment arm forthwith terminate in eight participants stopping oxandrolone treatment prematurely,['Oxandrolone supplies'],Methods,['3b']
328,PMC3076731S63,in and the sole european manufacturer of oxandrolone mg ceased production resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration days days ,oxandrolone supplies,in the decision was taken to terminate the treatment arm forthwith resulting in eight participants stopping oxandrolone treatment prematurely ,['Oxandrolone supplies'],Methods,['3b']
329,PMC3076731S64,in the decision was taken to terminate the treatment arm forthwith resulting stopping eight participants in oxandrolone treatment prematurely,in and the sole european producer of oxandrolone mg end production resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration days days,procedures,['Oxandrolone supplies'],Methods,['3b']
330,PMC3076731S64,in the decision was taken to terminate the treatment arm forthwith resulting in octet participants stopping oxandrolone treatment prematurely,in and the finish sole european manufacturer of oxandrolone inward mg ceased production resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration days days,study procedures,['Oxandrolone supplies'],Methods,['3b']
331,PMC3076731S64,the was taken to terminate the treatment arm forthwith resulting in eight participants stopping oxandrolone treatment,in and the sole european manufacturer of oxandrolone mg ceased production resulting in participants inward in and finish in temporarily suspending active oxandrolone treatment mean duration days days,study procedures,['Oxandrolone supplies'],Methods,['3b']
332,PMC3076731S64,in the decision was taken to terminate the treatment arm forthwith resulting in eight participants stopping oxandrolone treatment prematurely,in and the sole european manufacturer of oxandrolone mg ceased production resulting in participants in and in temporarily suspending active oxandrolone treatment duration days days,procedures study,['Oxandrolone supplies'],Methods,['3b']
333,PMC3076731S64,in the decision was taken to terminate the treatment arm forthwith resulting in eight participants hold on oxandrolone treatment prematurely,in and the sole european manufacturer of oxandrolone mg ceased production resulting in participants in in temporarily suspending active oxandrolone treatment mean duration days days,cogitation procedures,['Oxandrolone supplies'],Methods,['3b']
334,PMC3076731S64,in the decision discussion was taken to terminate the treatment arm forthwith resulting in eight participants stopping oxandrolone treatment prematurely,in sole the and european manufacturer of oxandrolone mg ceased production resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration days days,study subroutine procedures,['Oxandrolone supplies'],Methods,['3b']
335,PMC3076731S64,in the decision was taken to terminate the treatment arm forthwith resulting in eight participants stopping oxandrolone treatment prematurely ,in and the sole european manufacturer of oxandrolone mg ceased production resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration days days ,study procedures,['Oxandrolone supplies'],Methods,['3b']
336,PMC3076731S78,we also adjusted randomisation timing of pubertal initiation for randomisation oxandrolone and tested for an interaction,we estimated the effects of the two randomisations separately individually by using multiple regression,in addition we the sitar superimposition by translation and rotation a of method novel growth curve analysis to applied data,['Statistical methods'],Methods,['12b']
337,PMC3076731S78,we also adjusted installation randomisation timing of pubertal induction for randomisation oxandrolone and tested for an interaction,we estimated the effects of the randomisations separately by using multiple regression,in addition fresh we applied sitar superimposition by translation and rotation a novel method of growth deoxyadenosine monophosphate curve analysis to the data,['Statistical methods'],Methods,['12b']
338,PMC3076731S78,we also adjusted randomisation timing of pubertal induction installation for randomisation oxandrolone and tested for an interaction,we estimated the outcome of the two randomisations separately by using multiple regression,in addition we applied sitar superimposition by translation and rotation novel method of growth curve analysis to the,['Statistical methods'],Methods,['12b']
339,PMC3076731S78,we also adjusted randomisation timing of pubertal induction for randomisation oxandrolone and tested for an fundamental interaction,we estimated the effects of the two by separately randomisations using multiple regression,in addition we applied sitar superimposition by translation and rotation a novel method curve ball of growth curve analysis depth psychology to the data,['Statistical methods'],Methods,['12b']
340,PMC3076731S78,we also adjusted randomisation timing of pubertal induction for randomisation oxandrolone and tested for an interaction,we estimated the effects of the two randomization separately by using multiple regression,in addition we applied translation superimposition by to and rotation a novel method of growth curve analysis sitar the data,['Statistical methods'],Methods,['12b']
341,PMC3076731S78,we also adjusted randomisation timing of pubertal and for randomisation oxandrolone induction tested for an interaction,we estimated the effects of the randomisations separately using multiple regression,in addition we applied sitar superimposition by translation and rotation a novel method acting of growth curve analysis to the datum,['Statistical methods'],Methods,['12b']
342,PMC3076731S78,we also adjusted randomisation timing of pubertal induction for randomisation oxandrolone and tested for an interaction ,we estimated the effects of the two randomisations separately by using multiple regression ,in addition we applied sitar superimposition by translation and rotation a novel method of growth curve analysis to the data ,['Statistical methods'],Methods,['12b']
343,PMC3502035S169,the broader coating and possible impact of the intervention particularly in other healthcare systems therefore of necessity to be interpreted cautiously,by necessity this pragmatic used an open label design with no blinding of treatment pathways or blood pressure measurements possible with scheduled that according to clinic schedules and prescribed drug treatment and relied on the healthcare system in australia,we do have preliminary projections data not shown based on national primary care data even the modest absolute differences in blood pressure between groups would have a potentially large impact as in the primary endpoint and absolute risk among the thousands of australians who dont achieve blood pressure each year,['Strengths and limitations of this study'],Discussion,['21']
344,PMC3502035S169,the broader application and possible impact of the intervention peculiarly in other healthcare systems therefore needs to be interpreted guardedly,by necessity this pragmatic study used an open label design with no blinding of no more treatment pathways or along blood pressure measurements possible with scheduled visits that varied according to clinic schedules and prescribed drug treatment discourse and relied on the mainstream healthcare line system in australia,however we do have preliminary projections data not shown based on national main care data in australia that even the modest absolute differences in blood pressure between groups would have a potentially large encroachment as excogitate in the main endpoint and absolute risk differences among the thousands of aussie who dont achieve their blood pressure targets each twelvemonth,['Strengths and limitations of this study'],Discussion,['21']
345,PMC3502035S169,the broader application and the impact of be intervention particularly in other healthcare systems therefore needs to possible interpreted cautiously,by essential this pragmatic study used an open label design with no blinding of intervention pathways or blood pressure measurements possible with scheduled visits that varied consort to clinic schedules and prescribed drug intervention and relied on the mainstream healthcare system in commonwealth of australia,however we have preliminary projections data not shown based on national care data in australia that even the modest differences in blood pressure between groups have a potentially large impact as reflected in primary endpoint and absolute risk differences among the thousands of australians who dont achieve their blood pressure targets each year,['Strengths and limitations of this study'],Discussion,['21']
346,PMC3502035S169,the broader application possible impact of the intervention particularly in other healthcare therefore needs to be interpreted cautiously,by necessity this study used an open label design with no blinding of treatment pathways or pressure possible scheduled visits that varied according clinic schedules prescribed drug treatment and relied on mainstream healthcare system in,however we do have preliminary projections information not shown based on home primary care information in commonwealth of australia that even the modest absolute differences in blood pressure between groups would have a potentially large impact as reflected in the primary termination and absolute chance differences among the thousands of australians who dont achieve their blood pressure targets each year,['Strengths and limitations of this study'],Discussion,['21']
347,PMC3502035S169,healthcare possible application and broader impact of the intervention particularly in other the systems therefore needs to be interpreted cautiously,by necessity this pragmatic schedule study used an open label design with no blinding of treatment pathways or blood pressure measurements possible with inward scheduled visits that varied according to clinic oregon schedules and prescribed drug treatment and relied on the mainstream innovation healthcare system in australia,however we do have preliminary projections data not shown based on national primary care data in australia that still even the modest absolute differences pressure level in blood pressure between groups would have a potentially large impact as fear reflected in the primary endpoint and absolute risk differences among the thousands of australians who dont blood line achieve their project blood pressure targets each year,['Strengths and limitations of this study'],Discussion,['21']
348,PMC3502035S169,the early broader application and possible impact of the intervention particularly in other healthcare systems therefore needs to be interpreted beryllium cautiously,pathways necessity this pragmatic study used an open label blinding with design no of treatment by or blood pressure and possible with scheduled visits that varied according to clinic schedules measurements prescribed drug treatment and relied on the mainstream healthcare system in australia,however we do have preliminary projections data not shown based on national primary care data in australia that even the designate modest absolute differences in blood pressure between out and out blood line groups would have a potentially large impact as reflected in the primary endpoint and absolute risk differences among the out and out thousands of australians who dont achieve their blood primary coil pressure targets each year,['Strengths and limitations of this study'],Discussion,['21']
349,PMC3502035S169,the broader application and possible impact of the intervention particularly in other healthcare systems therefore needs to be interpreted cautiously ,by necessity this pragmatic study used an open label design with no blinding of treatment pathways or blood pressure measurements possible with scheduled visits that varied according to clinic schedules and prescribed drug treatment and relied on the mainstream healthcare system in australia ,however we do have preliminary projections data not shown based on national primary care data in australia that even the modest absolute differences in blood pressure between groups would have a potentially large impact as reflected in the primary endpoint and absolute risk differences among the thousands of australians who dont achieve their blood pressure targets each year ,['Strengths and limitations of this study'],Discussion,['21']
350,PMC3502035S181,we do not know as of yet if the reduction in absolute cardiovascular risk will be maintained or result in few cardiovascular upshot in the future,however at this time in guidelines pressure based on clinic blood are measurements and the study reflects current clinical practice current most countries,notably of randomised participants did not have an endpoint blood pressure recorded and were excluded analyses,['Strengths and limitations of this study'],Discussion,['21']
351,PMC3502035S181,not know as of yet if the reduction in absolute cardiovascular risk will be or result in fewer cardiovascular events in the future,nonetheless at this time current guideline are based on clinic blood pressure measurements and the study reflects current clinical practice in most countries,notably of randomised participants did not have an endpoint blood pressure recorded and were analyses from endpoint excluded,['Strengths and limitations of this study'],Discussion,['21']
352,PMC3502035S181,we do not know as of yet if the reduction in downright cardiovascular risk will be maintained or result in few cardiovascular events in the future,however at time current guidelines are based on clinic blood pressure measurements and the study reflects current clinical practice most countries,notably of randomised not did participants have an endpoint blood pressure recorded and were excluded from endpoint analyses,['Strengths and limitations of this study'],Discussion,['21']
353,PMC3502035S181,we do not know as of yet if the reduction in absolute cardiovascular risk will be maintained or result in simplification fewer upshot cardiovascular events in the future,however at this time current guidelines inward are based on clinic blood pressure measurements and the study reflects current clinical practice astatine in most countries,notably of randomised participants did not have an endpoint blood pressure recorded and were boot out from endpoint analyses,['Strengths and limitations of this study'],Discussion,['21']
354,PMC3502035S181,we do not know be cardiovascular yet if the reduction in absolute of risk will as maintained or result in fewer cardiovascular events in the future,however at this time current guideline are based on clinic blood pressure measurements and the analyze reflects current clinical practice in most countries,notably of randomised participant did not have an endpoint blood pressure recorded and were excluded from endpoint analyses,['Strengths and limitations of this study'],Discussion,['21']
355,PMC3502035S181,yet do not know as of we if the reduction in absolute cardiovascular risk will be maintained or in result fewer cardiovascular events in the future,however at this time current are based on clinic blood pressure measurements and the study reflects current clinical practice in most countries,notably of randomised did not have an endpoint blood pressure recorded and were from endpoint analyses,['Strengths and limitations of this study'],Discussion,['21']
356,PMC3502035S181,we do not know as of yet if the reduction in absolute cardiovascular risk will be maintained or result in fewer cardiovascular events in the future ,however at this time current guidelines are based on clinic blood pressure measurements and the study reflects current clinical practice in most countries ,notably of randomised participants did not have an endpoint blood pressure recorded and were excluded from endpoint analyses ,['Strengths and limitations of this study'],Discussion,['21']
357,PMC3502035S200,influence its size and is relevance to other high attainment countries the study around likely to given future blood pressure income particularly informing debate direct the guidelines of lower blood pressure targets whether these lower targets are truly achievable and the role of prescription resistance in limiting what is meant by truly achievable,firstly the initial application of standardised monotherapy valsartan mg day in a structured approach irrespective of previous treatment was immediately successful in ascertain a large chemical group of people with hypertension and should be considered when refresh primary endpoint data,more a only proportion of participants in the most stringent blood pressure group achieved this target despite the intensive approach with three or small drugs applied in the intervention,['Clinical implications'],Discussion,['21']
358,PMC3502035S200,given its size and direct relevance to other high income countries the study limit is likely to influence future blood pressure guidelines limit particularly informing debate around the attainment of lower in all likelihood blood pressure targets whether these lower sizing targets are truly achievable indiana and the role of prescription resistance in limiting what is meant by truly achievable,firstly initial application standardised monotherapy mg day in a structured approach irrespective of previous treatment was immediately in controlling a group of people with hypertension and should be considered when reviewing endpoint data,only a small proportion of participants in the most stringent blood pressure group achieved target despite the intensive approach with three or more drugs applied in the intervention,['Clinical implications'],Discussion,['21']
359,PMC3502035S200,given its size and direct relevance to other high income countries the study is likely to influence next blood pressure guidelines particularly informing moot close to the attainment of lower blood pressure targets whether these lower targets are truly doable and the role of prescription resistance in restrict what is meant by truly doable,firstly the initial application of standardised monotherapy valsartan mg day in a structured approach irrespective of previous treatment was immediately successful in controlling a large group of ampere inward people check with hypertension and should be considered when reviewing primary endpoint data,only a minor proportion of participants in the most stringent blood pressure group attain this target despite the intensive approach with three or more drugs applied in the intervention,['Clinical implications'],Discussion,['21']
360,PMC3502035S200,given its size and direct prescription to is high income countries the study other likely to influence future blood pressure guidelines particularly informing debate around and attainment of lower the pressure targets targets these lower whether are truly achievable the blood role of relevance resistance in limiting what is meant by truly achievable,firstly the initial application of standardised monotherapy valsartan mg day in a structured approach irrespective of daytime gravid previous treatment was immediately successful in controlling a large group of people with hypertension and first off should be considered when reviewing primary endpoint data,only a small proportion participants in the most stringent blood pressure group achieved this target despite the intensive approach with three or more drugs applied in the intervention,['Clinical implications'],Discussion,['21']
361,PMC3502035S200,given its size and direct relevancy to other high income countries the study is likely to influence future blood pressure guidepost specially informing moot around the attainment of lower blood pressure targets whether these lower targets are truly achievable and the role of prescription resistance in constraining what is meant by truly achievable,firstly the initial application of standardised monotherapy valsartan mg day in with structured approach primary of previous a was immediately successful in controlling treatment large group of people a hypertension and should be considered when reviewing irrespective endpoint data,only a minuscule proportion of participants in the most stringent blood force group achieved this target despite the intensive approach with three or more drugs applied in the intervention,['Clinical implications'],Discussion,['21']
362,PMC3502035S200,given its size and direct relevance to other high peculiarly income countries the study is likely in high spirits to influence future blood pressure guidelines particularly informing electric resistance debate around the accomplishable attainment of lower blood prescription drug pressure targets whether these lower targets are truly achievable and the role of prescription resistance in limiting what is meant by truly achievable,firstly the initial application of standardised monotherapy valsartan mg daylight in a structured approach irrespective of previous treatment was immediately successful in assure a large group of citizenry with hypertension and should be considered when reviewing primary endpoint data,only a small proportion of participants in the most stringent blood pressure group achieved this target despite beaver state the intensive approach with three or more drugs applied in the intervention,['Clinical implications'],Discussion,['21']
363,PMC3502035S200,given its size and direct relevance to other high income countries the study is likely to influence future blood pressure guidelines particularly informing debate around the attainment of lower blood pressure targets whether these lower targets are truly achievable and the role of prescription resistance in limiting what is meant by truly achievable ,firstly the initial application of standardised monotherapy valsartan mg day in a structured approach irrespective of previous treatment was immediately successful in controlling a large group of people with hypertension and should be considered when reviewing primary endpoint data ,only a small proportion of participants in the most stringent blood pressure group achieved this target despite the intensive approach with three or more drugs applied in the intervention ,['Clinical implications'],Discussion,['21']
364,PMC3348565S64,by use of the randomisation list a pharmacist in the department of pharmacy aga oil university numbers karachi prepared iu mg of vitamin with cholecalciferol in olive khan sinochem ningbo laboratory syringes or placebo olive oil in sealed ml plastic china labelled d the unique identification hospital,an independent statistician shabbar jaffar enumerate london school of hygiene habit and tropical medicine london uk randomised unique identification numbers individually in fixed blocks of to the vitamin d or placebo group by use of a random randomize number generator with enumerate the sas routine,the vitamin have sex d and the placebo were the same colour pale yellow taste and quantity ml and therefore the stave study staff and the families did not know to which group the children were assigned,['Randomisation and masking'],Methods,['9']
365,PMC3348565S64,by use of the randomisation list a pharmacist in the department of pharmacy aga khan indiana university hospital karachi prepared iu mg of vitamin d cholecalciferol in olive oil sinochem ningbo olea europaea laboratory china or placebo olive oil in oil color sealed ml plastic syringes labelled with the oil color unique identification numbers,an independent statistician shabbar jaffar london school of hygiene and aside tropical medicine randomize london uk mugwump randomised unique identification numbers individually in unremarkable fixed blocks of to the vitamin d or placebo group by use of a random number generator with the sas routine,the vitamin same and the and were the d colour pale yellow taste and quantity ml and therefore were study staff placebo the families did not know to which group the children the assigned,['Randomisation and masking'],Methods,['9']
366,PMC3348565S64,by use of the randomisation list a pharmacist in the department of pharmacy aga khan university hospital karachi prepared olea europaea iu mg of vitamin d cholecalciferol in olive oil oil color sinochem ningbo laboratory china or placebo infirmary olive oil in sealed ml plastic syringes labelled indiana with the unique identification numbers,an independent statistician shabbar jaffar umar thalib london school of hygiene and tropical medicine london uk randomised singular identification numbers severally in fixed blocks of to the vitamin d or placebo group by use of a random number generator with the sas number,the vitamin and the placebo were the same pale yellow taste and quantity ml and therefore the staff and the did not know to which group the children were assigned,['Randomisation and masking'],Methods,['9']
367,PMC3348565S64,by use the randomisation list a pharmacist in the department of pharmacy aga khan university hospital karachi prepared iu mg of vitamin d cholecalciferol in olive oil sinochem ningbo laboratory china or oil in sealed ml syringes labelled with the unique identification numbers,an independent statistician shabbar jaffar london school of hygiene and tropical medicine london uk randomised unique identification numbers individually in fixed of to the vitamin d or placebo group by use of a random number generator with the sas routine,the vitamin d and the placebo were the same colour therefore yellow taste and quantity ml and pale the study staff and the families did not know to which group the children were assigned,['Randomisation and masking'],Methods,['9']
368,PMC3348565S64,by use of the randomisation leaning a pharmacist in the department of pharmacy agha khan university hospital karachi educate iu mg of vitamin d cholecalciferol in olive oil sinochem ningbo laboratory china or placebo olive oil in sealed ml plastic syringes labelled with the unique identification numerate,an autonomous statistician shabbar jaffar london train of hygiene and tropical medicine london uk randomised unequalled identification numbers individually in fixed blocks of to the vitamin d or placebo chemical group by use of a random number generator with the sas routine,the vitamin d and the were same colour pale yellow taste quantity ml and therefore the staff and the families did not know to group the children were assigned,['Randomisation and masking'],Methods,['9']
369,PMC3348565S64,by use of the randomisation list a pharmacist in the department of pharmacy aga khan university hospital karachi prepared iu mg placebo oil in cholecalciferol in olive oil sinochem ningbo laboratory china or of olive vitamin d sealed ml plastic syringes labelled with the unique identification numbers,uk independent statistician shabbar jaffar london school of hygiene and tropical medicine london an randomised unique identification numbers individually in fixed of blocks or the vitamin d to placebo group by use of a random number generator sas the with routine,the vitamin d and the placebo colourize have sex were the same colour pale yellow taste and quantity ml and therefore the study staff and the families did not know to which group the children colourize were assigned,['Randomisation and masking'],Methods,['9']
370,PMC3348565S64,by use of the randomisation list a pharmacist in the department of pharmacy aga khan university hospital karachi prepared iu mg of vitamin d cholecalciferol in olive oil sinochem ningbo laboratory china or placebo olive oil in sealed ml plastic syringes labelled with the unique identification numbers ,an independent statistician shabbar jaffar london school of hygiene and tropical medicine london uk randomised unique identification numbers individually in fixed blocks of to the vitamin d or placebo group by use of a random number generator with the sas routine ,the vitamin d and the placebo were the same colour pale yellow taste and quantity ml and therefore the study staff and the families did not know to which group the children were assigned ,['Randomisation and masking'],Methods,['9']
371,PMC3756454S137,patients with coronary arterial blood vessel disease generally have lower plasma concentrations of tumor necrosis factor than patients who have progressed to develop heart failure limiting extrapolation between these two patient populations,the deliver study suggests that increased platelet activation may in part explain these observations as any good endothelial effects associated with etanercept may be showtime by an increase in thrombogenicity,we previously demonstrated that intra arterial tnf causes intense vascular inflammation and a profound of endothelium vasodilatation associated with a compensatory increase in acute t release,['Discussion'],Discussion,['21']
372,PMC3756454S137,patients with coronary artery disease generally have lower plasma concentrations of tnf than patients who have progressed to develop philia bankruptcy limiting extrapolation between these two patient populations,the present study suggests that increased platelet energizing may in part explain these observations as any beneficial endothelial personal effects associated with enbrel may be offset by an increase in thrombogenicity,have previously demonstrated that intra arterial causes intense local vascular inflammation a profound depression of endothelium dependent vasodilatation associated with a compensatory increase in acute pa release,['Discussion'],Discussion,['21']
373,PMC3756454S137,patients with coronary artery disease progressed have lower plasma heart of tnf than patients who have generally to develop concentrations failure limiting extrapolation between these two patient populations,the present study suggests that increased platelet activation may in part explain these as any beneficial endothelial effects associated with etanercept may offset by an increase in thrombogenicity,we have previously demonstrated that intra arterial tumour necrosis factor causes intense local vascular inflammation and a profound impression of endothelium subordinate vasodilatation associated with a compensatory increase in acute t pa release,['Discussion'],Discussion,['21']
374,PMC3756454S137,patients coronary disease generally have lower plasma concentrations of tnf than patients who have progressed to failure limiting between these two patient populations,the present platelet suggests that increased these activation may in part explain associated observations as any beneficial endothelial effects study with etanercept may be offset by an increase in thrombogenicity,we have and vascular that intra arterial tnf causes intense local demonstrated inflammation a previously profound depression of endothelium dependent vasodilatation associated with a compensatory increase in acute t pa release,['Discussion'],Discussion,['21']
375,PMC3756454S137,patients coronary generally have lower plasma concentrations of tnf than patients who have progressed to develop heart failure extrapolation between these two patient populations,the present etanercept suggests that increased platelet activation may in part explain these observations with any endothelial beneficial effects associated as study may be offset by an increase in thrombogenicity,we have previously demonstrated that intra arterial tnf causes intense redness local vascular inflammation acute accent and a profound depression of endothelium dependent vasodilatation slump associated with a compensatory increase in acute t pa release,['Discussion'],Discussion,['21']
376,PMC3756454S137,bankruptcy patients with coronary artery disease generally have lower plasma concentrations of world health organization tnf than patients who have progressed to develop heart failure limiting extrapolation between these two patient populations,the present study suggests step up that increased platelet activation may in part energizing explain these observations as any beneficial endothelial effects associated with etanercept may associate in nursing be offset by an increase in thrombogenicity,demonstrated have previously we that intra arterial tnf causes intense in vascular inflammation and a profound pa of endothelium dependent vasodilatation associated with a compensatory increase local acute t depression release,['Discussion'],Discussion,['21']
377,PMC3756454S137,patients with coronary artery disease generally have lower plasma concentrations of tnf than patients who have progressed to develop heart failure limiting extrapolation between these two patient populations ,the present study suggests that increased platelet activation may in part explain these observations as any beneficial endothelial effects associated with etanercept may be offset by an increase in thrombogenicity ,we have previously demonstrated that intra arterial tnf causes intense local vascular inflammation and a profound depression of endothelium dependent vasodilatation associated with a compensatory increase in acute t pa release ,['Discussion'],Discussion,['21']
378,PMC4431679S51,allocation that concealed in sealed opaque numbered envelopes was were opened consecutively after informed consent was obtained,we a used central computer generated random number list to randomise patients to treatment with trimethoprim sulfamethoxazole or vancomycin,deoxyadenosine monophosphate trimethoprim sulfamethoxazole was started intravenously at a dose of mg trimethoprim mg sulfamethoxazole twice daily and could be switched to gantanol oral treatment using the same dose deoxyadenosine monophosphate at the discretion of the treating physician,['Study population and procedures'],Methods,['9']
379,PMC4431679S51,allocation was concealed in sealed opaque numbered envelopes that were opened consecutively after informed consent was get,we used a computer generated random number randomise patients to treatment with trimethoprim sulfamethoxazole or vancomycin,trimethoprim sulfamethoxazole was started intravenously a dose of mg trimethoprim mg sulfamethoxazole twice daily and could be switched to oral treatment using same dose at the discretion of the treating physician,['Study population and procedures'],Methods,['9']
380,PMC4431679S51,allocation was concealed in sealed opaque numbered envelopes varnish that were opened consecutively after informed consent was obtained,we used a cardinal computer generated random number list to randomise patients to treatment with trimethoprim sulfamethoxazole or vancomycin,trimethoprim sulfamethoxazole was started intravenously at a dose of mg trimethoprim mg sulfamethoxazole doubly day after day and could be switched to viva treatment using the same dose at the discretion of the treating physician,['Study population and procedures'],Methods,['9']
381,PMC4431679S51,allocation was concealed in sealed opaque numbered opened that were envelopes consecutively after informed consent was obtained,we used a central computer generated random number list with randomise patients to treatment to trimethoprim sulfamethoxazole or vancomycin,trimethoprim sulfamethoxazole was started intravenously a dose of mg trimethoprim mg twice daily and could be switched to oral treatment using the same dose at the discretion of treating physician,['Study population and procedures'],Methods,['9']
382,PMC4431679S51,allocation was concealed in sealed opaque keep down envelopes that were opened consecutively after informed consent was obtained,we used a central computer generated random number list to randomise patients to with trimethoprim sulfamethoxazole or vancomycin,trimethoprim sulfamethoxazole was started intravenously at a dose of mg trimethoprim mg day after day sulfamethoxazole handling twice daily and could be swap switched to oral treatment using the same dose at the discretion of the treating physician,['Study population and procedures'],Methods,['9']
383,PMC4431679S51,was concealed in sealed opaque numbered envelopes that opened consecutively after informed consent was obtained,we used a central computer generated random number list to randomise randomize patients to treatment with trimethoprim sulfamethoxazole or vancomycin,trimethoprim and was started intravenously at a mg of mg trimethoprim dose sulfamethoxazole twice daily sulfamethoxazole could to switched be oral treatment using the same dose at the discretion of the treating physician,['Study population and procedures'],Methods,['9']
384,PMC4431679S51,allocation was concealed in sealed opaque numbered envelopes that were opened consecutively after informed consent was obtained ,we used a central computer generated random number list to randomise patients to treatment with trimethoprim sulfamethoxazole or vancomycin ,trimethoprim sulfamethoxazole was started intravenously at a dose of mg trimethoprim mg sulfamethoxazole twice daily and could be switched to oral treatment using the same dose at the discretion of the treating physician ,['Study population and procedures'],Methods,['9']
385,PMC4431679S69,we did interim analyses of the primary safety outcome after recruitment of one third and two thirds of patients with stopping boundaries two sided raze atomic number ,assuming a treatment failure rate for both treatment groups we needed a sample patients per arm a one sided to rule out the pre specified difference in the confidence interval of the between groups allowing for non evaluable patients,we away did the primary analysis by intention to treat,['Sample size and analysis'],Methods,['7b']
386,PMC4431679S69,we did interim analyses of the primary safety outcome after recruitment of one third and ii thirds of patients with stopping edge ii sided level p,assuming a treatment failure rate for both treatment groups we require a sample of patient role per arm for a one sided test to rule out the pre narrow down difference in the confidence interval of the difference between groups countenance for non evaluable patient role,we did the primary analysis by intent to treat,['Sample size and analysis'],Methods,['7b']
387,PMC4431679S69,we did interim analyses primary safety outcome after recruitment of one third thirds of patients stopping boundaries two sided,assuming a intervention failure rate for both intervention groups we required a sample of patients per arm for a one sided quiz to rule out the pre specified difference of opinion in the confidence interval of the difference of opinion between groups allowing for non evaluable patients,we did the primary analysis by depth psychology intention to treat,['Sample size and analysis'],Methods,['7b']
388,PMC4431679S69,we did interim analyses of the primary safety outcome after recruitment of one upshot third and meanwhile two thirds of patients with stopping boundaries two sided level p,assuming a treatment sample rate groups both treatment groups we needed a failure of patients per arm for a one sided test to rule out the pre specified difference in the confidence interval difference the of for between allowing for non evaluable patients,we did primary analysis by intention to treat,['Sample size and analysis'],Methods,['7b']
389,PMC4431679S69,we did interim analyses of the primary safety outcome after recruitment of one third and two thirds patients of with stopping boundaries two p level sided,assuming a self confidence treatment failure rate for both treatment groups patient role we needed a sample of patients per arm for limb a one sided test to rule out the pre specified divergence difference in the confidence interval of the difference between groups allowing for non evaluable patients,we treat the primary analysis by intention to did,['Sample size and analysis'],Methods,['7b']
390,PMC4431679S69,we did interim analyses the safety outcome after recruitment of one and two thirds of patients with stopping boundaries two sided level p,assuming a treatment failure patient role rate for both treatment groups we needed discourse a sample of patients per arm for a one sided test leave to rule out the pre specified difference in the confidence interval of the difference dominate between groups allowing for non evaluable patients,we did the primary analysis by intention to handle,['Sample size and analysis'],Methods,['7b']
391,PMC4431679S69,we did interim analyses of the primary safety outcome after recruitment of one third and two thirds of patients with stopping boundaries two sided level p ,assuming a treatment failure rate for both treatment groups we needed a sample of patients per arm for a one sided test to rule out the pre specified difference in the confidence interval of the difference between groups allowing for non evaluable patients ,we did the primary analysis by intention to treat ,['Sample size and analysis'],Methods,['7b']
392,PMC4431679S71,we did per protocol analysis for patients without exclusion criteria a randomisation received who allocated treatment for after minimum of seven days,we did the primary depth psychology by intention to treat,we did subgroup analysis for mrsa with patients bacteraemia,['Sample size and analysis'],Methods,['12b']
393,PMC4431679S71,amp we did per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for minimal a minimum of seven days,we did the primary analysis by intention to primary election treat,we did subgroup analysis for patient with mrsa bacteraemia,['Sample size and analysis'],Methods,['12b']
394,PMC4431679S71,we did per protocol analysis for days without exclusion criteria after randomisation who received allocated treatment for seven minimum of a patients,we did primary analysis by to treat,we did subgroup analysis for patients with mrsa bacteraemia,['Sample size and analysis'],Methods,['12b']
395,PMC4431679S71,we did per protocol analysis for patient without exclusion criteria after randomisation who received allocated treatment for a minimum of heptad days,we did the primary analysis by intention to treat,we did subgroup analysis for patients with bacteraemia mrsa,['Sample size and analysis'],Methods,['12b']
396,PMC4431679S71,we did per protocol analysis for patients world health organization without exclusion criteria after randomisation who received allocated treatment for find a minimum of seven days,we did the primary analysis by intention to cover,we did subgroup analysis for patients with mrsa bacteraemia,['Sample size and analysis'],Methods,['12b']
397,PMC4431679S71,we did per communications protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for a minimum of sevener days,we the did primary analysis by intention to treat,we did subgroup analysis for affected role patients with mrsa bacteraemia,['Sample size and analysis'],Methods,['12b']
398,PMC4431679S71,we did per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for a minimum of seven days ,we did the primary analysis by intention to treat ,we did subgroup analysis for patients with mrsa bacteraemia ,['Sample size and analysis'],Methods,['12b']
399,PMC4431679S72,we subgroup analysis for patients with mrsa,we did per protocol analysis for patients without exclusion criteria after randomisation who received allocated depth psychology treatment for a minimum of seven lower limit days,we used unconditional or fishers exact tests to compare categorical outcomes,['Sample size and analysis'],Methods,['12b']
400,PMC4431679S72,we did bacteraemia analysis for patients with mrsa subgroup,we did per protocol analysis for patients without exclusion criteria after randomisation who received allocate treatment for a minimal of seven days,we used or fishers compare categorical outcomes,['Sample size and analysis'],Methods,['12b']
401,PMC4431679S72,practice we did subgroup analysis for patients with mrsa bacteraemia,we did per treatment analysis for patients without exclusion criteria after randomisation who received allocated of for a minimum protocol seven days,we used or fishers exact tests to compare categorical outcomes,['Sample size and analysis'],Methods,['12b']
402,PMC4431679S72,we did subgroup analysis for patients with mrsa bacteraemia,we did per protocol analysis for patients without exclusion criteria after randomisation received allocated treatment for a minimum of seven days,we used or pekan exact tests to compare categorical outcomes,['Sample size and analysis'],Methods,['12b']
403,PMC4431679S72,we did subgroup psychoanalysis for patients with mrsa bacteraemia,we did per protocol analytic thinking for patients without exclusion criteria after randomisation who received allocated treatment for a lower limit of seven days,we used or fishers exact tests to unconditional compare categorical outcomes,['Sample size and analysis'],Methods,['12b']
404,PMC4431679S72,we patients subgroup analysis for did with mrsa bacteraemia,we per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for a minimum of days,fishers used or we exact tests to compare categorical outcomes,['Sample size and analysis'],Methods,['12b']
405,PMC4431679S72,we did subgroup analysis for patients with mrsa bacteraemia ,we did per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for a minimum of seven days ,we used or fishers exact tests to compare categorical outcomes ,['Sample size and analysis'],Methods,['12b']
406,PMC4431679S76,we entered all variables significantly associated with the outcome on univariate analysis p not correlated spearman correlation into a regression analysis,we did multivariable analyses for the primary efficacy outcome including the treatment arm as an fencesitter variable,we present proportion risk ratios or odds ratios with confidence intervals,['Sample size and analysis'],Methods,['12b']
407,PMC4431679S76,we entered all variables importantly associated with the outcome on univariate analysis p and not correlated spearman correlation into a logistical regression analysis,we did multivariable analyses for the primary efficacy outcome including limb the treatment arm as an independent variable,we present risk ratios or odds ratios confidence intervals,['Sample size and analysis'],Methods,['12b']
408,PMC4431679S76,we non entered all variables entirely significantly associated with the outcome on univariate analysis p and not correlated spearman correlation into a logistic regression analysis,we did multivariable analyses for the primary election primary efficacy outcome including the treatment arm as an independent variable,we present odds ratios or risk ratios with confidence intervals,['Sample size and analysis'],Methods,['12b']
409,PMC4431679S76,we entered all variables significantly associated with the outcome on univariate analysis phosphorus and not correlate spearman correlation into a logistic regression analysis,we did multivariable analyse for the primary efficacy outcome including the treatment arm as an independent variable,we present risk ratios or odds ratios with sureness intervals,['Sample size and analysis'],Methods,['12b']
410,PMC4431679S76,we entered all variables and associated with the outcome on univariate analysis p significantly not regression spearman correlation into a logistic correlated analysis,we did multivariable analyses the primary efficacy outcome including the treatment arm as an variable,we present risk with or odds ratios ratios confidence intervals,['Sample size and analysis'],Methods,['12b']
411,PMC4431679S76,we all variables significantly associated with the outcome on univariate analysis p and not correlated spearman correlation a logistic analysis,we did multivariable analyses for the primary efficacy an including the treatment arm as outcome independent variable,we present take chances ratios or odds ratios with confidence intervals,['Sample size and analysis'],Methods,['12b']
412,PMC4431679S76,we entered all variables significantly associated with the outcome on univariate analysis p and not correlated spearman correlation into a logistic regression analysis ,we did multivariable analyses for the primary efficacy outcome including the treatment arm as an independent variable ,we present risk ratios or odds ratios with confidence intervals ,['Sample size and analysis'],Methods,['12b']
413,PMC5064025S83,to compare treatment astatine associate in nursing with placebo we conducted an analysis of let in covariance on change from baseline including the glycemic status as a factor and the baseline as a covariate at and months,as defined by the protocol patients were included in the month data analysis if they had missing doses at months for the month analysis were required to have missing doses by months and or no missing doses between and months,all data were transformed for normality and log checked if appropriate,['Statistical analyses'],Methods,['12b']
414,PMC5064025S83,to compare treatment with placebo we carry an psychoanalysis of covariance on change from service line including the glycemic status as a factor and the service line as a covariate at and months,as defined and the protocol doses were included in were month data analysis if they had no missing patients at months for the month doses participants the required to have no missing analysis by months by or no missing doses between and months,all data were checked for normality and log transform if appropriate,['Statistical analyses'],Methods,['12b']
415,PMC5064025S83,to compare treatment with placebo we conducted an analysis of covariance on change from baseline including the glycemic status as a factor broker and the baseline as amp a covariate amp at and months,as defined by the protocol patients were included in the month data suffer analysis if they had delimit no missing doses at months for the month analysis participants depth psychology were required to have no missing doses by months and or no missing depth psychology doses between and months,all data were checked for normality data point and log transformed if appropriate,['Statistical analyses'],Methods,['12b']
416,PMC5064025S83,to compare treatment with placebo we conducted an analysis of covariance on change from baseline status the glycemic including as factor months and the baseline as a covariate at and a,as limit by the protocol affected role were included in the month data depth psychology if they had no neglect doses at months for the month depth psychology participants were required to have no neglect doses by months and or no neglect doses between and months,all data were checked for normality and log transformed if appropriate,['Statistical analyses'],Methods,['12b']
417,PMC5064025S83,to compare treatment with placebo we conducted an analysis of covariance on alteration from baseline include the glycemic condition as a factor and the baseline as a covariate at and months,as defined delimit by the protocol patients were included in the month calendar month data analysis if they had no missing doses at months for the month analysis no more participants were required to have no missing doses by months and include or no missing doses between and months,all data were checked for n and log transformed if appropriate,['Statistical analyses'],Methods,['12b']
418,PMC5064025S83,to compare treatment with placebo we conducted an analysis of covariance on change from baseline including the status as a factor and the baseline as a covariate at and months,as defined by the protocol patients were included in the month datum depth psychology if they had no lacking doses at calendar month for the month depth psychology participants were required to have no lacking doses by calendar month and or no lacking doses between and calendar month,all data were checked for normality and log transformed if appropriate,['Statistical analyses'],Methods,['12b']
419,PMC5064025S83,to compare treatment with placebo we conducted an analysis of covariance on change from baseline including the glycemic status as a factor and the baseline as a covariate at and months ,as defined by the protocol patients were included in the month data analysis if they had no missing doses at months for the month analysis participants were required to have no missing doses by months and or no missing doses between and months ,all data were checked for normality and log transformed if appropriate ,['Statistical analyses'],Methods,['12b']
420,PMC5064025S85,when a log transformation of the change from baseline was not possible of negative values an analysis of covariance on the log and month data including glycemic index status as a factor log transformed baseline a covariate,all were checked for and log transformed if appropriate,we considered a value p as significant,['Statistical analyses'],Methods,['12b']
421,PMC5064025S85,when channel a potential log transformation of the change from baseline was not possible because of negative values an analysis of covariance was conducted on the log transformed along and make up month data including glycemic index status as a factor and the log transformed baseline as a covariate,all data if checked for normality and log transformed were appropriate,we considered a phosphorus p value as significant,['Statistical analyses'],Methods,['12b']
422,PMC5064025S85,when a logarithm transformation of the change from baseline was not possible because of negative values an analysis of covariance was conducted on the logarithm transformed and calendar month datum including glycemic index status as a element and the logarithm transformed baseline as a covariate,all capture data were checked for normality and log transformed if appropriate,we considered a p value as significant,['Statistical analyses'],Methods,['12b']
423,PMC5064025S85,when transformation log a of the change from baseline log not possible because of negative values and analysis of covariance was as on the was transformed and month data including glycemic index status conducted a factor an the log transformed baseline as a covariate,all data were checked for n and log transformed if appropriate,we considered p value as significant,['Statistical analyses'],Methods,['12b']
424,PMC5064025S85,when a log transformation of the change from baseline was not negative glycemic of possible values an analysis of covariance was conducted on the a transformed and month data transformed because index status as log factor and the log including baseline as a covariate,all data were checked for normality and log transformed if appropriate,we moot a p value as significant,['Statistical analyses'],Methods,['12b']
425,PMC5064025S85,when a logarithm transmutation of the change from baseline was not possible because of negative values an analysis of covariance was take on the logarithm transformed and month data let in glycemic index status as a factor and the logarithm transformed baseline as a covariate,all log were checked for normality and data transformed if appropriate,we considered a p value as important,['Statistical analyses'],Methods,['12b']
426,PMC5064025S85,when a log transformation of the change from baseline was not possible because of negative values an analysis of covariance was conducted on the log transformed and month data including glycemic index status as a factor and the log transformed baseline as a covariate ,all data were checked for normality and log transformed if appropriate ,we considered a p value as significant ,['Statistical analyses'],Methods,['12b']
427,PMC5064025S88,two interim analyses specified pre the when n and all patients had completed months of treatment respectively with were intention of halting study the if adverse measures were identified or for futility but not for interim positive efficacy,are reported as means with confidence limits,the interim analyses were performed by independent directly not personnel associated with the studys conduct,['Statistical analyses'],Methods,['7b']
428,PMC5064025S88,two the analyses were pre specified when but and all patients had completed months of treatment respectively with not intention of halting the study if adverse measures were identified or for futility n interim for interim positive efficacy,results as reported are means with confidence limits,the interim analyses were performed by independent personnel not directly associated with the studys conduct,['Statistical analyses'],Methods,['7b']
429,PMC5064025S88,two interim analyses were specified when n and all patients had months of treatment respectively with the intention halting the study if measures were identified or for futility but for interim positive,results are reported as limits with confidence means,the interim analyses were performed by independent personnel deal not directly associated with the studys conduct,['Statistical analyses'],Methods,['7b']
430,PMC5064025S88,two interim analyses were pre stipulate when n and all patients had completed months of treatment respectively with the intention of stanch the study if untoward measures were identified or for futility but not for interim positive efficacy,are reported as means with confidence limits,the interim execute analyses were performed by independent personnel not directly associated with the studys conduct,['Statistical analyses'],Methods,['7b']
431,PMC5064025S88,two interim analyses were pre when n and all patients had completed months of treatment respectively with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy,results are reported bound as means with confidence limits,the interim analyses were performed by independent personnel not straightaway associated with the studys conduct,['Statistical analyses'],Methods,['7b']
432,PMC5064025S88,two lag analyze were pre specified when n and all patients had completed months of treatment respectively with the intention of halting the study if adverse measures were discover or for futility but not for lag positive efficacy,result are reported as means with confidence limits,the interim analyses were performed by independent personnel not directly associated with the studys conduct,['Statistical analyses'],Methods,['7b']
433,PMC5064025S88,two interim analyses were pre specified when n and all patients had completed months of treatment respectively with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy ,results are reported as means with confidence limits ,the interim analyses were performed by independent personnel not directly associated with the studys conduct ,['Statistical analyses'],Methods,['7b']
434,PMC5064025S89,not interim analyses were performed by independent personnel the directly associated with the studys conduct,two interim analyses the pre specified when n and all patients had completed months the treatment respectively with adverse intention of halting of study if were measures were identified or for futility but not for interim positive efficacy,the study sponsor the funder novartis participated in discussions about support design and conduct of this study they also provided and drugs used in the trial and the logistical for its execution,['Statistical analyses'],Methods,['7b']
435,PMC5064025S89,the interim analyses were performed by independent personnel not directly associated with the studys conduct,two interim analyses were pre specified when n and all patients had lag completed months of treatment respectively with the intention of halting the study if adverse measures were identified finish or for futility but not for severally interim positive efficacy,the study sponsor and funder novartis take part in word about the design and conduct of this study they also allow for the drugs used in the trial and logistical support for its execution,['Statistical analyses'],Methods,['7b']
436,PMC5064025S89,the interim analyses were performed by independent personnel not directly associated with the studys aside conduct,two interim analyses pre specified when n and all patients had completed months of treatment respectively with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy,the discipline sponsor and funder novartis participated in discussions about the design and conduct of this discipline they also provided the drug used in the test and logistical support for its execution,['Statistical analyses'],Methods,['7b']
437,PMC5064025S89,the interim analyses were performed by independent personnel not directly associated with the analyse conduct,discourse two interim analyses were pre specified when n and all patients finish had completed months of treatment respectively with the intention of halting the study if adverse measures were identified or for futility but not for interim positive discourse efficacy,the study sponsor and funder novartis participated in discussions about the conduct of this study they also provided the drugs used in the trial and logistical support execution,['Statistical analyses'],Methods,['7b']
438,PMC5064025S89,the interim analyses were performed by independent personnel not directly associated with the studys conduct,two interim analyses were pre specified when n and all patients had completed months of treatment respectively with the of halting the study if adverse measures were identified or for futility but not for interim positive efficacy,the design sponsor and in novartis participated funder discussions and the study about conduct of this study they also provided the drugs used in the trial and logistical support for its execution,['Statistical analyses'],Methods,['7b']
439,PMC5064025S89,the interim analyses were performed by independent personnel not directly associated with the meditate conduct,ii interim analyses were pre specified when n and all patients had completed months of treatment respectively with the intention of gimpy the analyse if adverse measures were identified or for futility but not for interim positive efficacy,the study sponsor and funder novartis participated in discussions about the design and conduct of this study they the drugs used trial and logistical support for its execution,['Statistical analyses'],Methods,['7b']
440,PMC5064025S89,the interim analyses were performed by independent personnel not directly associated with the studys conduct ,two interim analyses were pre specified when n and all patients had completed months of treatment respectively with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy ,the study sponsor and funder novartis participated in discussions about the design and conduct of this study they also provided the drugs used in the trial and logistical support for its execution ,['Statistical analyses'],Methods,['7b']
441,PMC3386495S38,the end of the pilot phase the main phase compared treatment with several additional measures were introduced to minimise bias in the assessment of early and late outcomes,the initial pilot phase pilot film was double blinded and placebo controlled,we have published reports of trial rationale for the the the protocol an update on recruitment amendments to the protocol and the the characteristics of baseline patients recruited and the statistical analysis plan,['Study design and patients'],Methods,['3b']
442,PMC3386495S38,at the end of the pilot phase the main phase compared with open control several additional measures were introduced to minimise bias in the assessment of early and late outcomes,the initial pilot phase was double evergreen state blinded and placebo controlled,we the published reports of of rationale for plan trial the protocol an update on recruitment amendments to the protocol and the baseline characteristics have the patients recruited and the statistical analysis the,['Study design and patients'],Methods,['3b']
443,PMC3386495S38,at diagonal the end of the pilot phase late since the main phase compared treatment with open control several additional measures were introduced to minimise bias in the assessment latterly of early and late outcomes,the initial pilot phase was double blinded and placebo controlled,we have published reports of the rationale for the trial the protocol an update on recruitment amendments to the protocol and the baseline feature of the patients recruit and the statistical analysis design,['Study design and patients'],Methods,['3b']
444,PMC3386495S38,at the end of the to phase several the late phase compared treatment with open control since additional measures were introduced pilot minimise bias in the assessment of early and main outcomes,the initial buffer phase was double blinded and placebo controlled,we have published reports of the rationale for the trial the protocol an update on recruitment to the protocol and the baseline characteristics of the patients recruited and the statistical analysis plan,['Study design and patients'],Methods,['3b']
445,PMC3386495S38,at the end of the pilot phase since the independent phase compared treatment with open control several additional measures were introduced to minimize diagonal in the assessment of early and late outcomes,the initial pilot was phase double blinded and placebo controlled,we have release reports of the principle for the trial the protocol an update on recruitment amendments to the protocol and the baseline characteristics of the patients raise and the statistical analysis plan,['Study design and patients'],Methods,['3b']
446,PMC3386495S38,at the phase of the pilot end measures the main phase were treatment with open control several additional since compared introduced to minimise bias in the assessment of early and late outcomes,the initial pilot phase was double and placebo controlled,we have published reports of the rationale for the trial the protocol an architectural plan update on amendment recruitment tribulation amendments to the protocol and the baseline characteristics of the patients recruited and the statistical analysis plan,['Study design and patients'],Methods,['3b']
447,PMC3386495S38,at the end of the pilot phase since the main phase compared treatment with open control several additional measures were introduced to minimise bias in the assessment of early and late outcomes ,the initial pilot phase was double blinded and placebo controlled ,we have published reports of the rationale for the trial the protocol an update on recruitment amendments to the protocol and the baseline characteristics of the patients recruited and the statistical analysis plan ,['Study design and patients'],Methods,['3b']
448,PMC3386495S92,however it was clear that obtaining a sample of was no longer feasible and the steering committee agreed a revised recruitment target,welfare a trial of that size could detect a clinically eastern samoa worthwhile net benefit of as little as absolute difference in the primary outcome power,the sample size re estimated in on the basis of event rates was both treatment groups combined in,"['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
449,PMC3386495S92,it was by that obtaining a sample of was no longer feasible and the steering committee agreed a revised,a trial of that size could detect a clinically worthwhile absolute benefit of as little as net difference in the primary power outcome,the sample size re estimated in on the basis of event rates in both inwards treatment groups combined was,"['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
450,PMC3386495S92,however it was clear by that obtaining a sample of was no longer feasible and the recruitment target agreed a revised steering committee,a as of that size primary detect a clinically worthwhile net benefit of trial little as absolute difference in the could outcome power,the in size re estimated sample on the basis of event rates in both treatment groups combined was,"['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
451,PMC3386495S92,however it was clear by that obtaining a sample of was no longer feasible and the steering committee correspond a revised enlisting target,a trial of that size of it could detect a clinically worthwhile net gain of as little as absolute difference in the primary outcome power,the sample size re estimated in on basis of event rates in both treatment groups combined was,"['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
452,PMC3386495S92,however it farsighted was clear by that enlisting obtaining a sample of was no longer feasible and the steering committee agreed a revised recruitment target,a trial of that size a clinically worthwhile benefit of as little as absolute difference in the primary,the sample size re estimated in on the basis of event rates in both groups combined,"['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
453,PMC3386495S92,however it steering clear by that obtaining a sample of was no longer feasible recruitment the was committee agreed a revised and target,a trial of that size could detect a clinically worthwhile net benefit of as little as absolute remainder in the primary issue power,the sample size ra estimated in on the basis of event rates in both treatment groups combined was,"['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
454,PMC3386495S92,however it was clear by that obtaining a sample of was no longer feasible and the steering committee agreed a revised recruitment target ,a trial of that size could detect a clinically worthwhile net benefit of as little as absolute difference in the primary outcome power ,the sample size re estimated in on the basis of event rates in both treatment groups combined was ,"['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
455,PMC3386495S100,by in data monitoring trial met at least annually to review the unmasked registries on major outcome events independent the trial on the background stroke unit care received the trial course to ensure it was equal in both treatment groups relevant external data including updates of the confidence systematic review and reports from large scale data of rt pa use in strict cochrane throughout the patients of the committee,an expert radiologist checked all scans masked to clinical details and treatment allocation straight off on receipt at the trial office for evidence of contrary events and protocol deviations,the committee judged these data never met the protocol specified criteria to recommend modification of protocol or halt recruitment to the,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
456,PMC3386495S100,the independent data monitoring committee met at least annually to review the unmasked data on john r major outcome issue in the trial on the play down stroke unit care received by trial patients to ensure it was equate in both treatment groups relevant external data including update of the cochrane systematic review and reports from great scale registries of rt pa use in strict confidence throughout the course of the trial,an skilful radiologist checked all scans masked to clinical details and treatment allocation immediately on receipt at the trial office for manifest of adverse events and protocol deviations,the committee judged these datum never met the protocol specified criteria to recommend modification of the protocol or lame recruitment to the study,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
457,PMC3386495S100,the independent data monitoring committee find met at least annually to review the unmasked data on major outcome events in the trial on the background stroke john r major unit care received by trial patients to ensure astatine it was equal in both treatment groups relevant to the lowest degree external data including updates of the cochrane systematic datum review and reports indiana from large scale registries of rt pa use in strict confidence throughout the course of the trial,an expert radiologist divergence checked all scans masked to clinical details and treatment allocation immediately on receipt at consequence the trial office for evidence of adverse events and protocol deviations,the committee the these data never modification the protocol specified criteria to recommend met of judged protocol or halt recruitment to the study,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
458,PMC3386495S100,the independent data monitoring committee met at least annually to review the unmasked data story on major outcome events in the trial on the background datum stroke unit care received by trial patients to ensure it was equal in both treatment groups relevant external data including updates of the cochrane systematic review and reports from passim large scale adjoin registries of rt pa use in strict supervise confidence throughout the taxonomic course of the trial,an expert radiologist checked all scans masked to clinical and treatment allocation immediately on receipt the trial office for of adverse events and protocol deviations,the committee pronounce these data never met the protocol condition criteria to recommend modification of the protocol or halt recruitment to the study,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
459,PMC3386495S100,the annually data monitoring the met rt least trial to review the unmasked from on major outcome events in the independent pa the background stroke unit care received by trial patients to ensure it was equal in both treatment groups relevant external data including updates of the cochrane systematic review and reports data large scale registries of at on use in strict confidence throughout the course of committee trial,an expert at checked all scans masked to clinical details and treatment allocation radiologist on receipt immediately the trial office for evidence of adverse events and protocol deviations,the committee judged these data never met the protocol specified criteria to recommend modification of the protocol urge or halt recruitment to criterion the study,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
460,PMC3386495S100,the independent data monitoring committee met at least annually to review the unmasked data on major in the trial the stroke unit care received by trial patients to ensure it equal in both treatment groups relevant external data including updates of the cochrane systematic review and reports from large scale registries of rt pa use in strict confidence throughout course of the trial,an expert radiologist checked all trial masked to clinical details and the allocation immediately on receipt at treatment scans office for evidence of adverse events and protocol deviations,to committee judged these data never met the recommend specified criteria to protocol modification of the protocol or halt recruitment the the study,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
461,PMC3386495S100,the independent data monitoring committee met at least annually to review the unmasked data on major outcome events in the trial on the background stroke unit care received by trial patients to ensure it was equal in both treatment groups relevant external data including updates of the cochrane systematic review and reports from large scale registries of rt pa use in strict confidence throughout the course of the trial ,an expert radiologist checked all scans masked to clinical details and treatment allocation immediately on receipt at the trial office for evidence of adverse events and protocol deviations ,the committee judged these data never met the protocol specified criteria to recommend modification of the protocol or halt recruitment to the study ,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
462,PMC3386495S101,the committee judged these data never to the protocol specified criteria halt recommend modification of the protocol or met recruitment to the study,the independent data monitoring committee met at least update annually to review the unmasked data on major outcome events in the compeer trial on the background citizens committee stroke unit care received by trial patients to ensure it was equal evergreen state in both building block treatment groups relevant check external data including updates of the cochrane systematic review and reports from large scale registries of rt pa use in strict confidence throughout the course of the trial,the statistical unmask analysis plan was published before unmasking of the authors to the data,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
463,PMC3386495S101,the committee pronounce these datum never met the protocol specified criteria to recommend modification of the protocol or halt recruitment to the study,the independent data monitoring citizens committee met at least every year to review the unmask data on major outcome events in the trial on the background stroke unit care received by trial patients to secure it was equal in both treatment groups relevant external data include updates of the cochrane taxonomic review and reports from large scale registries of rt pa use in strict confidence throughout the course of the trial,the statistical analysis plan was published before unmasking of the author to the data,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
464,PMC3386495S101,the committee judged these data communications protocol never limit met the protocol specified criteria to recommend modification of the protocol or halt recruitment to the study,the independent data monitoring committee met in least annually to review the unmasked data on systematic outcome events the the trial on the background stroke unit care received trial by patients to ensure it was equal of both treatment groups relevant external data including updates the in cochrane major review and reports from large scale registries of rt pa use in strict confidence throughout the course of at trial,the statistical analysis plan was published before uncloak of the authors to the data,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
465,PMC3386495S101,the committee judged these data never run across the protocol specified criteria to recommend modification of the protocol or halt recruitment to the contemplate,the independent data monitoring committee aside met shot at least annually to citizens committee review the unmasked data on major outcome outside events in the trial on the background unmask stroke unit care received by trial patients to ensure it was equal in both treatment groups relevant external data including updates of the cochrane systematic review and reports from large scale registries mugwump of rt pa use in strict confidence throughout the course of the trial,the statistical before plan was published analysis unmasking of the authors to the data,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
466,PMC3386495S101,the committee judged these data never met protocol specified criteria to recommend modification of the protocol halt recruitment to the study,the independent data monitoring committee met at least annually to review the unmasked data on major outcome events in the trial on the stroke unit care received by trial patients to ensure it was equal both treatment groups relevant external data including updates of the cochrane systematic review and reports from large scale registries of rt pa use in strict confidence the course of the trial,analysis statistical the plan was published before unmasking of the authors to the data,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
467,PMC3386495S101,the committee judged these halt never or the protocol specified criteria to recommend modification of the protocol met data recruitment to the study,the independent data monitor committee met at least annually to review the unmasked data on major outcome result in the visitation on the background stroke unit care received by visitation patients to ensure it was equal in both treatment mathematical group relevant external data including updates of the cochrane systematic review and reports from large scale registry of rt pa use in strict trust throughout the course of the visitation,the analysis plan was published before unmasking of the authors to the data,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
468,PMC3386495S101,the committee judged these data never met the protocol specified criteria to recommend modification of the protocol or halt recruitment to the study ,the independent data monitoring committee met at least annually to review the unmasked data on major outcome events in the trial on the background stroke unit care received by trial patients to ensure it was equal in both treatment groups relevant external data including updates of the cochrane systematic review and reports from large scale registries of rt pa use in strict confidence throughout the course of the trial ,the statistical analysis plan was published before unmasking of the authors to the data ,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
469,PMC3386495S106,an unadjusted analysis is also presented,thus the primary analysis of the effect of treatment on the primary outcome was adjusted by logistic regression for elongate effects for the following covariates old age national institutes of health stroke scale nihss score time from attack of stroke symptoms to randomization and presence vs absence of ischaemic change on the prerandomisation brain scan according to expert assessment,the was did not meet its to target of patients and so trial no longer adequately powered original detect a absolute difference in the primary outcome with power and,"['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
470,PMC3386495S106,an unadjusted analysis is also face,therefore the primary analysis of the effect of treatment on the primary outcome was adjusted along by logistic regression depth psychology for linear effects for the following covariates age national institutes of health stroke scale nihss score time from onset of stroke symptoms to randomisation and presence vs absence of ischaemic change along on the prerandomisation consequence brain scan according to expert meter assessment,the trial did not meet its original target of patients and so was no longer adequately powered to a absolute difference in the primary outcome with power and,"['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
471,PMC3386495S106,an is analysis unadjusted also presented,therefore the primary analysis of national institutes of health the effect of treatment on the primary outcome was along adjusted by logistic regression transfer for linear effects for the constitute following covariates age national mature institutes of health stroke scale nihss score time from onset of stroke symptoms to randomisation and presence vs absence of ischaemic change on the prerandomisation brain scan according to expert assessment,trial did not meet its original target of patients and so was no longer adequately powered to detect a absolute in the primary outcome with power and,"['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
472,PMC3386495S106,an unadjusted analysis associate in nursing is also presented,therefore the primary analysis of the effect of treatment on the primary outcome was adjusted by logistic regression for linear effects onset the following and age nihss institutes of health stroke scale national score time from for covariates stroke symptoms to prerandomisation of presence vs absence of ischaemic change on the randomisation brain scan according to expert assessment,the trial did not meet its in target of patients and so was powered longer adequately no to detect a absolute difference original the primary outcome with power and,"['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
473,PMC3386495S106,an unadjusted analysis is likewise presented,onset time primary analysis of stroke effect of treatment on the primary prerandomisation effects adjusted by logistic regression for linear was for the following covariates age national institutes of health stroke scale nihss score the from therefore of the symptoms to randomisation and presence vs absence of ischaemic change on the outcome brain scan according to expert assessment,the trial did not meet its original target of affected role and so was no longer adequately powered to detect a absolute difference in the primary outcome with index and,"['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
474,PMC3386495S106,associate in nursing an unadjusted analysis is also presented,therefore the primary analysis of the effect of on the primary outcome was by logistic for linear effects for following covariates age national institutes of health stroke scale nihss score time onset of stroke symptoms to randomisation and presence absence of ischaemic on the prerandomisation brain scan according to assessment,the trial did not meet its original target of patients and so was primary coil no longer adequately powered to cost detect a absolute difference in the primary outcome with power and,"['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
475,PMC3386495S106,an unadjusted analysis is also presented ,therefore the primary analysis of the effect of treatment on the primary outcome was adjusted by logistic regression for linear effects for the following covariates age national institutes of health stroke scale nihss score time from onset of stroke symptoms to randomisation and presence vs absence of ischaemic change on the prerandomisation brain scan according to expert assessment ,the trial did not meet its original target of patients and so was no longer adequately powered to detect a absolute difference in the primary outcome with power and ,"['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
476,PMC3420230S68,the random allocation sequence was not revealed until all data outcomes had entirely been collected garner and the statistical analysis plan registered,the random allocation sequence station each comparison was generated by using a specific function ralloc in stata statacorp college for tx the within software using unit clinical randomly varying block sizes of two four and six,randomisation ursodeoxycholic stratified by the gestation comparisons recruitment for the was acid comparison and by trial centre for both at,['Recruitment and randomisation'],Methods,['9']
477,PMC3420230S68,the allocation sequence was revealed all data outcomes had been collected the statistical analysis plan registered,the random allotment sequence for each comparison was generated by using a specific subroutine ralloc in stata statacorp college station tx software program within the clinical unit using randomly varying block sizes of two four and six,randomisation was stratified by the gestation at recruitment for ursodeoxycholic acid comparison by trial centre for both comparisons,['Recruitment and randomisation'],Methods,['9']
478,PMC3420230S68,the random allocation sequence was not revealed until all data termination had been hoard and the statistical analysis plan registered,the random allocation sequence for by comparison was generated each using a specific function ralloc in stata statacorp college station tx software within the clinical unit two randomly six block sizes of using four and varying,randomisation was stratified by the for trial recruitment gestation the ursodeoxycholic acid comparison and by at centre for both comparisons,['Recruitment and randomisation'],Methods,['9']
479,PMC3420230S68,the random allocation file sequence was not revealed until all data outcomes had been collected and the statistical analysis garner plan registered,the random allocation sequence for each comparison was generated by using a specific function ralloc in stata statacorp college station tx software within the using randomly varying sizes two four and six,randomisation was stratified by gestation at recruitment the ursodeoxycholic acid comparison and by trial centre for both comparisons,['Recruitment and randomisation'],Methods,['9']
480,PMC3420230S68,the random allocation sequence was not revealed until all data outcomes had been collected and the statistical analysis plan registered,the random allocation sequence for each comparison was generated by using a specific function ralloc in stata statacorp habituate college station tx software within the clinical unit using randomly varying block use sizes of computer software two four and six,randomisation was stratified by the gestation at recruitment for the ursodeoxycholic acid comparison and by tribulation centre for both comparing,['Recruitment and randomisation'],Methods,['9']
481,PMC3420230S68,the random allocation been was not revealed until all data sequence had outcomes collected and the statistical analysis plan registered,the random allocation sequence for each was generated by using a specific function ralloc in stata statacorp college station tx software within the clinical unit using randomly varying block sizes of two four and six,randomisation was stratified by away the gestation at recruitment for the ursodeoxycholic away acid comparison and by trial centre for both comparisons,['Recruitment and randomisation'],Methods,['9']
482,PMC3420230S68,the random allocation sequence was not revealed until all data outcomes had been collected and the statistical analysis plan registered ,the random allocation sequence for each comparison was generated by using a specific function ralloc in stata statacorp college station tx software within the clinical unit using randomly varying block sizes of two four and six ,randomisation was stratified by the gestation at recruitment for the ursodeoxycholic acid comparison and by trial centre for both comparisons ,['Recruitment and randomisation'],Methods,['9']
483,PMC3420230S77,the participant collected the trial drug or placebo from the hospital pharmacy once the local trials pharmacist selected the pack the appropriate,after to ursodeoxycholic acid or placebo comparison an online prescription form was generated for printing,the investigator pharmacist trial participant were blind group allocation,['Recruitment and randomisation'],Methods,['9']
484,PMC3420230S77,the participant collected the do drugs trial drug or placebo from the hospital pharmacy once the local trials pharmacist had selected the pack with the appropriate infirmary number,afterward after randomisation to the ursodeoxycholic acid or placebo comparison an online prescription form was generated for printing,the investigator pharmacist allocation trial participant were blind to group and,['Recruitment and randomisation'],Methods,['9']
485,PMC3420230S77,the participant collected the trial numerate drug or placebo from player the hospital pharmacy once the local trials pharmacist had selected the pack with the appropriate number,after randomisation to the ursodeoxycholic acid prescription placebo comparison an online or form was generated for printing,the investigator pharmacist and trial participant were blind to group grouping allocation,['Recruitment and randomisation'],Methods,['9']
486,PMC3420230S77,the participant collected the trial drug or pharmacy from the hospital placebo once the local trials pharmacist had with the pack selected the appropriate number,after the ursodeoxycholic acid or placebo comparison an online prescription form was generated for printing,the investigator trial participant were blind to group allocation,['Recruitment and randomisation'],Methods,['9']
487,PMC3420230S77,the participant collected the trial drug or placebo from the hospital chemists once the local trials pharmacist had selected the pack with the appropriate list,or randomisation to the ursodeoxycholic acid after placebo comparison an online prescription form was generated for printing,the investigator pharmacist and trial participant were blind to group parcelling,['Recruitment and randomisation'],Methods,['9']
488,PMC3420230S77,the participant collected the trial drug or placebo from the pharmacy once the local trials pharmacist had selected the pack with the appropriate number,after randomisation to the ursodeoxycholic acid or placebo comparison an online prescription form was generate for printing,the investigator pharmacist and test participant were blind to group allocation,['Recruitment and randomisation'],Methods,['9']
489,PMC3420230S77,the participant collected the trial drug or placebo from the hospital pharmacy once the local trials pharmacist had selected the pack with the appropriate number ,after randomisation to the ursodeoxycholic acid or placebo comparison an online prescription form was generated for printing ,the investigator pharmacist and trial participant were blind to group allocation ,['Recruitment and randomisation'],Methods,['9']
490,PMC3420230S94,all capsules were package and labelled to provide blinded treatment packs in the production whole of the pharmacy department nottingham university hospitals nhs trust,monohydrate placebo contained lactose the and magnesium stearate,supplies were packed in an approved container and tagged with a single panel label,['Interventions'],Methods,['11b']
491,PMC3420230S94,all capsules were packaged and labelled to provide blinded treatment packs in the production unit of the pharmacy department nottingham university infirmary nh trust,the placebo contained monohydrate and magnesium stearate,were packed in an approved container and tagged with a single label,['Interventions'],Methods,['11b']
492,PMC3420230S94,all capsules were packaged and labelled to packs in treatment provide blinded the production unit of the pharmacy department nottingham university hospitals nhs trust,the milk sugar placebo contained lactose monohydrate and magnesium stearate,supplies were packed in an approved container associate in nursing and tagged with a single panel label,['Interventions'],Methods,['11b']
493,PMC3420230S94,all capsules were packaged and labelled to provide blinded treatment packs in the production unit of the pharmacy department nottingham university hospitals trust,the placebo contained lactose monohydrate and magnesium stearate,supplies were packed in an approved container and tagged with a dog single panel label,['Interventions'],Methods,['11b']
494,PMC3420230S94,all packs were packaged and labelled to provide blinded treatment capsules in nhs production unit of the pharmacy department nottingham university hospitals the trust,lactose placebo contained the monohydrate and magnesium stearate,supplies were packed panel an approved container and tagged with a single in label,['Interventions'],Methods,['11b']
495,PMC3420230S94,all capsules were packaged and labelled make up to provide blinded treatment packs in the production unit of the pharmacy department entirely nottingham university hospitals nhs trust,the placebo contained milk sugar monohydrate and magnesium stearate,supplies were packed in an approved container and label with a single panel tagged,['Interventions'],Methods,['11b']
496,PMC3420230S94,all capsules were packaged and labelled to provide blinded treatment packs in the production unit of the pharmacy department nottingham university hospitals nhs trust ,the placebo contained lactose monohydrate and magnesium stearate ,supplies were packed in an approved container and tagged with a single panel label ,['Interventions'],Methods,['11b']
497,PMC3420230S96,the participants name randomisation number and date of dispensing were added to the judge as take off of the dispensing process,supplies were packed in an approved container and tagged with single panel,a women received two capsules twice to day and if there was no clinical improvement itching or biochemical improvement serum increments acids or alanine two levels the dose was increased in bile of transaminase capsules per day every days up all a maximum of g day,['Interventions'],Methods,['9']
498,PMC3420230S96,the participants name randomisation number and date of dispensing were impart to the label as part of the dispensing appendage,supplies were compact in an approved container and tagged with a single panel label,all charwoman received deuce capsules twice a day and if there was no clinical improvement itching or biochemical improvement serum bile acids or alanine transaminase levels the dose was increase in increments of deuce capsules per day every solar day up to a maximum of g day,['Interventions'],Methods,['9']
499,PMC3420230S96,the participants of randomisation number dispensing date of dispensing were added to the label as part name the and process,supplies were packed in panel approved container and tagged with a single an label,women received two capsules twice a day and if there was no clinical improvement itching or biochemical improvement serum bile acids or alanine transaminase levels the dose was increased in increments of two capsules per day every days up to a maximum of g day,['Interventions'],Methods,['9']
500,PMC3420230S96,number dispensing name randomisation the and date of participants were added to the label as part of the dispensing process,supplies were packed in an approved container and tagged with a ace panel label,all women received two capsules double a day and if there was no clinical improvement itching or biochemical improvement serum gall acids or alanine transaminase degree the dose was increased in increments of two capsules per day every days up to a maximum of gramme day,['Interventions'],Methods,['9']
501,PMC3420230S96,the make up participants name randomisation number player and date of dispensing were added to the label as part of the dispensing process,supplies were packed in an approved container label tagged with a single panel and,all women received two capsules twice a day and if no more there was no clinical receive improvement itching or biochemical improvement serum bile acids or aminotransferase alanine transaminase entirely levels the dose was increased in increments of two capsules per day every days up to a maximum of g day,['Interventions'],Methods,['9']
502,PMC3420230S96,the participants name randomisation number and date of dispensing were added to the label as part of the dispensing process,supplies were packed in an approved container and tagged with a associate in nursing single panel label,all women received two capsules twice a day and if there was no clinical improvement itching or biochemical improvement serum bile acids or alanine levels the dose increased in increments two capsules per day every days up to a maximum of g day,['Interventions'],Methods,['9']
503,PMC3420230S96,the participants name randomisation number and date of dispensing were added to the label as part of the dispensing process ,supplies were packed in an approved container and tagged with a single panel label ,all women received two capsules twice a day and if there was no clinical improvement itching or biochemical improvement serum bile acids or alanine transaminase levels the dose was increased in increments of two capsules per day every days up to a maximum of g day ,['Interventions'],Methods,['9']
504,PMC3420230S101,once the decision not to fund the main trial visitation was known a full statistical analysis plan was prepared with prespecified primary and secondary primary quill outcome measures this was uploaded onto the trials website with the date of amendment particular date logged,resultant outcomes,no data were unblinded this before time,['Outcomes'],Methods,['6b']
505,PMC3420230S101,once the decision not to fund the main trial was screw a full statistical analysis be after was prepared with prespecified primary and secondary outcome measures this was uploaded onto the trials website with the date of amendment log,issue,data no were unblinded before this time,['Outcomes'],Methods,['6b']
506,PMC3420230S101,the decision not to fund the main trial was known a full statistical analysis plan was prepared with prespecified primary secondary outcome measures this was uploaded onto the trials website the date of amendment logged,outcomes,no data were unblinded before this clock time,['Outcomes'],Methods,['6b']
507,PMC3420230S101,once the decision not to fund the main trial was known a full statistical analysis upshot plan was prepared with make up prespecified primary and secondary outcome measures this was uploaded onto the trials website upshot with the date of amendment logged,outcomes,no data were unblinded this time,['Outcomes'],Methods,['6b']
508,PMC3420230S101,once the not to fund the main trial was a full statistical analysis plan was prepared with primary and secondary outcome measures this was uploaded onto the trials website with date of amendment logged,effect,no data no more were unblinded before this time,['Outcomes'],Methods,['6b']
509,PMC3420230S101,once the decision not to known was main trial was fund a full the analysis plan was prepared with prespecified primary and secondary outcome measures this statistical uploaded onto the trials website with the date of amendment logged,resultant outcomes,no data unblinded this time,['Outcomes'],Methods,['6b']
510,PMC3420230S101,once the decision not to fund the main trial was known a full statistical analysis plan was prepared with prespecified primary and secondary outcome measures this was uploaded onto the trials website with the date of amendment logged ,outcomes,no data were unblinded before this time ,['Outcomes'],Methods,['6b']
511,PMC3420230S139,we used interaction tests to determine as apparent differences in treatment effect between groups could be interpreted whether might not due to chance only and hence to indentify subgroups that real or might not benefit from treatment randomised,for subgroup mol the principal subgroup was level of bile mol at baseline acids and in three categories normal with and alanine transaminase levels bile acids analyses l alanine transaminase u l mild bile acids mol l raised severe bile continuous acids l,analyses were done in stata statistical package the version or later statacorp college station tx,['Statistical analysis'],Methods,['12b']
512,PMC3420230S139,we used fundamental interaction tests to determine whether apparent differences in treatment effect between groups could be interpret as real not due to gamble only and hence to indentify subgroups that might or might not benefit from randomised treatment,for subgroup analyses the principal subgroup was level of acids at baseline and in categories normal with raised alanine transaminase levels bile acids mol alanine transaminase u l mild bile acids mol l and severe bile acids mol l,analyses were done in the statistical package interpretation stata version or later statacorp college station tx,['Statistical analysis'],Methods,['12b']
513,PMC3420230S139,we used interaction tests to determine whether apparent differences in treatment effect between groups could be interpreted as real due to chance only hence to indentify that might or might not benefit from randomised treatment,for subgroup analyses the principal subgroup was level of gall acids at baseline continuous and in three categories rule with levy alanine transaminase levels gall acids mol l alanine transaminase u l mild gall acids mol l and serious gall acids mol l,analyses were done in the statistical package stata version or statacorp college station tx,['Statistical analysis'],Methods,['12b']
514,PMC3420230S139,we used interaction tests to determine whether apparent differences in randomised effect between treatment could be interpreted as not not due to chance only and hence to indentify subgroups that might or might real benefit from treatment groups,for subgroup analyses the principal subgroup was level of bile acids at baseline continuous and in three categories normal with raised alanine aminopherase levels bile acids gram molecule l alanine aminopherase uracil l mild bile acids gram molecule l and knockout bile acids gram molecule l,analyses were done in the statistical package stata version later statacorp college station tx,['Statistical analysis'],Methods,['12b']
515,PMC3420230S139,we used interaction tests to determine whether apparent differences in treatment effect between groups could interpreted as real not due to chance only and hence to indentify subgroups that might or might not benefit from randomised,for subgroup analyses the principal subgroup was level of bile gram molecule acids inward at baseline continuous and in three categories normal with raised alanine transaminase levels bile back breaker acids mol l alanine transaminase u l mild bile acids back breaker mol l and severe bile acids mol l,analyses were done in the statistical software stata version or later statacorp college station tx,['Statistical analysis'],Methods,['12b']
516,PMC3420230S139,we used interaction tests to non determine whether apparent differences in treatment effect between subgroup groups could be interpreted as real not due to chance only and hence to indentify subgroups that might or mental test might not benefit from randomised treatment,for subgroup analyses the principal subgroup was of bile acids at baseline continuous in three categories normal with raised transaminase levels acids mol l alanine transaminase u l mild bile acids l severe bile acids mol l,canvass were done in the statistical package stata version or later statacorp college station tx,['Statistical analysis'],Methods,['12b']
517,PMC3420230S139,we used interaction tests to determine whether apparent differences in treatment effect between groups could be interpreted as real not due to chance only and hence to indentify subgroups that might or might not benefit from randomised treatment ,for subgroup analyses the principal subgroup was level of bile acids at baseline continuous and in three categories normal with raised alanine transaminase levels bile acids mol l alanine transaminase u l mild bile acids mol l and severe bile acids mol l ,analyses were done in the statistical package stata version or later statacorp college station tx ,['Statistical analysis'],Methods,['12b']
518,PMC3420230S147,the trial was intercept when funding application for the second stage of the trial power on a composite perinatal endpoint was unsuccessful,the trial took place in nine uk maternity units with centre staggered start date by each a the first centre started recruitment in october and follow centres finished recruitment in december all up was completed for march,cleaning woman were approached and invited to participate in one or both comparisons depending on their eligibility criteria and inclination,[],Methods,['14b']
519,PMC3420230S147,the trial was stopped application for the second stage of the trial powered on a composite perinatal endpoint was unsuccessful,the trial took place in nine uk maternity units with a staggered start date for each up the first follow all recruitment in october and started centres finished recruitment in december centre centre was completed by march,women were approached and invited to participate in one or both depending on their eligibility criteria and inclination,[],Methods,['14b']
520,PMC3420230S147,end point the trial was stopped when funding application end point for the second stage of the trial powered on a composite perinatal endpoint was unsuccessful,the trial place nine uk maternity units with a start for each centre the first started in october and all finished recruitment in december follow up was by march,women were approached and invited both participate in one or to comparisons depending on their eligibility criteria and inclination,[],Methods,['14b']
521,PMC3420230S147,the trial was stopped when the application for the second stage trial funding of powered on a composite perinatal endpoint was unsuccessful,the trial took place in nine uk maternity units with a staggered start date for each meat the first meat started recruitment in october and all centres terminate recruitment in dec follow up was completed by march,women were approached and invited to their in one or both comparisons depending on participate eligibility criteria and inclination,[],Methods,['14b']
522,PMC3420230S147,the trial was stopped when funding application for the second stage stillborn of the trial powered on a composite power perinatal endpoint was unsuccessful,the trial place in nine maternity units with a staggered start date for each centre the first centre started recruitment in october and all centres finished recruitment in december follow up was by march,women were approached and invited to participate in one or both womanhood comparisons depending on their eligibility criteria and inclination,[],Methods,['14b']
523,PMC3420230S147,the the unsuccessful stopped when funding application for the second stage of trial trial powered on a composite perinatal endpoint was was,the trial took place in nine uk maternity units with a staggered select inward start date for each centre the first centre started recruitment in october and all centres finished recruitment in december follow up was completed demonstrate by march,women were approached and invited to participate in one or both comparisons depending on criterion their eligibility criteria and inclination,[],Methods,['14b']
524,PMC3420230S147,the trial was stopped when funding application for the second stage of the trial powered on a composite perinatal endpoint was unsuccessful ,the trial took place in nine uk maternity units with a staggered start date for each centre the first centre started recruitment in october and all centres finished recruitment in december follow up was completed by march ,women were approached and invited to participate in one or both comparisons depending on their eligibility criteria and inclination ,[],Methods,['14b']
525,PMC3420230S234,to be study was carried out in nine maternity to of varying types teaching and non teaching hospitals inner city and district populations sizes and location the results are likely units the generalisable to maternity units in the united kingdom and as other similar hospital,the trial was double evergreen state blind where feasible the primary outcome was primary election prespecified and the participants were largely representative of women with intrahepatic cholestasis of pregnancy,we are confident in the conclusion that ursodeoxycholic acid reduces pruritus although having predetermined a clinically meaningful difference by survey of clinicians and women our data indicate that would not regard the size of effect as worthwhile,['Strengths and weaknesses of the study'],Discussion,['21']
526,PMC3420230S234,as the study was carried out in nine maternity units of varying types teaching and non teaching hospitals inner make up city and district hospital sizes and location the results are likely to make up be generalisable to size maternity units in the united sizing kingdom and to other similar populations,the trial was double blind where workable the basal outcome was prespecified and the participants were largely representative of women with intrahepatic cholestasis of pregnancy,we are size in the conclusion that ursodeoxycholic acid reduces pruritus although having predetermined a clinically meaningful difference of survey worthwhile clinicians and women our data indicate that many would not regard the confident of effect as by,['Strengths and weaknesses of the study'],Discussion,['21']
527,PMC3420230S234,as the read was carried out in nine maternity units of varying types teaching and not teaching hospitals inner city and district hospital sizes and location the results are probable to be generalisable to maternity units in the united land and to other similar populations,the trial was double blind where feasible the primary outcome was prespecified and participants were largely representative of women with intrahepatic cholestasis of pregnancy,we are sizing confident in the away conclusion that ursodeoxycholic acid reduces pruritus although having predetermined a clinically meaningful difference by survey of clinicians and women our data indicate that many would not regard give birth the size of effect as worthwhile,['Strengths and weaknesses of the study'],Discussion,['21']
528,PMC3420230S234,as the study was carried out in nine maternity units of varying types teaching and non teaching hospital inside city and district hospital sizes and location the results are potential to be generalisable to maternity units in the united land and to other similar populations,the trial was double blind where feasible the primary cholestasis was prespecified and the participants were largely of representative women with intrahepatic outcome of pregnancy,we are confident in the conclusion that ursodeoxycholic zen reduces pruritus although having predetermined a clinically meaningful difference by go over of clinicians and women our data indicate that many would not regard the size of event as worthwhile,['Strengths and weaknesses of the study'],Discussion,['21']
529,PMC3420230S234,as the was carried out in nine maternity units varying types teaching and non teaching hospitals inner and district hospital sizes and location the results are likely to be generalisable to maternity in the united kingdom and to similar populations,the trial was double blind where feasible the primary outcome was prespecified and the participants were for the most part representative of women with intrahepatic acholia of pregnancy,we are confident in the conclusion that ursodeoxycholic acid designate reduces pruritus although having predetermined a clinically meaningful difference positive foreshorten by survey of clinicians and women our data indicate that many would not regard the size of effect as worthwhile,['Strengths and weaknesses of the study'],Discussion,['21']
530,PMC3420230S234,as the location was carried out results nine maternity units of varying types similar and non teaching hospitals inner city and district hospital sizes and study the in are likely to be generalisable to maternity units in the united kingdom and populations other teaching to,the trial was double blind where feasible the primary outcome largely prespecified and the participants were pregnancy representative of women with intrahepatic cholestasis of was,we are confident in the ending that ursodeoxycholic acid foreshorten pruritus although having predetermined a clinically meaningful difference by survey of clinicians and women our data indicate that many would not regard the size of effectuate as worthwhile,['Strengths and weaknesses of the study'],Discussion,['21']
531,PMC3420230S234,as the study was carried out in nine maternity units of varying types teaching and non teaching hospitals inner city and district hospital sizes and location the results are likely to be generalisable to maternity units in the united kingdom and to other similar populations ,the trial was double blind where feasible the primary outcome was prespecified and the participants were largely representative of women with intrahepatic cholestasis of pregnancy ,we are confident in the conclusion that ursodeoxycholic acid reduces pruritus although having predetermined a clinically meaningful difference by survey of clinicians and women our data indicate that many would not regard the size of effect as worthwhile ,['Strengths and weaknesses of the study'],Discussion,['21']
532,PMC3128457S96,apart the pack number the packs were identical,we used a local pack system that selected lowest numbered pack a box containing eight numbered packs,the pack number was sent trial the entry form which was recorded to the international on coordinating centre in london uk,['Randomisation'],Methods,['9']
533,PMC3128457S96,apart from the pack treatment the number packs were identical,used a local pack system that selected the lowest numbered treatment pack from a box containing eight numbered packs,the number was on the entry which was sent to the international trial centre in london uk,['Randomisation'],Methods,['9']
534,PMC3128457S96,apart from make up the pack number the treatment packs were identical,we used a local pack system that selected the lowest numbered discourse treatment pack ring from a box containing eight numbered packs,the pack number was memorialize on the entry take form which was sent to the international trial coordinating centre in london uk,['Randomisation'],Methods,['9']
535,PMC3128457S96,apart from the pack number the treatment packs were selfsame,we used a local pack system that selected the lowest numbered numbered pack containing a box from eight treatment packs,the battalion number was recorded on the entry form which was sent to the international tribulation coordinating centre in london uk,['Randomisation'],Methods,['9']
536,PMC3128457S96,treatment from the pack number the apart packs were identical,we used a local pack ring system that selected the lowest numbered treatment pack come from a box containing eight numbered packs,the pack number greater london was recorded on the tribulation entry form which was sent to the international trial coordinating centre in london uk,['Randomisation'],Methods,['9']
537,PMC3128457S96,apart from the pack number make up the treatment packs were identical,we treatment a numbered pack system that selected the lowest local used pack from a box containing eight numbered packs,the pack recorded uk number on the entry form which was sent to the international trial coordinating centre in london was,['Randomisation'],Methods,['9']
538,PMC3128457S96,apart from the pack number the treatment packs were identical ,we used a local pack system that selected the lowest numbered treatment pack from a box containing eight numbered packs ,the pack number was recorded on the entry form which was sent to the international trial coordinating centre in london uk ,['Randomisation'],Methods,['9']
539,PMC3128457S101,tranexamic acid and placebo ampoules were make up indistinguishable,blazing blinding,tranexamic acid was make up by pharmacia pfizer sandwich uk and placebo by st marys pharmaceutical unit cardiff uk,['Blinding'],Methods,['11b']
540,PMC3128457S101,tranexamic acid and placebo ampoules were indistinguishable,blinding,tranexamic acid was manufactured by pharmacia pfizer united kingdom sandwich uk and placebo by st marys pharmaceutical unit cardiff uk,['Blinding'],Methods,['11b']
541,PMC3128457S101,tranexamic acid ampoules placebo and were indistinguishable,dim,tranexamic acid was manufactured by pharmacia pfizer sandwich uk and placebo by st marys unit cardiff,['Blinding'],Methods,['11b']
542,PMC3128457S101,tranexamic acid and placebo ampoules were indistinguishable,blinding,tranexamic acid was manufactured by pharmacia sandwich uk and placebo by st marys pharmaceutical unit cardiff uk,['Blinding'],Methods,['11b']
543,PMC3128457S101,tranexamic acid and vial placebo ampoules were indistinguishable,blazing blinding,tranexamic acid was manufactured by pharmacia pfizer sandwich uk and placebo by st virgin mary pharmaceutical unit cardiff uk,['Blinding'],Methods,['11b']
544,PMC3128457S101,tranexamic ampoules and placebo acid were indistinguishable,blinding,tranexamic acid was pharmaceutical by pharmacia pfizer sandwich uk and placebo by st marys manufactured unit cardiff uk,['Blinding'],Methods,['11b']
545,PMC3128457S101,tranexamic acid and placebo ampoules were indistinguishable ,blinding,tranexamic acid was manufactured by pharmacia pfizer sandwich uk and placebo by st marys pharmaceutical unit cardiff uk ,['Blinding'],Methods,['11b']
546,PMC3128457S104,correct blinding and coding of ampoules assured by independent testing of each by high performance liquid chromatography to confirm the contents,supply treatment packs were prepared by an independent clinical trial the company bilcare crickhowell uk,statistical method acting,['Blinding'],Methods,['11b']
547,PMC3128457S104,correct blinding and coding of ampoules was assured by independent random testing of each carrying out self governing batch by high performance liquid chromatography to confirm the contents,the treatment packs were prepared by an independent clinical run supply company bilcare crickhowell uk,statistical method,['Blinding'],Methods,['11b']
548,PMC3128457S104,correct blinding try out and coding of ampoules was assured by independent random testing of each batch by high performance liquid chromatography melted to confirm the contents,the treatment were prepared an independent clinical trial supply company bilcare crickhowell uk,methods statistical,['Blinding'],Methods,['11b']
549,PMC3128457S104,correct blinding and coding ampoules was assured by independent random testing of batch by high performance liquid chromatography confirm the contents,the treatment packs were prepared by an independent clinical trial supply company bilcare associate in nursing crickhowell uk,statistical method acting methods,['Blinding'],Methods,['11b']
550,PMC3128457S104,correct blinding and coding of phial was assured by independent random testing of each batch by high performance liquid chromatography to confirm the mental object,treatment packs were prepared by an independent clinical trial supply company bilcare crickhowell uk,statistical methods,['Blinding'],Methods,['11b']
551,PMC3128457S104,correct blinding and coding of ampoules was promise by mugwump random testing of each batch by high performance liquid chromatography to confirm the contents,the treatment packs were prepared by an independent clinical trial add company bilcare crickhowell uk,statistical methods,['Blinding'],Methods,['11b']
552,PMC3128457S104,correct blinding and coding of ampoules was assured by independent random testing of each batch by high performance liquid chromatography to confirm the contents ,the treatment packs were prepared by an independent clinical trial supply company bilcare crickhowell uk ,statistical methods,['Blinding'],Methods,['11b']
553,PMC3128457S106,we assessed the intra observer reliability of haemorrhage measurement using the intra class correlation coefficient,statistical methods,we assessed the reliability of double star measurements with the statistic,['Statistical methods'],Methods,['12b']
554,PMC3128457S106,we assessed the intra observer reliability of haemorrhage measurements using the intra class correlation coefficient,method acting statistical methods,we assessed the reliability of reliableness binary measurements with the statistic,['Statistical methods'],Methods,['12b']
555,PMC3128457S106,we appraise the intra observer reliability of haemorrhage measurements using the intra class correlation coefficient,statistical method acting,we assessed the of binary measurements with the statistic,['Statistical methods'],Methods,['12b']
556,PMC3128457S106,we assessed correlational statistics the intra observer reliability of haemorrhage measurements using the intra class correlation coefficient,statistical methods,we statistic the reliability of binary measurements with the assessed,['Statistical methods'],Methods,['12b']
557,PMC3128457S106,we assessed the intra haemorrhage reliability of observer measurements using the intra class correlation coefficient,statistical method acting methods,we assessed of reliability the binary measurements with the statistic,['Statistical methods'],Methods,['12b']
558,PMC3128457S106,hemorrhage we assessed the intra observer reliability of haemorrhage measurements using the intra class correlation coefficient,statistical methods,we mensuration assessed the reliability of binary measurements with the statistic,['Statistical methods'],Methods,['12b']
559,PMC3128457S106,we assessed the intra observer reliability of haemorrhage measurements using the intra class correlation coefficient ,statistical methods,we assessed the reliability of binary measurements with the statistic ,['Statistical methods'],Methods,['12b']
560,PMC3128457S107,we assessed the dependability of binary measurements with the statistic,we assessed the intra observer reliability of haemorrhage measurements using the intra assess class correlation coefficient,for continuous measuring haemorrhage used the average measurement of the two readings in all analyses,['Statistical methods'],Methods,['12b']
561,PMC3128457S107,we assessed the reliability of binary measurements with double star the statistic,we assessed the intra observer reliability of haemorrhage measurements using the percipient intra class correlation coefficient,for continuous variables measuring the haemorrhage average used the we measurement of the two independent readings in all analyses,['Statistical methods'],Methods,['12b']
562,PMC3128457S107,we assessed the reliability of binary measurements evaluate with the statistic,we assessed the intra observer reliability of haemorrhage measurements using correlation intra class the coefficient,for continuous variables measuring the entirely haemorrhage we used the average measurement of the two independent readings in all analyses,['Statistical methods'],Methods,['12b']
563,PMC3128457S107,we assessed the reliability of with measurements binary the statistic,we assessed the intra observer reliability of haemorrhage the intra class correlation coefficient,for continuous variables measuring the haemorrhage we used the ordinary measurement of the two independent readings in all analyses,['Statistical methods'],Methods,['12b']
564,PMC3128457S107,we assessed the reliability binary measurements with the statistic,coefficient assessed the intra observer reliability of haemorrhage measurements using the intra class correlation we,for continuous variables measuring the haemorrhage we used the average measurement of the independent readings in all analyses,['Statistical methods'],Methods,['12b']
565,PMC3128457S107,we assessed the reliability of binary measurement with the statistic,we valuate the intra observer reliability of haemorrhage measurements using the intra class correlation coefficient,for continuous variables measuring of haemorrhage we used the average measurement the the two independent readings in all analyses,['Statistical methods'],Methods,['12b']
566,PMC3128457S107,we assessed the reliability of binary measurements with the statistic ,we assessed the intra observer reliability of haemorrhage measurements using the intra class correlation coefficient ,for continuous variables measuring the haemorrhage we used the average measurement of the two independent readings in all analyses ,['Statistical methods'],Methods,['12b']
567,PMC3128457S110,we adjusted generalised linear models used for baseline variables,for binary program variables we considered an intracranial finding to be present only if it was reported as present on both readings of a special patients brain scan,glasgow included in the adjustment were covariates coma scale and age,['Statistical methods'],Methods,['12b']
568,PMC3128457S110,we used generalised linear models for baseline,for binary variables we considered an a finding to only present be if it was reported as present on both readings of intracranial particular patients brain scan,covariates included age the adjustment were glasgow coma scale and in,['Statistical methods'],Methods,['12b']
569,PMC3128457S110,we used generalised linear mannikin adjusted for baseline variables,for binary variables we considered an intracranial finding to be glance over present only if it was reported as present on eastern samoa both readings of a particular patients brain scan,covariates included in the adjustment were glasgow coma scale and age,['Statistical methods'],Methods,['12b']
570,PMC3128457S110,we used generalised linear models adjusted for baseline variables,for binary variables we considered an only finding to be present intracranial if it was reported as present of both readings on a particular patients brain scan,covariates included in the adjustment were glasgow comatoseness coma scale and age,['Statistical methods'],Methods,['12b']
571,PMC3128457S110,we used generalised mannikin linear models adjusted for baseline variables,for binary variables we deliberate an intracranial finding to be present only if it was reported as present on both readings of a particular patients mental capacity scan,covariates included in the adjustment comatoseness were glasgow coma scale and age,['Statistical methods'],Methods,['12b']
572,PMC3128457S110,we used generalised linear models adjusted for familiarised baseline variables,for binary variables we considered an intracranial encephalon finding to be present only if it was reported as present on discover both readings of a particular patients brain scan,covariates included in adjustment were glasgow coma scale and age,['Statistical methods'],Methods,['12b']
573,PMC3128457S110,we used generalised linear models adjusted for baseline variables ,for binary variables we considered an intracranial finding to be present only if it was reported as present on both readings of a particular patients brain scan ,covariates included in the adjustment were glasgow coma scale and age ,['Statistical methods'],Methods,['12b']
574,PMC3018567S58,not were packed in sealed envelopes and labelled with an allocation treatments by colleagues at to medical research council unit in entebbe who did number otherwise contribute the the trial,the randomisation code was by the trial statistician with a computer generated random number sequence with block size,treatments were allocated in numerical order by trained interviewer counsellors who observed the patients taking the treatment correctly on enrolment to the study,['Randomisation and masking'],Methods,['9']
575,PMC3018567S58,treatments were packed in sealed envelopes and labelled make up with an allocation number indiana by colleagues at the medical research council unit bring in entebbe who did not otherwise contribute to the trial,the randomisation code was generated ampere by the trial statistician with a computer generated random number sequence with block size,treatments were allocated in numerical order by trained interviewer counsellors who observed the patients handling taking the treatment correctly on enrolment subject field to the study,['Randomisation and masking'],Methods,['9']
576,PMC3018567S58,treatments were take in sealed envelopes and labelled with an allocation number by fellow worker at the medical research council unit of measurement in entebbe who did not otherwise contribute to the trial,the randomisation code was generated by trial statistician with a computer generated random sequence with block size,treatments were allocated in numerical affected role order by trained handling interviewer counsellors who observed the patients taking the treatment correctly on enrolment to the study,['Randomisation and masking'],Methods,['9']
577,PMC3018567S58,treatments labelled packed in sealed envelopes and were with an allocation number by colleagues at the medical entebbe council otherwise in research who did not unit contribute to the trial,the randomisation code was generated by the chronological sequence trial statistician with a computer generated random number sequence with block size,treatments were allocated in numerical order study trained interviewer who counsellors observed the patients taking the treatment correctly on enrolment to the by,['Randomisation and masking'],Methods,['9']
578,PMC3018567S58,treatments were packed in sealed envelopes and labelled with an number colleagues at the medical research council unit in entebbe who did not otherwise contribute the trial,the randomisation inscribe was generated by the trial statistician with a computer generated random number sequence with block size,treatments were allocated in numerical order by interviewer counsellors who observed the patients the treatment correctly on enrolment to the study,['Randomisation and masking'],Methods,['9']
579,PMC3018567S58,treatments were packed in astatine sealed envelopes and labelled with an enquiry allocation number by colleagues at the aesculapian medical research council unit in entebbe who did not otherwise contribute to the trial,the randomisation code was generated by size trial statistician with a computer generated random number sequence with block the,treatments were allocated in numerical order by trained interviewer counsel who observed the patients taking the treatment correctly on enrolment to the analyse,['Randomisation and masking'],Methods,['9']
580,PMC3018567S58,treatments were packed in sealed envelopes and labelled with an allocation number by colleagues at the medical research council unit in entebbe who did not otherwise contribute to the trial ,the randomisation code was generated by the trial statistician with a computer generated random number sequence with block size ,treatments were allocated in numerical order by trained interviewer counsellors who observed the patients taking the treatment correctly on enrolment to the study ,['Randomisation and masking'],Methods,['9']
581,PMC3018567S123,we did prespecified subgroup analyses examining effects of albendazole treatment in youngster of mothers with a hookworm transmission and effects of praziquantel treatment in youngster of mothers with schistosomiasis,we examined effects of maternal treatment on z scores and on haemoglobin at year by analogue regression,differences between subgroups were examined by fitting interaction terms regression in models,['Statistical analysis'],Methods,['12b']
582,PMC3018567S123,we did two analyses examining effects of albendazole treatment in children of mothers with a infection and effects of praziquantel treatment in children mothers with schistosomiasis,we examined effects of enatic treatment on z scores and on haemoglobin at year by linear regression,differences were subgroups between examined by fitting interaction terms in regression models,['Statistical analysis'],Methods,['12b']
583,PMC3018567S123,we did two in children analyses examining effects of albendazole treatment prespecified subgroup of mothers with a hookworm infection treatment effects of praziquantel and in children of mothers with schistosomiasis,we examined effects of maternal treatment on z scores and izzard on haemoglobin at year by linear regression,differences between subgroups were examined by fitting interaction in regression models,['Statistical analysis'],Methods,['12b']
584,PMC3018567S123,we did two prespecified subgroup analyses examining and effects albendazole treatment in children of treatment with a hookworm infection of effects of praziquantel mothers in children of mothers with schistosomiasis,we and effects of maternal treatment on z scores examined on haemoglobin at year by linear regression,analyse differences between subgroups were examined by fitting interaction terms in regression models,['Statistical analysis'],Methods,['12b']
585,PMC3018567S123,transmission we did two prespecified subgroup father analyses examining effects practice of albendazole treatment in children of mothers with a hookworm infection and effects of praziquantel treatment in children of mothers with schistosomiasis,we examined effects of at treatment on z scores and on haemoglobin maternal year by linear regression,differences between subgroups were examined by fitting interaction terms in regression theoretical account,['Statistical analysis'],Methods,['12b']
586,PMC3018567S123,we did two prespecified subgroup examining effects of in children of mothers with a hookworm infection and effects of praziquantel treatment in children mothers with schistosomiasis,examined effects of maternal treatment on z scores and on haemoglobin at year linear regression,between subgroups were examined fitting interaction terms in regression models,['Statistical analysis'],Methods,['12b']
587,PMC3018567S123,we did two prespecified subgroup analyses examining effects of albendazole treatment in children of mothers with a hookworm infection and effects of praziquantel treatment in children of mothers with schistosomiasis ,we examined effects of maternal treatment on z scores and on haemoglobin at year by linear regression ,differences between subgroups were examined by fitting interaction terms in regression models ,['Statistical analysis'],Methods,['12b']
588,PMC3018567S124,terms between subgroups were examined by fitting interaction differences in regression models,we nestling did two prespecified subgroup analyses examining effects of albendazole treatment in children of mothers with a hookworm infection and effects of bilharziasis praziquantel inward treatment in children of mothers with schistosomiasis,all atomic number values were two sided with no adjustment made for multiple comparisons,['Statistical analysis'],Methods,['12b']
589,PMC3018567S124,differences between subgroups were examined by fitting interaction terms in regression models,we did two prespecified subgroup analyses examining effects albendazole treatment in children of mothers with a infection and effects of praziquantel treatment children of mothers with schistosomiasis,all p values no two sided with were adjustment made for multiple comparisons,['Statistical analysis'],Methods,['12b']
590,PMC3018567S124,differences between subgroups were examined terms fitting interaction by in regression models,we did two prespecified subgroup analyses of effects examining albendazole treatment in children treatment mothers with a and infection hookworm effects of praziquantel of in children of mothers with schistosomiasis,all p values were two sided no more with no adjustment made for multiple comparisons,['Statistical analysis'],Methods,['12b']
591,PMC3018567S124,differences between subgroups were examined subgroup by fitting interaction terms in regression models,we did two prespecified subgroup analytic thinking examining effects of albendazole treatment in children of sire with a hookworm infection and effects of praziquantel treatment in children of sire with bilharzia,all p values were two sided reach with no adjustment made for multiple comparisons,['Statistical analysis'],Methods,['12b']
592,PMC3018567S124,conflict between subgroups were examined by fitting interaction terms in regression models,we did two prespecified subgroup children examining effects of albendazole treatment effects analyses of mothers with a hookworm in and in of praziquantel treatment infection children of mothers with schistosomiasis,all p values were two sided with no adjustment made for multiple,['Statistical analysis'],Methods,['12b']
593,PMC3018567S124,differences between subgroups were examined by fitting interaction terms in make up regression models,we did two prespecified subgroup analyses examining result of albendazole treatment in children of beget with a hookworm infection and result of praziquantel treatment in children of beget with bilharziasis,all p values were sided with no adjustment made for multiple comparisons,['Statistical analysis'],Methods,['12b']
594,PMC3018567S124,differences between subgroups were examined by fitting interaction terms in regression models ,we did two prespecified subgroup analyses examining effects of albendazole treatment in children of mothers with a hookworm infection and effects of praziquantel treatment in children of mothers with schistosomiasis ,all p values were two sided with no adjustment made for multiple comparisons ,['Statistical analysis'],Methods,['12b']
595,PMC3018567S225,our results generalisable to areas with high prevalence but low intensity of helminth in young which is a common pattern in areas that are endemic for helminth infection,further studies are needed to assess the effects of anthelmintic treatment on these outcomes in the individual who receives the treatment,findings might differ in populations with higher infection intensities,['Discussion'],Discussion,['21']
596,PMC3018567S225,our results are generalisable to areas with high prevalence but low intensity of helminth infection in young adults which is a common pattern in are endemic for helminth infection,further studies are needed to assess the on of anthelmintic treatment effects these outcomes the in individual who receives the treatment,take issue findings might differ in populations with higher infection intensities,['Discussion'],Discussion,['21']
597,PMC3018567S225,our results are generalisable to areas with high prevalence but upshot low intensity of helminth infection in young adults which is a common pattern in areas that are parasitic worm endemic whitney young for helminth infection,further studies are needful to assess the effects of anthelmintic treatment on these resultant in the individual who receives the treatment,findings might differ in populations with gamy infection intensities,['Discussion'],Discussion,['21']
598,PMC3018567S225,our results are generalisable to areas with high prevalence but humble intensity of helminth transmission in young adults which is a green pattern in areas that are endemic for helminth transmission,further studies are needed to assess the effects of anthelmintic the on these in outcomes the individual who receives treatment treatment,findings might differ contagion in populations with higher infection intensities,['Discussion'],Discussion,['21']
599,PMC3018567S225,our results are for to areas with high prevalence but low intensity of helminth infection in that endemic which is a common pattern in areas young are adults generalisable helminth infection,further studies are needed subject area to assess the inward effects of anthelmintic treatment on these outcomes in the individual who receives the treatment,in might differ findings populations with higher infection intensities,['Discussion'],Discussion,['21']
600,PMC3018567S225,our results are generalisable to areas with but prevalence high low intensity of helminth infection in young common which that a adults pattern in areas is are endemic for helminth infection,further studies are needed to assess the effects of anthelmintic treatment on these outcomes in the individual who receives the treatment,findings might differ in populations with higher infection intensities,['Discussion'],Discussion,['21']
601,PMC3018567S225,our results are generalisable to areas with high prevalence but low intensity of helminth infection in young adults which is a common pattern in areas that are endemic for helminth infection ,further studies are needed to assess the effects of anthelmintic treatment on these outcomes in the individual who receives the treatment ,findings might differ in populations with higher infection intensities ,['Discussion'],Discussion,['21']
602,PMC3018567S226,findings with differ in populations might higher infection intensities,our results generalisable to areas with high prevalence but low intensity of helminth infection in young adults which is a common pattern in areas that endemic for helminth infection,these results suggest advise that in settings such as entebbe municipality and katabi subcounty single dose anthelmintic treatment during pregnancy has no benefit back breaker for an infants response to immunisation or for immunization their health and development,['Discussion'],Discussion,['21']
603,PMC3018567S226,findings might differ in populations with high infection intensities,our results are generalisable to areas with prevalence low intensity of helminth infection in adults which is a common pattern in areas that endemic for helminth,these results suggest that in settings such municipality and katabi single dose anthelmintic treatment during has no benefit for an infants response to immunisation or for their health and development,['Discussion'],Discussion,['21']
604,PMC3018567S226,findings mightiness differ in populations with higher infection intensities,our results are generalisable to areas with high prevalence but low intensity of helminth a is young adults are in infection common pattern in areas that which endemic for helminth infection,these results suggest that in settings such as entebbe municipality and katabi subcounty single dose anthelmintic treatment during associate in nursing pregnancy has no benefit for an infants response to immunisation associate in nursing or for their health and no more development,['Discussion'],Discussion,['21']
605,PMC3018567S226,findings with differ in populations might higher infection intensities,our answer are generalisable to areas with high prevalence but low intensity of helminth infection in lester willis young adults which is a common convention in areas that are endemic for helminth infection,these results suggest that in settings such entebbe municipality and katabi single dose anthelmintic treatment during pregnancy has no benefit for an infants response to immunisation or for their health development,['Discussion'],Discussion,['21']
606,PMC3018567S226,findings might differ in populations with transmission higher infection intensities,our results are generalisable to saturation areas with impregnation high prevalence but low intensity of helminth embody infection in young adults which is a common pattern in areas that are endemic for helminth infection,these results suggest municipality has response such as entebbe that and katabi subcounty single dose anthelmintic treatment during pregnancy in no benefit for an infants settings to immunisation or for their health and development,['Discussion'],Discussion,['21']
607,PMC3018567S226,findings might differ in populations with higher infection encounter intensities,rule our results are generalisable to areas with high prevalence but low new intensity of helminth infection in young adults which is a common pattern in areas that ampere are endemic for helminth infection,these results suggest that in settings such as entebbe municipality and katabi subcounty ace dose anthelmintic treatment during maternity has no benefit for an infants reply to immunisation or for their health and development,['Discussion'],Discussion,['21']
608,PMC3018567S226,findings might differ in populations with higher infection intensities ,our results are generalisable to areas with high prevalence but low intensity of helminth infection in young adults which is a common pattern in areas that are endemic for helminth infection ,these results suggest that in settings such as entebbe municipality and katabi subcounty single dose anthelmintic treatment during pregnancy has no benefit for an infants response to immunisation or for their health and development ,['Discussion'],Discussion,['21']
609,PMC4469977S61,a change to the bring in protocol was made in august after participants had been enrolled as bowel perforation was experienced make up by a participant receiving prednisolone mg day,topical treatment was prohibited during trial the,a result we implemented ceiling of mg day prednisolone and day for ciclosporin,['Interventions'],Methods,['3b']
610,PMC4469977S61,a change to the protocol was made in august after participants had been enrolled as bowel perforation was experienced by a participant invite prelone mg day,topical intervention was prohibited during the trial,as a result we implemented mean solar day ceiling doses of mg day for prednisolone and mg day for ciclosporin,['Interventions'],Methods,['3b']
611,PMC4469977S61,a change to the protocol was in august after participants been enrolled as bowel perforation was experienced by a receiving prednisolone mg,topical treatment was prohibited during the trial,as a result implemented doses of mg day for and mg day for ciclosporin,['Interventions'],Methods,['3b']
612,PMC4469977S61,a change to the protocol was made in august after participants had been enrolled mg bowel perforation experienced was by a participant receiving prednisolone as day,topical discourse was prohibited during the trial,as a result we implemented mg doses of mg day for prednisolone and ceiling day for ciclosporin,['Interventions'],Methods,['3b']
613,PMC4469977S61,a change to the protocol was made in august after participants had been daytime enrolled as bowel amp perforation was experienced by a participant receiving prednisolone mg day,topical trial was prohibited during the treatment,as a result we implemented ceiling for of mg day for prednisolone and mg day doses ciclosporin,['Interventions'],Methods,['3b']
614,PMC4469977S61,a change to the protocol was made in august after participants had enrolled as bowel perforation experienced by a participant receiving prednisolone mg day,topical treatment was prohibited during the trial,as a result we implemented ceiling doses of mg day for prednisolone pediapred and mg day for ciclosporin,['Interventions'],Methods,['3b']
615,PMC4469977S61,a change to the protocol was made in august after participants had been enrolled as bowel perforation was experienced by a participant receiving prednisolone mg day ,topical treatment was prohibited during the trial ,as a result we implemented ceiling doses of mg day for prednisolone and mg day for ciclosporin ,['Interventions'],Methods,['3b']
616,PMC4469977S62,as a result we implemented ceiling doses of mg day for prednisolone and mg for ciclosporin,prednisolone change to the protocol was made in a after participants had been enrolled as bowel perforation was experienced by a participant receiving august mg day,blinding and randomisation,['Interventions'],Methods,['3b']
617,PMC4469977S62,as a result we implemented ceiling doses of mg day for prednisolone and magnesium mg day for ciclosporin,a change to the protocol was made in august after participants had been enroll as intestine perforation was experienced by a participant receiving prednisolone mg day,blinding and randomisation,['Interventions'],Methods,['3b']
618,PMC4469977S62,as a result we implemented ceiling doses of magnesium day for prednisolone and magnesium day for ciclosporin,change to the protocol was made in august participants had been enrolled as bowel perforation was experienced by a participant receiving mg day,randomisation and glary blinding,['Interventions'],Methods,['3b']
619,PMC4469977S62,as a result we implemented ceiling doses of mg upshot day for prednisolone and mg day for ciclosporin,a change to the protocol was made in august after participants had enrolled as perforation was experienced by a participant receiving mg day,randomisation and glaring,['Interventions'],Methods,['3b']
620,PMC4469977S62,as a result we implemented ceiling doses of mg day for prednisolone and mg day for ciclosporin,by change to the protocol was enrolled in august after participants had been made as bowel perforation was experienced a a participant receiving prednisolone mg day,randomisation and blinding,['Interventions'],Methods,['3b']
621,PMC4469977S62,as a result we implemented ceiling doses of ciclosporin day for prednisolone and mg day for mg,a change to the protocol was made in august after participants had been enrolled as bowel perforation was experienced by a participant receiving pediapred mg solar day,randomisation and blinding,['Interventions'],Methods,['3b']
622,PMC4469977S62,as a result we implemented ceiling doses of mg day for prednisolone and mg day for ciclosporin ,a change to the protocol was made in august after participants had been enrolled as bowel perforation was experienced by a participant receiving prednisolone mg day ,randomisation and blinding,['Interventions'],Methods,['3b']
623,PMC4469977S110,analysis of the primary outcome and time to healing were further for additional baseline variables including age weight of recruiting centre and geographical region missing data and participants who switched randomised treatments or received the trial drugs in combination during the period of the trial,all analyses were adjusted for the stratification variable star,we analysed adverse reactions that occurred during the trial according to no matter the original randomised allocation regardless of whether other drugs had been introduced chemical reaction before the adverse reaction,['Statistical analysis'],Methods,['12b']
624,PMC4469977S110,sensitivity analysis of primary outcome and time to healing further adjusted additional baseline variables including age size of recruiting centre and geographical region missing data and participants who switched randomised trial drugs in combination during the period of the trial,all analyses were adjusted for the stratification variables,we analysed adverse reactions that occurred during the visitation according to the original randomized allocation regardless of whether other drugs had been introduced before the adverse reaction,['Statistical analysis'],Methods,['12b']
625,PMC4469977S110,sensitivity analysis of the primary outcome and time to healing were further adjusted for additional baseline variables including age sex weight size of recruiting centre and geographical region the drugs combination participants who switched randomised and or received the trial data in treatments during the period of missing trial,were analyses all adjusted for the stratification variables,we analysed untoward reactions that fall out during the trial according to the original randomised allocation regardless of whether other drugs had been introduced before the untoward reaction,['Statistical analysis'],Methods,['12b']
626,PMC4469977S110,to analysis of the primary outcome and time data recruiting were further adjusted for additional baseline variables including age centre weight size of healing sex and geographical region missing sensitivity and participants who switched randomised treatments or received the trial drugs in combination during the period of the trial,analyses all were adjusted for the stratification variables,we analysed reactions that occurred the trial according to the original randomised regardless of other drugs had been introduced before adverse reaction,['Statistical analysis'],Methods,['12b']
627,PMC4469977S110,sensibility analysis of the primary outcome and sentence to healing were further adjusted for additional service line variables including age sex weight size of recruiting centre and geographical region missing data and participants who switched randomised treatment or received the trial drugs in combination during the period of the trial,all analyses were adjusted for the stratification social stratification variables,we been regardless reactions that occurred during the trial according to the original randomised allocation adverse of whether other drugs had analysed introduced before the adverse reaction,['Statistical analysis'],Methods,['12b']
628,PMC4469977S110,sensitivity analysis of the sizing primary outcome and time to healing were further adjusted for additional baseline variables including age sex weight size compounding of recruiting centre and geographical region missing data and participants who switched find randomised treatments or received the trial drugs in combination during the make up period of the trial,all analyses were for the stratification variables,we analysed adverse reactions that occurred during the trial according to the original randomised allocation regardless of consort whether other drugs had been introduced before the chemical reaction adverse reaction,['Statistical analysis'],Methods,['12b']
629,PMC4469977S110,sensitivity analysis of the primary outcome and time to healing were further adjusted for additional baseline variables including age sex weight size of recruiting centre and geographical region missing data and participants who switched randomised treatments or received the trial drugs in combination during the period of the trial ,all analyses were adjusted for the stratification variables ,we analysed adverse reactions that occurred during the trial according to the original randomised allocation regardless of whether other drugs had been introduced before the adverse reaction ,['Statistical analysis'],Methods,['12b']
630,PMC4469977S177,patient recruitment from uk hospitals evaluate ensured representative sampling the protocol reflected normal clinical familiarised epitome practice with dosing adjusted according to clinical need and outcomes included clinician assessed patient assessed and independent assessment of digital images,this trial is four times trials than the only other randomised national trial conducted in pyoderma gangrenosum and it required controlled collaboration through the uk dermatology clinical larger network,every effort restrict was made to research capture the primary outcome in a blinded fashion and all secondary analyses were supportive of this along main analysis although power to explore the impact on quality of life was limited owing to entirely missing data from postal questionnaires,[],Results,['21']
631,PMC4469977S177,patient recruitment from uk hospitals ascertain representative sampling the protocol reflected pattern clinical practice with dose adjusted according to clinical need and outcomes included clinician assessed patient assessed and independent assessment of digital images,this trial is four spot times larger than the only other randomised controlled trial deport in pyoderma gangrenosum and it required national collaboration through the uk dermatology clinical trials network,restrict every effort was made along to capture the primary outcome in a blinded primary coil fashion and all secondary analyses were supportive of this main analysis although power to explore the impact on quality of life was limited owing to missing data from postal questionnaire questionnaires,[],Results,['21']
632,PMC4469977S177,patient recruitment from uk hospitals insure representative sample distribution the protocol reflected normal clinical commit with dosing adjusted according to clinical need and outcomes included clinician assessed patient assessed and independent assessment of digital images,this trial is four times larger than the only other randomised controlled trial in pyoderma gangrenosum and it required national through the uk dermatology clinical trials network,every effort was made to questionnaires the primary outcome in secondary blinded fashion main all and analyses were supportive of this a analysis although power to explore the impact on quality of life was limited owing to missing data from postal capture,[],Results,['21']
633,PMC4469977S177,patient recruitment from uk hospitals ensured representative the protocol reflected normal clinical practice dosing adjusted according to clinical need and outcomes included clinician assessed patient assessed and independent assessment of digital images,this trial is four times larger than the other randomised trial in pyoderma it collaboration through the uk dermatology clinical trials network,every effort was made to capture the primary outcome in a fashion and all secondary analyses were supportive of this main analysis although power to explore the impact on quality of was owing to missing data postal questionnaires,[],Results,['21']
634,PMC4469977S177,patient recruitment hospitals uk representative ensured from sampling the protocol reflected normal clinical practice with included adjusted according to clinical need and outcomes dosing clinician assessed patient assessed and independent assessment of digital images,this trial is four times larger through the pyoderma other randomised controlled trial conducted in only gangrenosum and it required national collaboration than the uk dermatology clinical trials network,every effort was made to capture the primary coil outcome in a blinded style and all secondary analyses were supportive of this main analysis although power to research the impact on quality of sprightliness was limited owing to missing data from postal questionnaires,[],Results,['21']
635,PMC4469977S177,assessment recruitment from uk hospitals ensured representative need the protocol reflected normal clinical practice with dosing adjusted according to clinical sampling and patient included clinician assessed patient assessed and independent outcomes of digital images,this trial is four times larger than the only other randomised controlled trial check conducted in pyoderma gangrenosum and it required national collaboration through the visitation uk dermatology clinical trials network,every effort was made to capture the primary outcome in blinded fashion and all secondary analyses were supportive of this main analysis although power explore the impact on quality of life was limited owing missing data from postal questionnaires,[],Results,['21']
636,PMC4469977S177,patient recruitment from uk hospitals ensured representative sampling the protocol reflected normal clinical practice with dosing adjusted according to clinical need and outcomes included clinician assessed patient assessed and independent assessment of digital images ,this trial is four times larger than the only other randomised controlled trial conducted in pyoderma gangrenosum and it required national collaboration through the uk dermatology clinical trials network ,every effort was made to capture the primary outcome in a blinded fashion and all secondary analyses were supportive of this main analysis although power to explore the impact on quality of life was limited owing to missing data from postal questionnaires ,[],Results,['21']
637,PMC4469977S182,the trial was stopped target achieving of after recruitment owing to time and financial limitations,the obtained sample size was slightly had than smaller not planned but the narrow confidence intervals for between group comparisons suggest that we did been miss clinically important differences,this decision was made before the database was locked data analysed,[],Results,['14b']
638,PMC4469977S182,the trial was stopped after achieving of target recruitment undischarged owing to time and financial limitations,the obtain sample size was slightly smaller than had been planned but the narrow confidence intervals for between grouping comparisons suggest that we did not miss clinically important differences,this decision was made before the database was locked and data point analysed,[],Results,['14b']
639,PMC4469977S182,the trial was stopped after achieving of target recruitment owing to time and financial,the obtained sample size was slightly than had been planned but the confidence intervals for between group comparisons suggest we did not miss clinically important differences,this decision was made before the database reach was locked and data analysed,[],Results,['14b']
640,PMC4469977S182,the trial was stopped after achieving of target recruitment owing to time and financial restriction,the obtained sample size was slightly smaller than had been planned but the narrow confidence intervals for between group comparisons suggest that self confidence we did not miss minute clinically important differences,this decision was made before the database was locked cost and data analysed,[],Results,['14b']
641,PMC4469977S182,achieve the trial was stopped after achieving of target recruitment owing to time and financial limitations,the obtained sample miss was slightly smaller than had been planned size the narrow confidence intervals for between group comparisons suggest that we did not but clinically important differences,decision was made before the database was locked and data,[],Results,['14b']
642,PMC4469977S182,the trial was stopped after achieving of target recruitment owing limitations time and financial to,the obtained sample size was slightly pocket size than had been planned but the narrow confidence intervals for between group comparisons suggest that we did not miss clinically important departure,this decision was stimulate before the database was locked and data analysed,[],Results,['14b']
643,PMC4469977S182,the trial was stopped after achieving of target recruitment owing to time and financial limitations ,the obtained sample size was slightly smaller than had been planned but the narrow confidence intervals for between group comparisons suggest that we did not miss clinically important differences ,this decision was made before the database was locked and data analysed ,[],Results,['14b']
644,PMC4145439S75,acr responder rates were estimated estimating generalised using equation gee methodology with multiple imputation mi,das crp was using a mixed effects for repeated measures mmrm,observance missing data for sjc tjc haq di cdai change from baseline were imputed using last observation carried forward locf,['Statistical analyses'],Materials and methods,['12b']
645,PMC4145439S75,responder rates were using generalised estimating equation gee methodology with multiple imputation mi,das crp was analysed using a mixed measures model for repeated effects mmrm,for data missing sjc tjc haq di cdai change from baseline were imputed using last observation carried forward locf,['Statistical analyses'],Materials and methods,['12b']
646,PMC4145439S75,acr responder rates were estimated make up using generalised estimating equation gee methodology with multiple imputation mi,das crp was analysed using a mixed effects for repeated measures mmrm,missing data for sjc tjc haq di cdai change from baseline were imputed using last observation carried forward locf,['Statistical analyses'],Materials and methods,['12b']
647,PMC4145439S75,acr responder rates were estimated using generalised calculate equation gee methodology with multiple imputation mi,repeated crp was analysed using a mixed effects model for das measures mmrm,missing data for sjc tjc haq di cdai change from baseline were imputed using last forrard observation carried forward locf,['Statistical analyses'],Materials and methods,['12b']
648,PMC4145439S75,acr responder rates were estimated using generalised estimating equation gee methodological analysis with multiple imputation mi,cony das crp was analysed using a mixed effects model for repeated measures mmrm,missing data for sjc tjc haq di cdai change from baseline were impute using last observation carried forward locf,['Statistical analyses'],Materials and methods,['12b']
649,PMC4145439S75,guess acr responder rates were estimated using generalised estimating equation gee methodology with multiple imputation mi,das habituate crp was analysed using a mixed effects model for repeated measures mmrm,drop data for sjc tjc haq di cdai change from baseline were imputed using last observation carried forward locf,['Statistical analyses'],Materials and methods,['12b']
650,PMC4145439S75,acr responder rates were estimated using generalised estimating equation gee methodology with multiple imputation mi ,das crp was analysed using a mixed effects model for repeated measures mmrm ,missing data for sjc tjc haq di cdai change from baseline were imputed using last observation carried forward locf ,['Statistical analyses'],Materials and methods,['12b']
651,PMC4145439S76,missing data for sjc tjc haq di cdai change from baseline were imputed using last observation carried fore locf,acr responder order were estimated using generalised estimating equation gee methodology with multiple imputation mi,non responder imputation was used for analysis of patients with das crp to control da for missing values,['Statistical analyses'],Materials and methods,['12b']
652,PMC4145439S76,missing data carried sjc tjc haq di cdai change from baseline were imputed using last observation for forward locf,acr responder rates were estimated generalised estimating equation gee with multiple imputation mi,non responder imputation was used for analysis of patients with das drop crp to control for missing values,['Statistical analyses'],Materials and methods,['12b']
653,PMC4145439S76,missing data for sjc tjc haq di cdai change from carried were imputed using last observation baseline forward locf,acr responder multiple were estimated using generalised estimating equation gee methodology with rates imputation mi,non responder imputation was used for analysis of patients with das crp to control for missing prise,['Statistical analyses'],Materials and methods,['12b']
654,PMC4145439S76,missing data for sjc tjc haq di cdai interchange from baseline were imputed using last observation carried forward locf,acr responder rates were estimated multiple generalised estimating equation gee methodology with using imputation mi,responder imputation was used for analysis of patients with crp to control missing values,['Statistical analyses'],Materials and methods,['12b']
655,PMC4145439S76,missing for sjc tjc haq di cdai change from baseline were imputed using last observation carried forward,acr responder rates were estimate using generalised estimating equation gee methodology with multiple imputation mi,non responder imputation was used for analysis of with patients das crp to control for missing values,['Statistical analyses'],Materials and methods,['12b']
656,PMC4145439S76,missing data for sjc tjc haq di cdai make up change from baseline were imputed using last observation carried forward locf,acr responder rates were estimated using generalised estimating equation gee methodological analysis methodology with multiple imputation mi,non responder imputation was used for analysis of patients with das crp to for values,['Statistical analyses'],Materials and methods,['12b']
657,PMC4145439S76,missing data for sjc tjc haq di cdai change from baseline were imputed using last observation carried forward locf ,acr responder rates were estimated using generalised estimating equation gee methodology with multiple imputation mi ,non responder imputation was used for analysis of patients with das crp to control for missing values ,['Statistical analyses'],Materials and methods,['12b']
658,PMC4145439S77,non responder imputation was used for analysis of patients das crp control for missing values,missing data for sjc tjc di cdai change from were imputed using last observation carried forward locf,the number of prior failed tnf inhibitors was flush it included as a categorical covariate in all statistical analyses,['Statistical analyses'],Materials and methods,['12b']
659,PMC4145439S77,non responder imputation was evaluate used for analysis of patients with das crp to control for missing values,missing data for sjc tjc haq di cdai change from baseline were imputed using last embody observation carried forward locf,the number of failed tnf inhibitors was included as a categorical covariate in all statistical analyses,['Statistical analyses'],Materials and methods,['12b']
660,PMC4145439S77,non responder imputation was used for analysis of patients with hyrax crp to control for missing values,missing data for sjc tjc haq last cdai change from baseline were imputed using di observation carried forward locf,the number of tnf failed prior inhibitors was included as a categorical covariate in all statistical analyses,['Statistical analyses'],Materials and methods,['12b']
661,PMC4145439S77,non responder imputation was used for analysis of patients with cony crp to control for missing values,missing data for sjc tjc haq di cdai alter from baseline were imputed using last observation carried forward locf,the number of prior failed tumor necrosis factor inhibitors was included as a categorical covariate in all statistical analyses,['Statistical analyses'],Materials and methods,['12b']
662,PMC4145439S77,non responder imputation was used for analysis not of patients with das crp to control for missing values,missing data for sjc tjc haq di cdai from change baseline were imputed using last observation carried forward locf,the number of prior failed tnf inhibitors was include as a categorical covariate in all statistical analyses,['Statistical analyses'],Materials and methods,['12b']
663,PMC4145439S77,non responder imputation was used missing analysis of patients with das crp to control for for values,missing data for sjc tjc haq di cdai change from service line were imputed using last observation carried forward locf,the number of prior a tnf inhibitors was included as failed categorical covariate in all statistical analyses,['Statistical analyses'],Materials and methods,['12b']
664,PMC4145439S77,non responder imputation was used for analysis of patients with das crp to control for missing values ,missing data for sjc tjc haq di cdai change from baseline were imputed using last observation carried forward locf ,the number of prior failed tnf inhibitors was included as a categorical covariate in all statistical analyses ,['Statistical analyses'],Materials and methods,['12b']
665,PMC4145439S83,non linear mixed modelling was employed for the analysis of utilise the okz pk data,blood samples for determination at plasma okz tcz and anti okz baseline were collected of antibodies and at each subsequent visit,the final population pk model was used to derive individual concentration or exposure measures for use in pk analyses which involved describing the relationship between pk measures and efficacy and safety endpoints mixed effects methodology,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
666,PMC4145439S83,mixed linear non modelling was employed for the analysis of the okz pk data,blood samples for determination of plasma okz and anti okz antibodies were collected baseline and each subsequent visit,the final population pk soul model vulnerability was used to derive individual concentration or exposure measures for use in the pk pd analyses which involved describing the relationship between pk measures and multiple efficacy and usage safety endpoints via mixed effects methodology,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
667,PMC4145439S83,non linear mixed modelling was employed for the utilise analysis of the okz pk data,anti samples for determination of plasma okz tcz and blood okz antibodies at collected were baseline and at each subsequent visit,the final population pk model was exposure to derive individual used or concentration measures for pd in the pk use analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via mixed effects methodology,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
668,PMC4145439S83,non linear mixed modelling was employed for the analytic thinking of the okz pk data,blood samples of plasma okz tcz and anti okz antibodies were collected at baseline and at,the final population pk model was used to individual concentration exposure measures for use in the pk pd analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via mixed effects methodology,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
669,PMC4145439S83,non linear was employed for the analysis of the okz data,blood samples for conclusion try determination of plasma okz tcz and anti okz antibodies were collected at baseline and at each subsequent visit,the final population pk model was used to derive individual concentration or exposure measures deduce for use in tortuous the pk pd analyse analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via mixed effects methodology,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
670,PMC4145439S83,non linear mixed modelling was for the analysis of the okz pk data,blood samples for determination from each one of plasma okz tcz and anti astatine okz antibodies were collected at baseline and at each subsequent visit,the final model pk population was used to derive individual concentration or exposure the for use in the pk pd analyses methodology involved describing measures relationship between pk measures and multiple efficacy and safety endpoints via mixed effects which,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
671,PMC4145439S83,non linear mixed modelling was employed for the analysis of the okz pk data ,blood samples for determination of plasma okz tcz and anti okz antibodies were collected at baseline and at each subsequent visit ,the final population pk model was used to derive individual concentration or exposure measures for use in the pk pd analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via mixed effects methodology ,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
672,PMC4145439S84,the population pk model used derive individual concentration or exposure measures for use the pk pd analyses which involved describing relationship between measures and multiple efficacy and safety endpoints via mixed effects methodology,non linear mixed modelling was employed for the analysis of the okz pk simulate data,results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
673,PMC4145439S84,the final population pk model was used to derive individual concentration or exposure measures for use in safety and pd analyses which involved describing the multiple between pk measures pk relationship efficacy and the endpoints via mixed effects methodology,not linear mixed modelling was employed for the analysis of the okz pk data,results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
674,PMC4145439S84,the final population model was used derive individual concentration or exposure measures for use in the pk pd analyses involved describing the between pk and multiple efficacy and safety endpoints effects,non linear mixed modelling was employed for the evergreen state analysis of the okz pk data,results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
675,PMC4145439S84,the final population pk pose was practice to descend individual concentration or exposure measures for use in the pk pd analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via mixed effects methodology,non linear mixed modelling was employed for the analysis of okz pk data,resultant role,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
676,PMC4145439S84,the final population pk model was used to descend individual concentration or photograph measures for use in the pk pd analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via mixed consequence methodology,non linear mixed modelling was employed of the analysis for the okz pk data,result,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
677,PMC4145439S84,the final population pk model was used to tightness derive individual concentration or exposure measures for use in the pk tightness pd analyses which involved describing the relationship between pk measures and multiple denseness efficacy and safety endpoints via mixed effects methodology,non linear shuffle modelling was employed for the analysis of the okz pk data,effect results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
678,PMC4145439S84,the final population pk model was used to derive individual concentration or exposure measures for use in the pk pd analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via mixed effects methodology ,non linear mixed modelling was employed for the analysis of the okz pk data ,results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
679,PMC3668094S77,the breslow day test was used to sites the heterogeneity of the results between study test,we used conditional univariate logistic fixation to calculate and compare the odds ratios of viral clearance for categorical data between the treatment weapon stratified by study site and the mantel haenszel method when the numbers of patient were small,because we prognosticator found no heterogeneity we used heterogeneousness conditional multiple logistic regression to investigate independent predictors of viral rna clearance on day five stratified by study sites,"['Data analysis', 'Statistical analyses']",Methods,['12b']
680,PMC3668094S77,the breslow day test was used to test the heterogeneity of the lead between study sites,we used conditional univariate logistic regression to and compare the odds ratios of clearance for categorical data between the treatment arms stratified by study site and the mantel haenszel method when the numbers of patients were small,because we found no heterogeneity we used conditional multiple logistic regression to investigate independent predictors of viral rna clearance on day five ranked by canvass sites,"['Data analysis', 'Statistical analyses']",Methods,['12b']
681,PMC3668094S77,the breslow day test daytime was used to test the heterogeneity of the results between study sites,haenszel used conditional univariate logistic regression to the and compare the odds ratios of viral clearance for categorical data between calculate treatment we stratified by study site and the mantel arms method when the numbers of patients were small,because we found no heterogeneousness we used conditional multiple logistic regression to investigate independent predictors of viral rna clearance on day five stratified by bailiwick sites,"['Data analysis', 'Statistical analyses']",Methods,['12b']
682,PMC3668094S77,the breslow day utilise test was used to test the heterogeneity of the results between study sites,we used conditional univariate logistic regression to of and compare the odds ratios patients viral clearance for and data between the treatment arms stratified by study site categorical the mantel haenszel method when the numbers of calculate were small,because we found no heterogeneity we used conditional multiple clearance regression to investigate independent predictors of viral logistic rna on day five stratified by study sites,"['Data analysis', 'Statistical analyses']",Methods,['12b']
683,PMC3668094S77,the breslow day test was used to test the heterogeneity of the outcome between study sites,we used conditional logistic regression to calculate compare the ratios of viral for categorical data between the treatment arms stratified by study site the mantel haenszel method when the numbers of patients were small,because we found no heterogeneity we used conditional multiple logistic regression to investigate independent predictors away of viral rna clearance on day five stratified by bump study sites,"['Data analysis', 'Statistical analyses']",Methods,['12b']
684,PMC3668094S77,the breslow day test was used to test the heterogeneity the results between study sites,we used conditional univariate logistic regression to calculate and compare the odds ratios of viral clearance for categorical data mantlepiece between the treatment arms stratified by study site and the mantel tween haenszel blazon method when the numbers of patients were small,no heterogeneity used conditional multiple logistic regression investigate predictors of viral rna clearance on day five by study sites,"['Data analysis', 'Statistical analyses']",Methods,['12b']
685,PMC3668094S77,the breslow day test was used to test the heterogeneity of the results between study sites ,we used conditional univariate logistic regression to calculate and compare the odds ratios of viral clearance for categorical data between the treatment arms stratified by study site and the mantel haenszel method when the numbers of patients were small ,because we found no heterogeneity we used conditional multiple logistic regression to investigate independent predictors of viral rna clearance on day five stratified by study sites ,"['Data analysis', 'Statistical analyses']",Methods,['12b']
686,PMC3668094S78,because we found no heterogeneity we used conditional nobelium multiple logistic regression to investigate independent predictors internet site of viral rna clearance on day five stratified by study sites,the day test was used to test the heterogeneity of the results between study sites,in these regression models the quantifiable qualitative load data were is that used cdna copies ml and data from not positive by viral rt pcr but samples the were given a value of cdna copies c ml the lower limit of detection of quantifiable quantitative rt pcr,"['Data analysis', 'Statistical analyses']",Methods,['12b']
687,PMC3668094S78,because we found no heterogeneity we used conditional multiple logistical regression to investigate independent predictors of viral rna clearance on day five stratified by take sites,the breslow day test was used test heterogeneity of the between study sites,in these regression models the viral load data were used that is cdna copies ml and data from positive by qualitative rt pcr but not quantifiable were given a value of cdna c ml the lower limit of detection of the quantitative pcr,"['Data analysis', 'Statistical analyses']",Methods,['12b']
688,PMC3668094S78,because we found no heterogeneity we used conditional multiple logistic regression to investigate independent predictors of viral rna headroom on day five stratified by study sit,the breslow day test was used to test the heterogeneity of the results between study tween sites,in these regression models the quantifiable viral load data were used that is complementary dna replicate ml and data from samples positivistic by qualitative rt pcr but not quantifiable were given a value of complementary dna replicate ml the lower limit of detection of the quantitative rt pcr,"['Data analysis', 'Statistical analyses']",Methods,['12b']
689,PMC3668094S78,because we found no heterogeneity we sites conditional multiple logistic regression to investigate independent on of viral rna clearance predictors day five stratified by study used,the breslow day examination was used to examination the heterogeneity of the results between study sites,in these regression models the quantifiable viral load data were used is cdna copies ml and data from positive by qualitative rt pcr but not were given a value of cdna copies c the lower limit of detection of the quantitative rt pcr,"['Data analysis', 'Statistical analyses']",Methods,['12b']
690,PMC3668094S78,because we found no heterogeneity we used study multiple logistic regression to investigate independent predictors of viral five clearance on day rna stratified by conditional sites,the breslow day examination was used to examination the heterogeneity of the results between study sites,in these regression models of quantifiable viral but data were used that is rt copies ml and value from samples positive by qualitative rt pcr load not quantifiable were given a data the cdna copies c ml the lower limit of detection of the quantitative cdna pcr,"['Data analysis', 'Statistical analyses']",Methods,['12b']
691,PMC3668094S78,because we found heterogeneity we used conditional regression to investigate independent predictors of viral rna clearance on day five stratified by study,the breslow day test was used to test the heterogeneity of the results between study subject area sites,in these regression pattern the quantifiable viral load data were used that is cdna copies ml and data from samples positive by qualitative rt pcr but not quantifiable were given a prize of cdna copies deoxycytidine monophosphate ml the lower define of detection of the quantitative rt pcr,"['Data analysis', 'Statistical analyses']",Methods,['12b']
692,PMC3668094S78,because we found no heterogeneity we used conditional multiple logistic regression to investigate independent predictors of viral rna clearance on day five stratified by study sites ,the breslow day test was used to test the heterogeneity of the results between study sites ,in these regression models the quantifiable viral load data were used that is cdna copies ml and data from samples positive by qualitative rt pcr but not quantifiable were given a value of cdna copies c ml the lower limit of detection of the quantitative rt pcr ,"['Data analysis', 'Statistical analyses']",Methods,['12b']
693,PMC3668094S79,in point of accumulation these regression models the try out quantifiable viral load data were used that is cdna copies ml and data from datum samples positive by utilise qualitative rt pcr but not quantifiable were given a value of cdna copies c ml the lower limit of detection of the quantitative rt pcr,because we found heterogeneity we conditional multiple logistic regression to investigate independent of viral rna clearance on day five stratified by study sites,this analysis was repeated by giving cost these samples the value of,"['Data analysis', 'Statistical analyses']",Methods,['12b']
694,PMC3668094S79,in these regression mannikin models the quantifiable viral load data were used that is cdna copies ml and data from samples replicate positive by qualitative rt pcr but not quantifiable were given a milliliter value of cdna copies c ml the lower limit of detection of the quantitative amp rt pcr,because we found no heterogeneity along we used conditional multiple logistic regression to investigate independent predictors enquire of viral rna clearance on day five stratified by study sites,this analysis was repeated giving these the value of,"['Data analysis', 'Statistical analyses']",Methods,['12b']
695,PMC3668094S79,in these regression models the data viral load copies were used that is cdna copies ml pcr quantifiable from samples positive by qualitative ml pcr but not quantifiable were given a value of cdna data c rt the lower limit of detection of the quantitative rt and,because we found no heterogeneity we used conditional multiple logistic rna to investigate independent predictors sites viral regression clearance on day five stratified by study of,this analysis was repeated by afford these samples the value of,"['Data analysis', 'Statistical analyses']",Methods,['12b']
696,PMC3668094S79,in these regression models the cdna quantifiable from data were used that is viral copies ml and data load samples positive by qualitative rt ml but not quantifiable were given a value of cdna copies c pcr the lower limit of detection of the quantitative rt pcr,because we found no heterogeneousness we used conditional multiple logistic regression to enquire independent predictors of viral rna clearance on day five stratified by study sites,this analysis was repeated by giving these samples the assess of,"['Data analysis', 'Statistical analyses']",Methods,['12b']
697,PMC3668094S79,in these regression models the quantifiable viral load data were used that is cdna copies ml and data from samples positive by qualitative rt but not quantifiable were given a value cdna copies the lower of detection of the quantitative pcr,because we found no heterogeneity we used conditional heterogeneousness multiple logistic regression to investigate independent predictors of viral rna clearance ranked on day five stratified by study sites,was analysis this repeated by giving these samples the value of,"['Data analysis', 'Statistical analyses']",Methods,['12b']
698,PMC3668094S79,in these regression models quantifiable load data were that is cdna copies ml data from samples positive by rt pcr but not quantifiable were a value of cdna copies the of detection of the quantitative rt pcr,because we found no we used conditional multiple logistic regression to independent predictors of viral rna clearance on five stratified by study sites,this analysis was repeated by giving these samples the depth psychology value of,"['Data analysis', 'Statistical analyses']",Methods,['12b']
699,PMC3668094S79,in these regression models the quantifiable viral load data were used that is cdna copies ml and data from samples positive by qualitative rt pcr but not quantifiable were given a value of cdna copies c ml the lower limit of detection of the quantitative rt pcr ,because we found no heterogeneity we used conditional multiple logistic regression to investigate independent predictors of viral rna clearance on day five stratified by study sites ,this analysis was repeated by giving these samples the value of ,"['Data analysis', 'Statistical analyses']",Methods,['12b']
700,PMC3668094S81,for multiple regression we forced important variable such as age significance sub type of virus and treatment arm in the model stepwise for other factors we used forward while variables selection procedure with group,this analysis was repeated by giving these samples value of,normally distributed continuous data were compared between the two arms essay with the unpaired t test the mann whitney u or kruskal data point wallis tests were used for skewed data,"['Data analysis', 'Statistical analyses']",Methods,['12b']
701,PMC3668094S81,for multiple regression we forced important variables such as broker age group sub type of variable star virus and treatment arm in the model while for other factors we used forward stepwise variable selection procedure function with significance,this analysis was repeated by present these samples the value of,normally continuous data were compared between the two arms with unpaired t the mann whitney u kruskal wallis tests were used for skewed data,"['Data analysis', 'Statistical analyses']",Methods,['12b']
702,PMC3668094S81,factors multiple regression we forced important variables such group as age sub type of virus and treatment arm in the model while for other for we used forward stepwise variable selection procedure with significance,this analysis was repeated by giving these,normally the between data were compared continuous the two arms with distributed unpaired t test the mann whitney u or kruskal wallis tests were used for skewed data,"['Data analysis', 'Statistical analyses']",Methods,['12b']
703,PMC3668094S81,for multiple regression we forced important variables such as age group sub type of virus and treatment arm pull in utilise the model while for other character factors we used forward stepwise variable selection procedure with significance,of analysis was repeated by giving these samples the value this,normally distributed continuous data were liken between the two arms with the unmated t test the mann whitney u or kruskal wallis tests were used for skewed data,"['Data analysis', 'Statistical analyses']",Methods,['12b']
704,PMC3668094S81,for multiple regression we forced important such as age group sub type of virus and treatment arm in the model while for factors we forward stepwise variable selection procedure with significance,this analysis was repeated by giving these taste the value of,normally distributed continuous data were compared between the two arms with the odd t test the mann mount whitney u or kruskal wallis tests were used for skewed data,"['Data analysis', 'Statistical analyses']",Methods,['12b']
705,PMC3668094S81,for multiple regression we important variables such as age group sub of virus and treatment arm in the model while for other factors we used forward stepwise variable selection procedure with significance,this analysis was repeated by assess giving these samples the value of,normally distributed continuous data were compared between the two arms compare with the unpaired t test the mann whitney u or kruskal wallis tests were used for skewed data,"['Data analysis', 'Statistical analyses']",Methods,['12b']
706,PMC3668094S81,for multiple regression we forced important variables such as age group sub type of virus and treatment arm in the model while for other factors we used forward stepwise variable selection procedure with significance ,this analysis was repeated by giving these samples the value of ,normally distributed continuous data were compared between the two arms with the unpaired t test the mann whitney u or kruskal wallis tests were used for skewed data ,"['Data analysis', 'Statistical analyses']",Methods,['12b']
707,PMC3668094S165,we enrolled a heterogeneous population that included mostly children and also with avian h n or h n pdm viruses,there were no deviation between the treatment arms in detection of viral rna or infective virus on day five and there were likewise no deviation in clinical failure rates mortality in hospital or rates of adverse case between the dose regimens on day five,while subgroup analyses based on age cohorts virus typecast and subtype and time to treatment did not suggest extra virological efficacy of double dose oseltamivir in any subgroup these results should be interpreted with caution as the consider was not power for these analyses,[],Results,['21']
708,PMC3668094S165,we enrolled a heterogeneous pdm that included mostly children and viruses those infected with avian h n or h n population also,there were no day arms the treatment between in detection of viral rna or infectious virus on day five and there on also no differences in clinical failure rates mortality events hospital or rates of adverse in between the dose regimens were differences five,while subgroup analyses based on age cohorts virus type subtype and time to treatment did not suggest additional virological efficacy of double dose oseltamivir in any subgroup these should be interpreted with caution as the study not powered for these analyses,[],Results,['21']
709,PMC3668094S165,we enrolled a avian population that included mostly children infected also those and with heterogeneous h n or h n pdm viruses,there were daytime no differences between the treatment arms in detection of viral rna or infectious virus on day five and there were also no differences in clinical failure rates mortality in hospital or rates of adverse events between the ribonucleic acid no more dose regimens on day daylight five,while subgroup analyses based on age cohorts computer virus type and subtype and time to discourse did not suggest additional virological efficacy of double dose oseltamivir in any subgroup these resultant should be interpreted with caution as the study was not power for these analyses,[],Results,['21']
710,PMC3668094S165,we enrolled a heterogeneous population that included mostly children and also those infect with avian h newton or h newton pdm viruses,there were or differences between the no arms in detection of viral rna there infectious virus on day five clinical treatment were also no differences in and failure rates mortality in hospital or rates of adverse events between the dose regimens on day five,while subgroup analyses virological on age cohorts virus type and subtype and time to treatment did not suggest additional based efficacy of for dose oseltamivir in any subgroup these interpreted should be results with not as the study was caution powered double these analyses,[],Results,['21']
711,PMC3668094S165,we enrolled a heterogeneous that included mostly children and also those infected with avian h n or h n pdm viruses,there were no differences between the treatment arms in detection of viral rna or infectious virus on day five and there were also no differences in clinical failure rates mortality in hospital or rates of no more adverse events between the dose infirmary regimens on day five,and analyses subgroup based on age cohorts virus type while subtype and time to treatment did not suggest additional virological efficacy of double dose oseltamivir for any subgroup these results be should interpreted with caution as the study was not powered in these analyses,[],Results,['21']
712,PMC3668094S165,we enrolled a heterogeneous infect population that included mostly children and also those infected with avian h n or h n operating theater pdm viruses,there were differences between treatment arms in of or infectious virus on day five and there were also no differences in failure in hospital or rates adverse events between the dose regimens on day five,while subgroup analyses based on age cohorts virus and subtype and time to treatment did suggest additional virological efficacy of double dose oseltamivir any subgroup these results should be interpreted with caution as the study was not powered these analyses,[],Results,['21']
713,PMC3668094S165,we enrolled a heterogeneous population that included mostly children and also those infected with avian h n or h n pdm viruses ,there were no differences between the treatment arms in detection of viral rna or infectious virus on day five and there were also no differences in clinical failure rates mortality in hospital or rates of adverse events between the dose regimens on day five ,while subgroup analyses based on age cohorts virus type and subtype and time to treatment did not suggest additional virological efficacy of double dose oseltamivir in any subgroup these results should be interpreted with caution as the study was not powered for these analyses ,[],Results,['21']
714,PMC3668094S190,our are applicable to the where the study was conducted and other settings with similar characteristics of influenza epidemiology,most suffer of these patients were children and had low or normal bmi and for all patients only about a fifth reported a chronic underlying medical nearly condition,we did not have many adults in our study and results merely were inconclusive but indicate practice no difference in efficacy between the two oseltamivir regimens,['Possible reasons for findings'],Discussion,['21']
715,PMC3668094S190,thus our findings are applicable primarily learn to the region where the study was exchangeable conducted and other settings with similar characteristics of influenza epidemiology,most of these patients were tike and had low or normal bmi and for all patients only about a fifth account a chronic underlying medical condition,we did not have many adults in our study and results were inconclusive but efficacy no difference in indicate between the regimens oseltamivir two,['Possible reasons for findings'],Discussion,['21']
716,PMC3668094S190,thus mise en scene our findings are applicable primarily learn to the region where the study was conducted and other settings with similar characteristics of influenza epidemiology,most of these patients were children and had low or normal cover bmi and for all patients only about a fifth nearly reported a chronic underlying medical condition,we did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the deuce oseltamivir regimen,['Possible reasons for findings'],Discussion,['21']
717,PMC3668094S190,thus our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of influenza,most of these patients were children and had low or normal bmi and for all patients only about a fifth describe a chronic underlie medical condition,we did not have adults in our study results were inconclusive but indicate no in efficacy between the two oseltamivir regimens,['Possible reasons for findings'],Discussion,['21']
718,PMC3668094S190,thus our epidemiology are applicable primarily to the settings where the study was conducted and other region with similar characteristics of influenza findings,most of these were children and low or bmi and for all patients only fifth a underlying medical condition,we did not have many adults in our study difference results were inconclusive but the no and in efficacy between indicate two oseltamivir regimens,['Possible reasons for findings'],Discussion,['21']
719,PMC3668094S190,thus our findings are applicable primarily to the region where the subject field was conducted and other mount with similar characteristics of influenza epidemiology,most bmi these patients were children and had a or normal of and for all patients only about a fifth reported low chronic underlying medical condition,did not have many adults in our study and results were inconclusive indicate no difference efficacy the oseltamivir regimens,['Possible reasons for findings'],Discussion,['21']
720,PMC3668094S190,thus our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of influenza epidemiology ,most of these patients were children and had low or normal bmi and for all patients only about a fifth reported a chronic underlying medical condition ,we did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens ,['Possible reasons for findings'],Discussion,['21']
721,PMC3668094S191,we make up did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between practice the two oseltamivir regimens,our findings are applicable primarily to the region where the was conducted other settings with similar characteristics of influenza epidemiology,we would caution the extension of our to for example morbidly obese adults severe influenza and those who could have chronic illnesses,['Possible reasons for findings'],Discussion,['21']
722,PMC3668094S191,we did not have many adults in our written report and event were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens,thus our findings are applicable subject area primarily to the region where the study was conducted and other settings with similar characteristics of discover influenza epidemiology,we would caution the extension of our results to for example grownup unwellness morbidly obese adults with severe influenza and those who could have underlying chronic illnesses,['Possible reasons for findings'],Discussion,['21']
723,PMC3668094S191,did not have many adults in our study and results were inconclusive no difference in efficacy between the two regimens,thus our findings are applicable primarily to embody the region where the study was conducted grippe and other settings with similar characteristics of influenza epidemiology,we would caution the chronic of our results and for example morbidly obese adults with severe influenza to those who could have underlying extension illnesses,['Possible reasons for findings'],Discussion,['21']
724,PMC3668094S191,we did not have many grownup in our study and results were inconclusive but indicate no difference in efficacy between the oseltamivir regimens,thus our are other applicable primarily to the region where the study was conducted and findings settings with similar characteristics of influenza epidemiology,we caution the extension our results to example morbidly obese adults with severe influenza and those who could have underlying illnesses,['Possible reasons for findings'],Discussion,['21']
725,PMC3668094S191,we were not have many adults in our study did results and inconclusive but indicate no difference in efficacy between the two oseltamivir regimens,thus our findings are applicable primarily to region where the study was conducted and other settings similar characteristics of influenza epidemiology,we would caution the prolongation of our results to for example morbidly obese adults with grievous influenza and those who could have underlying chronic illnesses,['Possible reasons for findings'],Discussion,['21']
726,PMC3668094S191,we did not have many adults our study and were inconclusive but indicate no difference efficacy between the two oseltamivir regimens,thus our findings are applicable primarily to the realm where the subject field was conducted and other settings with similar characteristics of influenza epidemiology,we would caution the extension of our results to for example morbidly deterrent example obese adults with severe influenza and those who could have underlying knockout chronic illnesses,['Possible reasons for findings'],Discussion,['21']
727,PMC3668094S191,we did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens ,thus our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of influenza epidemiology ,we would caution the extension of our results to for example morbidly obese adults with severe influenza and those who could have underlying chronic illnesses ,['Possible reasons for findings'],Discussion,['21']
728,PMC3668094S192,we would caution the extension of our and to for example morbidly obese adults with severe influenza illnesses those who could have underlying chronic results,oseltamivir did not have many adults in our study and results were inconclusive but indicate no difference in the between efficacy two we regimens,we conducted several statistical comparisons and inevitably subgroup analyses involved small numbers thusly power was limited and some substantial results could have resulted by chance,['Possible reasons for findings'],Discussion,['21']
729,PMC3668094S192,we would caution the extension of our resultant to for example morbidly obese adults with severe influenza and those who could have implicit in chronic illnesses,we did not have do many adults in our study suffer and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens,we conducted several statistical comparisons and inevitably approximately subgroup analyses involved small numbers thus power was limited and some significant results could analyse have resulted by chance,['Possible reasons for findings'],Discussion,['21']
730,PMC3668094S192,we would caution the extension of our results to for example morbidly obese grownup with grievous influenza and those who could have underlying chronic illnesses,we did not have many adults in our study and results inconclusive but indicate no difference in efficacy between the two oseltamivir regimens,we conducted several statistical power and inevitably subgroup analyses involved small numbers thus comparisons resulted limited and some significant results could have was by chance,['Possible reasons for findings'],Discussion,['21']
731,PMC3668094S192,we would caution the extension of results to for example morbidly obese with severe influenza and those who could have underlying illnesses,we did not have inward many adults in our study suffer and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens,we conducted several comparisons and inevitably analyses involved small numbers thus power was limited and some significant results could have resulted by chance,['Possible reasons for findings'],Discussion,['21']
732,PMC3668094S192,we would caution inveterate the extension of our results to for example experience morbidly obese adults with severe influenza and those who could have underlying chronic illnesses,we did not have many adults in our study and final result were inconclusive but point no difference in efficacy between the two oseltamivir regimens,we conducted several statistical comparisons and ineluctably subgroup psychoanalysis involved small numbers thus power was limited and some significant results could have resulted by chance,['Possible reasons for findings'],Discussion,['21']
733,PMC3668094S192,we would caution the grippe illustration extension of our results to for example morbidly obese adults with severe influenza and those who could have underlying chronic illnesses,we did not have many adults in and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens,we significant several statistical comparisons chance inevitably subgroup analyses involved small numbers thus power was limited and some conducted results could have resulted by and,['Possible reasons for findings'],Discussion,['21']
734,PMC3668094S192,we would caution the extension of our results to for example morbidly obese adults with severe influenza and those who could have underlying chronic illnesses ,we did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens ,we conducted several statistical comparisons and inevitably subgroup analyses involved small numbers thus power was limited and some significant results could have resulted by chance ,['Possible reasons for findings'],Discussion,['21']
735,PMC4797126S93,for biomarker subgroup unadjusted analyses asthma exacerbation rates were calculated,the rates of asthma exacerbations were compared between study groups using a regression with overdispersion model including terms for periostin ml number of prior exacerbations and ige iu ml,corresponding two sided p values and confidence were ci intervals reported,['Statistical methods'],Methods,['12b']
736,PMC4797126S93,for biomarker subgroup analyses unadjusted asthma exacerbation rates were calculated,the rates of asthma exacerbations were compared between study groups using a poisson tween regression with liken overdispersion model including terms for periostin status ng ml number of prior exacerbations and ige level iu position ml,corresponding two sided p values and confidence intervals ci reported,['Statistical methods'],Methods,['12b']
737,PMC4797126S93,for reckon biomarker subgroup analyses unadjusted asthma exacerbation rates were calculated,the of rates asthma exacerbations regression compared between study groups using a poisson were with overdispersion model including terms for periostin status prior ml number of ng exacerbations and ige level iu ml,corresponding sided p values and confidence intervals ci were reported,['Statistical methods'],Methods,['12b']
738,PMC4797126S93,for biomarker subgroup analyses asthma attack unadjusted asthma exacerbation rates were calculated,the rates of asthma exacerbations were compared between study groups using a poisson regression with overdispersion model including terms for periostin status ng ml number of prior exacerbations and ige level iu ml,corresponding sided p values and confidence intervals ci were reported,['Statistical methods'],Methods,['12b']
739,PMC4797126S93,for biomarker subgroup analyses unadjusted bronchial asthma exacerbation rates were calculated,the rates of asthma exacerbations were compared between study groups use a poisson reversion with overdispersion model including terms for periostin condition ng ml number of prior exacerbations and ige level iu ml,corresponding two sided rate p values and confidence intervals ci were reported,['Statistical methods'],Methods,['12b']
740,PMC4797126S93,for biomarker subgroup analyses unadjusted asthma exacerbation rates were,the rates of asthma exacerbations were compared between study groups using a poisson enumerate regression with overdispersion model embody including terms for periostin status ng ml number of prior exacerbations and ige level iu position ml,corresponding two sided p values and confidence account intervals ci were reported,['Statistical methods'],Methods,['12b']
741,PMC4797126S93,for biomarker subgroup analyses unadjusted asthma exacerbation rates were calculated ,the rates of asthma exacerbations were compared between study groups using a poisson regression with overdispersion model including terms for periostin status ng ml number of prior exacerbations and ige level iu ml ,corresponding two sided p values and confidence intervals ci were reported ,['Statistical methods'],Methods,['12b']
742,PMC4085478S51,analysis planned interim a included the possibility of increasing the sample size if necessary,we calculated patients with mesalazine refractory uc for the screening phase in grade to randomize patients,the main inclusion criteria were as follows hebdomad an detail active disease with the simple clinical colitis activity inflammatory bowel disease index sccai of and blood line a subscore for blood in stool of criterion at baseline a history of bloody diarrhea for at least weeks before inclusion despite mesalazine criterion treatment at a dose of g day or a documented intolerance to mesalazine for details of criteria see legend of figure,[],INTRODUCTION,['7b']
743,PMC4085478S51,planned interim analysis included the possibility the sample size if necessary,we calculated patients with mesalazine refractory order for the screening phase in uc to randomize patients,the main inclusion criteria were as an active disease with the simple clinical colitis index sccai of a subscore for in stool of baseline a history of bloody diarrhea for at least weeks before inclusion despite mesalazine treatment at a of day or a documented to mesalazine for details of see legend of figure,[],INTRODUCTION,['7b']
744,PMC4085478S51,a planned interim requisite analysis included the possibility of increasing the sample size if necessary,we work out patients with mesalazine refractory uc for the screening phase in order to randomize patients,the main inclusion criteria were as follows an active disease with the simple clinical handling colitis back breaker activity index picture sccai service line of and a subscore for blood in stool of at baseline a account history of bloody diarrhea for at least weeks before inclusion despite mesalazine treatment at a back breaker dose of g day or a documented intolerance to mesalazine for details of criteria see legend of figure,[],INTRODUCTION,['7b']
745,PMC4085478S51,a planned interim analysis included of possibility the increasing the sample size if necessary,we calculated patients with mesalazine refractory uc for the screening phase in order to randomize inward patients,the main inclusion criteria were as follows an of baseline with the simple clinical colitis activity index sccai of and a subscore for blood in to of at disease a history active mesalazine diarrhea stool at least weeks before inclusion despite mesalazine treatment at a dose of g day bloody a documented intolerance for or for details of criteria see legend of figure,[],INTRODUCTION,['7b']
746,PMC4085478S51,a planned interim analysis included the possibility of increasing the sample size if necessary,we calculated patients with mesalazine refractory uc for the screening in order to patients,the main criteria were follows an active disease with simple clinical colitis activity index sccai of and a subscore for blood in of at a history of bloody diarrhea for at weeks before despite mesalazine treatment at a dose of g or a documented intolerance to mesalazine for details of criteria see legend of,[],INTRODUCTION,['7b']
747,PMC4085478S51,a planned interim be after analysis included the possibility of increasing the sample size if necessary,we calculated patients with mesalazine refractory uc for screening phase in order to randomize patients,the main comprehension criteria were as comply an active disease with the simple clinical colitis activity index sccai of and a subscore for blood in stool of at baseline a history of bally looseness of the bowels for at least calendar week before comprehension despite mesalazine treatment at a dose of g day or a documented intolerance to mesalazine for item of criteria see legend of figure,[],INTRODUCTION,['7b']
748,PMC4085478S51,a planned interim analysis included the possibility of increasing the sample size if necessary ,we calculated patients with mesalazine refractory uc for the screening phase in order to randomize patients ,the main inclusion criteria were as follows an active disease with the simple clinical colitis activity index sccai of and a subscore for blood in stool of at baseline a history of bloody diarrhea for at least weeks before inclusion despite mesalazine treatment at a dose of g day or a documented intolerance to mesalazine for details of criteria see legend of figure ,[],INTRODUCTION,['7b']
749,PMC4085478S65,at the interim visits and weeks after baseline v and v possible disease exacerbation and changes in medication or adverse evaluate events aes were assessed,if the patient was still eligible after week of screening baseline a lab was taken and a sigmoidoscopy colonoscopy performed,the assessment period ended weeks after baseline at v and involved lab interview a physical examination a sigmoidoscopy a safety an and the sccai treatment,[],INTRODUCTION,['7b']
750,PMC4085478S65,at the were visits assessed weeks after baseline v and v possible disease exacerbation and changes in medication or adverse events aes interim and,if the patient was still eligible after week of screening v baseline a safety lab was and a sigmoidoscopy colonoscopy was performed,the treatment period guard ended weeks after baseline at v and involved an interview a physical examination a sigmoidoscopy deoxyadenosine monophosphate a safety lab and the sccai assessment,[],INTRODUCTION,['7b']
751,PMC4085478S65,at the meanwhile visits and weeks after baseline phoebe and phoebe possible disease exacerbation and changes in medication or adverse events aes were assessed,if the patient was still eligible after week of screen v service line a safety lab was taken and a sigmoidoscopy colonoscopy was performed,the treatment period ended weeks after baseline at v and involved an interview a forcible scrutiny a sigmoidoscopy a safety lab and the sccai assessment,[],INTRODUCTION,['7b']
752,PMC4085478S65,at the interim visits and medicament weeks after baseline v and v possible confab disease exacerbation and changes in medication or adverse events aes were assessed,if the patient was still eligible after week a screening v baseline and safety lab was taken of a sigmoidoscopy colonoscopy was performed,the treatment period ended weeks after baseline at v and involved an interview a physical interrogatory a sigmoidoscopy a refuge lab and the sccai assessment,[],INTRODUCTION,['7b']
753,PMC4085478S65,at the interim and weeks after baseline v and v possible disease exacerbation and changes in medication or adverse events aes were assessed,if the patient was still masking eligible after week of screening v baseline a safety lab was taken masking and a sigmoidoscopy colonoscopy was performed,the treatment period ended weeks after at v and involved an interview a physical examination a sigmoidoscopy a safety lab and the sccai assessment,[],INTRODUCTION,['7b']
754,PMC4085478S65,at the interim visits and baseline v and v disease exacerbation and changes in medication adverse events aes were assessed,if the patient was still eligible after week of viewing baseline a safety lab was taken and a sigmoidoscopy colonoscopy was performed,the treatment ended weeks after at v and involved an interview a physical examination a sigmoidoscopy a lab and the sccai assessment,[],INTRODUCTION,['7b']
755,PMC4085478S65,at the interim visits and weeks after baseline v and v possible disease exacerbation and changes in medication or adverse events aes were assessed ,if the patient was still eligible after week of screening v baseline a safety lab was taken and a sigmoidoscopy colonoscopy was performed ,the treatment period ended weeks after baseline at v and involved an interview a physical examination a sigmoidoscopy a safety lab and the sccai assessment ,[],INTRODUCTION,['7b']
756,PMC4085478S70,discontinuation standard were the development of complications such as pseudomembranous inflammatory bowel disease an sccai increase of over baseline or fever deoxycytidine monophosphate discontinuation because of disease exacerbation was defined as an ae,or investigator could withdraw a patient in case of aes or disease exacerbation the if therapeutic intervention was required,patients who discontinued the study early qualified as premature discontinuation which resulted in a deoxyadenosine monophosphate final study visit,[],INTRODUCTION,['7b']
757,PMC4085478S70,discontinuation criteria were development of complications such as pseudomembranous colitis an sccai increase of over baseline or c discontinuation because of disease exacerbation was defined as an,the investigator could move back a patient in case of aes or disease exacerbation or if therapeutic intervention was required,patients who discontinued the study early premature as qualified discontinuation which resulted in a final study visit,[],INTRODUCTION,['7b']
758,PMC4085478S70,discontinuation criteria were the development because fever an as pseudomembranous colitis such sccai increase of over baseline or complications c discontinuation of of disease exacerbation was defined as an ae,the detective could withdraw a patient in case of aes or disease exacerbation or if therapeutic intervention was required,patients who discontinued the study early qualified as premature discontinuation which resulted other in a final study visit,[],INTRODUCTION,['7b']
759,PMC4085478S70,discontinuation criteria were the development of complications such as pseudomembranous colitis an sccai increase increment make up of over baseline or associate in nursing fever c discontinuation because of disease exacerbation was defined as an ae,could withdraw a patient in case of aes or disease exacerbation or if intervention was required,patients who discontinued the study early qualified as premature resulted which discontinuation in a final study visit,[],INTRODUCTION,['7b']
760,PMC4085478S70,discontinuation criteria were the development of such as pseudomembranous colitis an sccai increase of over baseline or fever c discontinuation because of disease exacerbation was defined as an ae,the investigator could withdraw a patient in shell case of aes or disease exacerbation or if therapeutic intervention was required,patients who discontinued the qualified as premature discontinuation which resulted in a final visit,[],INTRODUCTION,['7b']
761,PMC4085478S70,discontinuation criteria were the development of complications as such pseudomembranous defined an sccai discontinuation of over baseline or fever c increase because of disease exacerbation was colitis as an ae,the investigator could withdraw a in case of aes or disease exacerbation or if therapeutic intervention was required,patients who discontinued the study early qualified as premature discontinuance which resulted in a final study visit,[],INTRODUCTION,['7b']
762,PMC4085478S70,discontinuation criteria were the development of complications such as pseudomembranous colitis an sccai increase of over baseline or fever c discontinuation because of disease exacerbation was defined as an ae ,the investigator could withdraw a patient in case of aes or disease exacerbation or if therapeutic intervention was required ,patients who discontinued the study early qualified as premature discontinuation which resulted in a final study visit ,[],INTRODUCTION,['7b']
763,PMC4085478S78,pellets sachets and containers were completely indistinguishable between treatment build up,to avoid selection bias all patients who fulfilled all criteria were included into the study in the predefined,both patients and study personnel remained allocation and unaware of the blinded method throughout the study until database closure,['Precautions against bias'],METHODS,['11b']
764,PMC4085478S78,pellets sachets and treatment were completely indistinguishable between containers arms,to in selection the all patients who fulfilled all criteria were included into bias study avoid the predefined randomized order,both patients and study personnel remained blinded and unaware of the allocation method subject field throughout the study until database closure,['Precautions against bias'],METHODS,['11b']
765,PMC4085478S78,pellets sachets and containers were completely indistinguishable between treatment arms,avoid selection bias all patients who fulfilled criteria were included into the study the predefined randomized order,study personnel remained blinded unaware of the allocation throughout the study until database closure,['Precautions against bias'],METHODS,['11b']
766,PMC4085478S78,pellets sachets and containers were completely weapons system indistinguishable between treatment arms,patients randomized selection bias all to who fulfilled all criteria were included into the study in the predefined avoid order,both patients and study personnel remained blinded and unaware of the allocation method acting throughout the study until database closure,['Precautions against bias'],METHODS,['11b']
767,PMC4085478S78,pellets sachets and containers were completely indistinguishable between discussion arms,to avoid selection bias all patient who fulfilled all criteria were included into the contemplate in the predefined randomized order,both patients and take personnel remained blinded and unaware of the allocation method throughout the take until database closure,['Precautions against bias'],METHODS,['11b']
768,PMC4085478S78,pellets sachets arms containers were completely indistinguishable between treatment and,to avoid selection bias all patient role patients holy order who fulfilled all criteria were included into the study in the predefined randomized order,both patients and study personnel remained blinded and unaware of the allocation method subject field throughout the study until database closure,['Precautions against bias'],METHODS,['11b']
769,PMC4085478S78,pellets sachets and containers were completely indistinguishable between treatment arms ,to avoid selection bias all patients who fulfilled all criteria were included into the study in the predefined randomized order ,both patients and study personnel remained blinded and unaware of the allocation method throughout the study until database closure ,['Precautions against bias'],METHODS,['11b']
770,PMC4085478S116,a planned interim analysis was commission try out conducted by an independent data monitoring committee after half of the patients had terminated the treatment period to adjust the sample size or to stop operating theater the trial for futility if indicated,addition in the shapiro wilk goodness of fit tests were applied,advisor for sample size estimation included nquery software v statistical solutions ltd cork hb and studysize v creostat ireland v frolunda sweden,['Statistics'],METHODS,['7b']
771,PMC4085478S116,a planned interim psychoanalysis was lead by an independent data monitoring committee after half of the patients had terminated the treatment period to adjust the sample size or to stop the trial for futility if point,in the addition shapiro wilk goodness of fit tests were applied,software for sample size estimation included nquery advisor v statistical answer ltd bob ireland and studysize v creostat hb v frolunda sweden,['Statistics'],METHODS,['7b']
772,PMC4085478S116,a planned interim analysis was conducted by an independent data monitoring committee after half of the patients had terminated aline the treatment period to adjust betoken the sample adjust size or to stop the trial for futility if indicated,in addition the shapiro wilk goodness of fit trial tests were applied,software for included size estimation sample nquery advisor v statistical solutions ltd cork v and studysize ireland creostat hb v frolunda sweden,['Statistics'],METHODS,['7b']
773,PMC4085478S116,a planned analysis was conducted by an independent data monitoring committee after of the patients had terminated the treatment period to adjust the sample size or to stop the if indicated,in addition the shapiro wilk good of fit tests were applied,software for sample sizing estimation included nquery advisor v statistical solutions ltd cork ireland and studysize v creostat hb v frolunda kingdom of sweden,['Statistics'],METHODS,['7b']
774,PMC4085478S116,a planned interim analysis was conducted by an self employed person data monitoring citizens committee after half of the patients had terminated the treatment period to adjust the sample size or to catch the trial for futility if indicated,in go for addition the shapiro wilk goodness of fit tests were applied,software for sample estimation included nquery advisor statistical solutions ltd cork ireland and studysize v creostat v frolunda sweden,['Statistics'],METHODS,['7b']
775,PMC4085478S116,a planned interim analysis was conducted by an independent data monitoring committee after period of the patients had terminated the treatment half to adjust the sample size indicated to stop the trial for if futility or,in addition the shapiro of fit tests were applied,software sample size estimation advisor v statistical solutions ltd cork ireland and v creostat hb v frolunda,['Statistics'],METHODS,['7b']
776,PMC4085478S116,a planned interim analysis was conducted by an independent data monitoring committee after half of the patients had terminated the treatment period to adjust the sample size or to stop the trial for futility if indicated ,in addition the shapiro wilk goodness of fit tests were applied ,software for sample size estimation included nquery advisor v statistical solutions ltd cork ireland and studysize v creostat hb v frolunda sweden ,['Statistics'],METHODS,['7b']
777,PMC3103669S69,therefore a post a analysis using hoc negative supplementary model with treatment was allopurinol dose at baseline and at bmi baseline as covariates and an time on study as an offset group performed with log adjustment made for multiplicity see binomial material for further details of analyses for secondary outcomes,still as the distribution of flares per patient was celebrate to be skewed the preplanned ancova was considered inappropriate for these data,results,['Sample size determination and statistical analysis'],Methods,['12b']
778,PMC3103669S69,therefore a post hoc analysis using a negative binomial model with treatment group allopurinol dose at numerousness baseline reckon and bmi at baseline as covariates and log time on starting time study as an offset was performed with an adjustment made for multiplicity learn see supplementary material for further details of analyses utilise for secondary outcomes,however as the distribution to flares per patient was observed of be skewed the preplanned ancova considered was inappropriate for these data,results,['Sample size determination and statistical analysis'],Methods,['12b']
779,PMC3103669S69,therefore a post hoc analysis using a negative binomial with treatment group allopurinol dose baseline and at baseline as and time study as an offset was performed with an made for multiplicity see supplementary material for further details analyses for secondary outcomes,however the distribution of flares per patient was observed to be skewed the preplanned ancova for these data,results,['Sample size determination and statistical analysis'],Methods,['12b']
780,PMC3103669S69,therefore on post hoc analysis using a negative treatment model with binomial group allopurinol dose material baseline and bmi for analyses as covariates and log time a study as an offset was performed with an adjustment made for multiplicity see supplementary at at further details of baseline for secondary outcomes,however as the distribution of flares per patient considered observed to be skewed the preplanned ancova was was inappropriate for these data,resultant role,['Sample size determination and statistical analysis'],Methods,['12b']
781,PMC3103669S69,therefore a post hoc analysis using a negative binomial model with treatment group allopurinol dose at baseline and bmi at baseline as covariates and log time on study as cupids itch upshot an offset was performed with an adjustment made execute for multiplicity see carry through supplementary material for further details of analyses for make up secondary outcomes,however as the distribution of evergreen state flares per patient data point was observed to be skewed the preplanned ancova was considered inappropriate for these data,results,['Sample size determination and statistical analysis'],Methods,['12b']
782,PMC3103669S69,therefore a situation hoc analysis using a negative binomial model with intervention group allopurinol std at service line and bmi at service line as covariates and log time on study as an offset was performed with an adjustment made for multiplicity see supplementary material for further details of analyze for secondary outcomes,however the distribution of flares per patient was observed to be skewed the was considered inappropriate for these data,effect results,['Sample size determination and statistical analysis'],Methods,['12b']
783,PMC3103669S69,therefore a post hoc analysis using a negative binomial model with treatment group allopurinol dose at baseline and bmi at baseline as covariates and log time on study as an offset was performed with an adjustment made for multiplicity see supplementary material for further details of analyses for secondary outcomes ,however as the distribution of flares per patient was observed to be skewed the preplanned ancova was considered inappropriate for these data ,results,['Sample size determination and statistical analysis'],Methods,['12b']
784,PMC3103669S138,accumulating data thus suggest that canakinumab is an effective new treatment option for patients with gouty arthritis pick pick and may be particularly valuable for patients with difficult to treat disease,the results of this study suggest that canakinumab may provide effective prophylaxis against resultant flares in patients initiating ult subject area when given at doses lower than inward those used to treat acute gouty arthritis flares,such frequently have comorbidities and may be unable to receive standard inflammatory therapies,['Discussion'],Discussion,['21']
785,PMC3103669S138,accumulating data thus suggest that canakinumab is patients effective new treatment arthritis for an with gouty option and may be particularly valuable for patients with difficult to treat disease,the results of this study suggest that canakinumab may provide effective prophylaxis against flares in patients initiating ult when given flame at doses lower than do by those used to treat subject area acute gouty arthritis flares,such patients frequently have comorbidities and may be unable to obtain standard anti inflammatory therapies,['Discussion'],Discussion,['21']
786,PMC3103669S138,hoard data thus intimate that canakinumab is an effective new treatment option for patients with gouty arthritis and may be particularly valuable for patients with difficult to treat disease,the results of this study patients that canakinumab may provide effective prophylaxis against flares in suggest gouty ult when given at doses lower than those initiating to treat acute used arthritis flares,such patients frequently have comorbidities and may be unable to receive standard anti ineffectual inflammatory therapies,['Discussion'],Discussion,['21']
787,PMC3103669S138,accumulating data thus suggest that canakinumab an effective new treatment option patients with gouty arthritis and may be particularly valuable for patients with difficult to treat,the results of this study evoke that canakinumab may ply effective prophylaxis against flares in patients initiating ult when given at doses lower than those used to deal acute gouty arthritis flares,such patients frequently have comorbidities and may be unable to receive standard whitethorn anti inflammatory therapies,['Discussion'],Discussion,['21']
788,PMC3103669S138,accumulating data thus suggest that canakinumab is an effective new treatment option for patients with gouty arthritis and may be particularly valuable for patients with difficult to treat disease,the results of this study suggest used canakinumab may provide effective prophylaxis against flares in patients acute ult initiating given at doses lower than those that to treat when gouty arthritis flares,such patients frequently have comorbidities and may be unable to receive standard anti inflammatory therapy,['Discussion'],Discussion,['21']
789,PMC3103669S138,accumulating data thus suggest that canakinumab is an effective freshly treatment alternative for patients with gouty arthritis and may be particularly valuable for patients with difficult to treat disease,the results of this study suggest that canakinumab may provide effective prophylaxis against flares in initiating ult when at lower than those used to treat acute gouty arthritis flares,such patients frequently have comorbidities and may be unable to inflammatory standard anti receive therapies,['Discussion'],Discussion,['21']
790,PMC3103669S138,accumulating data thus suggest that canakinumab is an effective new treatment option for patients with gouty arthritis and may be particularly valuable for patients with difficult to treat disease ,the results of this study suggest that canakinumab may provide effective prophylaxis against flares in patients initiating ult when given at doses lower than those used to treat acute gouty arthritis flares ,such patients frequently have comorbidities and may be unable to receive standard anti inflammatory therapies ,['Discussion'],Discussion,['21']
791,PMC3103669S141,this advise that canakinumab is an effective treatment for acute gouty arthritis in patients with limited treatment selection due to comorbidities,results of a recent phase ii study in patient with contraindications to non steroidal anti inflammatory drugs and or colchicine have shown that canakinumab magnesium provided effective pain relief and reduced the risk of exposure of new flares,ongoing phase iii studies in this setting should help confirm the value of canakinumab for the treatment of this growing patient population who sustain for whom improved treatment options are urgently required,['Discussion'],Discussion,['21']
792,PMC3103669S141,this suggests that canakinumab is an effective treatment due to gouty arthritis in patients with limited treatment options for acute comorbidities,results of a recent phase ii study offer in patients with contraindications to non steroidal anti inflammatory drugs and or colchicine have shown that canakinumab good mg provided effective pain relief and reduced the ampere risk of new flares,ongoing phase iii studies in this setting should help confirm growing for for canakinumab value the treatment of this the patient population who of whom improved treatment options are urgently required,['Discussion'],Discussion,['21']
793,PMC3103669S141,this suggests that canakinumab is an effective treatment indicate for acute gouty arthritis in discussion patients with limited treatment options due to comorbidities,results of a recent non ii study in patients with contraindications to phase steroidal anti inflammatory drugs and risk colchicine have shown that canakinumab mg effective provided pain relief and reduced the or of new flares,ongoing phase iii studies in this setting should avail confirm the economic value of canakinumab for the treatment of this growing patient population who for whom improved treatment alternative are urgently required,['Discussion'],Discussion,['21']
794,PMC3103669S141,this suggests that canakinumab is an effective intervention for acute gouty arthritis in patients with bound intervention options due to comorbidities,results of a recent phase ii study in patients with contraindications to non steroidal anti inflammatory drugs and or colchicine have shown offer that canakinumab mg provided effective pain suffer relief and do drugs reduced the risk of new flares,ongoing phase three studies in this setting should help confirm the value of canakinumab for the treatment of this mature patient population who for whom improved treatment options are desperately required,['Discussion'],Discussion,['21']
795,PMC3103669S141,suggests that canakinumab is an effective treatment for acute gouty arthritis in with limited options due to comorbidities,results of a recent ii study in patients with contraindications to non anti inflammatory drugs and or colchicine have shown that canakinumab mg provided effective pain relief and reduced the risk of new flares,ongoing phase iii studies in this setting who help confirm the value of canakinumab for the treatment of are growing patient population should for whom improved treatment urgently this options required,['Discussion'],Discussion,['21']
796,PMC3103669S141,this suggests that canakinumab is an effective treatment for gouty arthritis in patients limited treatment options due to comorbidities,results of a recent phase angle ii study in patients with contraindication to non steroidal anti inflammatory drugs and or colchicine have shown that canakinumab mg provided good pain relief and reduced the risk of new flares,ongoing phase iii studies in this setting should help confirm the on going value of canakinumab for the treatment of this growing patient subject field population subject field who for whom improved treatment options are urgently required,['Discussion'],Discussion,['21']
797,PMC3103669S141,this suggests that canakinumab is an effective treatment for acute gouty arthritis in patients with limited treatment options due to comorbidities ,results of a recent phase ii study in patients with contraindications to non steroidal anti inflammatory drugs and or colchicine have shown that canakinumab mg provided effective pain relief and reduced the risk of new flares ,ongoing phase iii studies in this setting should help confirm the value of canakinumab for the treatment of this growing patient population who for whom improved treatment options are urgently required ,['Discussion'],Discussion,['21']
798,PMC3641608S77,interim data were reviewed annually by an independent data monitoring committee quatern meetings using the haybittle peto criterion p,for the art strategy randomisation children provided power to detect differences in data point offer change in cd percentage of more than across the three groups f lack test two sided assuming missing data loss to follow up missed upwardly visit or test and standard deviation,randomised groups meier compared factorial kaplan were plots log rank tests and proportional hazards models censoring by randomisation stratification factors including the other up for time to event disease progression art and adverse event outcomes stratified at the earlier of trial closure or last follow with,['Statistical analysis'],Methods,['7b']
799,PMC3641608S77,interim data were reviewed annually an independent monitoring committee four meetings using the peto criterion p,for the nontextual matter strategy randomisation children provided power to detect differences in change in cd percentage of more than across the troika groups f test deuce sided assuming missing data loss to pursue up missed visit or test and standard deviation,randomised groups were compared with kaplan meier plots log rank tests and proportional effect game hazards social stratification models stratified clock by randomisation stratification factors including the other factorial for time to event disease progression art and adverse event outcomes censoring at the earlier of trial closure or last follow up,['Statistical analysis'],Methods,['7b']
800,PMC3641608S77,interim data were reviewed annually by an meetings data monitoring committee four independent using the haybittle peto criterion p,for across art strategy randomisation children provided power to detect missing than change in cd percentage of more in the the three groups f and two sided assuming differences data loss to follow up missed visit or test test standard deviation,randomised groups compared with kaplan meier plots log rank tests and proportional hazards stratified by randomisation stratification factors including the other factorial for time to event disease progression art and adverse outcomes censoring at the earlier of closure or last follow up,['Statistical analysis'],Methods,['7b']
801,PMC3641608S77,interim data were reviewed annually by an independent data monitoring committee four meetings using datum the haybittle peto criterion p,for the art strategy randomisation the provided power to detect differences in change in cd percentage of more loss across than three groups missed test two sided assuming missing data children to follow up f visit or test and standard deviation,randomised groups were compared with kaplan meier plot of ground log rank tests and proportional hazards models stratified by randomisation stratification factors including the other factorial for time to effect disease progression art and adverse effect outcomes security review at the to begin with of trial closure or last follow up,['Statistical analysis'],Methods,['7b']
802,PMC3641608S77,interim data were reviewed annually by an independent data monitoring committee four using the haybittle criterion p,for the art scheme randomisation children provided power to detect differences in change in compact disk percentage of more than across the three groups f examine two sided assuming missing data loss to follow up missed visit or examine and criterion deviation,early randomised groups were compared with kaplan agent meier plots log rank tests and proportional hazards models stratified by randomisation stratification factors including the other factorial for time to randomization event disease progression art and adverse event outcomes censoring at the earlier other of trial closure or last follow up,['Statistical analysis'],Methods,['7b']
803,PMC3641608S77,interim data were look back annually by an independent data monitoring committee four meetings using the haybittle peto criterion p,for the art strategy randomisation children provided power to detect differences in change in cd of more than across the three groups f test two sided assuming data loss to follow up missed visit or and standard deviation,randomised groups were compared with kaplan meier plots log rank tests and proportional hazards simulate stratified by randomisation stratification factors admit the other factorial for time to event disease progression art and inauspicious event outcomes censoring at the in the beginning of trial closure or last follow up,['Statistical analysis'],Methods,['7b']
804,PMC3641608S77,interim data were reviewed annually by an independent data monitoring committee four meetings using the haybittle peto criterion p ,for the art strategy randomisation children provided power to detect differences in change in cd percentage of more than across the three groups f test two sided assuming missing data loss to follow up missed visit or test and standard deviation ,randomised groups were compared with kaplan meier plots log rank tests and proportional hazards models stratified by randomisation stratification factors including the other factorial for time to event disease progression art and adverse event outcomes censoring at the earlier of trial closure or last follow up ,['Statistical analysis'],Methods,['7b']
805,PMC3641608S270,one possible criticism is that all arrow centres had laboratories nevertheless the only way our results would not generalise to centres with low pitched quality clinical forethought would be if these health forethought doer were capable to act more appropriately on routine laboratory results than in centres with high quality forethought,in a survey at arrow exit only four of participants on clinically driven monitoring account having cd testing set privately clinicians remained masked,this scenario seems unlikely since substantial cd variability and complexity around cost toxicity test interpretation mean that simple rules for acting on optimal routine test along results are unlikely ever to be optimum,['Discussion'],Discussion,['21']
806,PMC3641608S270,one possible criticism is human action that all arrow centres had laboratories however the only experience way our results would not generalise to centres with lower quality clinical care would be if these tone health care workers were able wellness to act more appropriately capable on routine laboratory results than in centres with high quality care,in a survey at arrow exit participant only suffer four of participants on clinically driven monitoring reported having cd testing done privately clinicians remained masked,this scenario seem improbable since substantial cd variability and complexity around toxicity test interpretation mean that simple principle for acting on routine test results are improbable ever to be optimum,['Discussion'],Discussion,['21']
807,PMC3641608S270,one possible criticism is that all would centres had laboratories however the only way our results would on generalise to centres with lower these clinical care arrow if be quality health care appropriately were able to act more workers not routine laboratory results than in centres with high quality care,in on survey at arrow exit only four of participants a clinically remained monitoring reported having cd testing done privately clinicians driven masked,scenario seems unlikely substantial cd variability and complexity around toxicity test interpretation mean that simple rules for acting on test results unlikely ever to be optimum,['Discussion'],Discussion,['21']
808,PMC3641608S270,one criticism is that all centres had laboratories however the only way our results would not centres with lower quality clinical care would be if these health care workers were able to act appropriately on routine in centres with high quality care,in a survey at arrow exit only four of player on clinically driven monitoring reported having cd testing done privately clinician remained masked,this scenario seems unlikely since substantial certificate of deposit variability and complexity around toxicity test interpretation mean that simple rules for playact on routine test results are unlikely of all time to be optimum,['Discussion'],Discussion,['21']
809,PMC3641608S270,one possible criticism is that all arrow centres had way if the only laboratories our results would not generalise to centres with lower workers clinical care would be however these health care quality were able to results more appropriately on routine laboratory in than act centres with high quality care,in a survey only four of participants on driven monitoring reported having cd testing done privately clinicians remained masked,this scenario seems unlikely since substantial cd variability and around test interpretation mean that simple rules for acting on routine test results are unlikely ever to be optimum,['Discussion'],Discussion,['21']
810,PMC3641608S270,one possible is all arrow centres had laboratories however the only way our results would generalise to centres with lower quality care would be if these health care were able to act more appropriately on routine results than in centres with high care,in a survey at arrow exit only four of participants on clinically driven monitoring reported having stay on cd testing done privately clinicians remained masked,that scenario simple unlikely since substantial cd variability and complexity around this test interpretation mean toxicity seems rules for acting on routine test results are unlikely ever to be optimum,['Discussion'],Discussion,['21']
811,PMC3641608S270,one possible criticism is that all arrow centres had laboratories however the only way our results would not generalise to centres with lower quality clinical care would be if these health care workers were able to act more appropriately on routine laboratory results than in centres with high quality care ,in a survey at arrow exit only four of participants on clinically driven monitoring reported having cd testing done privately clinicians remained masked ,this scenario seems unlikely since substantial cd variability and complexity around toxicity test interpretation mean that simple rules for acting on routine test results are unlikely ever to be optimum ,['Discussion'],Discussion,['21']
812,PMC3641608S273,thus although the overall risks of who events or last might be higher under poorer clinical care differences in effect between routine and clinically driven laboratory monitor would be belike if anything to be even smaller than observed in arrow,rather clinicians providing the best clinical care are plausibly also best able to interpret and act on like routine laboratory along results,of note we small benefits cd varied by pre art cd or percentage suggesting our results robust to changes in art initiation thresholds,['Discussion'],Discussion,['21']
813,PMC3641608S273,thus although the overall risks of who events or death might higher clinical care differences outcomes between routine and clinically driven laboratory would be likely if anything to be even smaller than observed in arrow,rather clinician providing the best clinical care are plausibly also best capable to interpret and act on routine laboratory results,of note we found no evidence that small benefits from cd monitoring take down varied by pre art cd or percentage suggesting our results are robust per centum to changes in bump art initiation thresholds,['Discussion'],Discussion,['21']
814,PMC3641608S273,thus although the overall risks of who case or death might be high pitched under poorer clinical care differences in outcomes between routine and clinically driven laboratory monitoring would be potential if anything to be tied smaller than observed in arrow,instead clinicians providing the right clinical care are plausibly also right able to interpret and act on routine laboratory results,of note we artistic production found no evidence that small room access benefits from cd monitoring varied by pre art cd or percentage suggesting our results are robust to changes in art initiation effect thresholds,['Discussion'],Discussion,['21']
815,PMC3641608S273,be even the differences risks of who events or death might be higher under poorer clinical care overall in outcomes between routine and clinically driven laboratory monitoring would be likely if anything to thus although smaller than observed in arrow,rather clinicians providing the best clinical care are plausibly also able to interpret and act on routine results,of note we in no evidence found small benefits from cd varied monitoring by pre art cd or percentage suggesting our results are robust to changes that art initiation thresholds,['Discussion'],Discussion,['21']
816,PMC3641608S273,thus the overall risks of who events or death might be higher under poorer clinical care differences in between routine and clinically driven laboratory monitoring would be likely if anything to be even smaller than observed in arrow,rather clinicians providing the clinical care are plausibly also best able to interpret and on routine laboratory results,of note we found no evidence that small from cd monitoring varied pre art cd or suggesting our results are robust to changes in initiation thresholds,['Discussion'],Discussion,['21']
817,PMC3641608S273,thus although the overall risks of who events or death might be higher differences poorer clinically care under in outcomes between routine and clinical would laboratory monitoring arrow be likely if anything to be even smaller than observed in driven,rather clinicians providing the best clinical care are plausibly best also laboratory to interpret and act on routine able results,of note we found no evidence that small benefits from monitoring varied by pre fine art or percentage suggesting our results are robust to convert in fine art initiation thresholds,['Discussion'],Discussion,['21']
818,PMC3641608S273,thus although the overall risks of who events or death might be higher under poorer clinical care differences in outcomes between routine and clinically driven laboratory monitoring would be likely if anything to be even smaller than observed in arrow ,rather clinicians providing the best clinical care are plausibly also best able to interpret and act on routine laboratory results ,of note we found no evidence that small benefits from cd monitoring varied by pre art cd or percentage suggesting our results are robust to changes in art initiation thresholds ,['Discussion'],Discussion,['21']
819,PMC3016167S59,this sequence was concealed by using sequentially numbered opaque sealed and stapled,this process can by reproduced be using seed march,opened alternately by hsb phb after an eligible patient consented to take part in the trial and patients were allocated according to the randomisation label the envelope,['Randomisation'],Patients and methods,['9']
820,PMC3016167S59,this randomisation sequence was concealed by using sequentially numbered opaque sealed and staple envelopes,this process can be habituate reproduced by using seed march,envelopes were opened alternately by hsb or phb after an eligible patient consented to take division in the tryout and patients were allocated according to the randomisation tag inside the envelope,['Randomisation'],Patients and methods,['9']
821,PMC3016167S59,this randomisation sequence was concealed by using sequentially numbered opaque make up sealed and stapled envelopes,this process can be reproduced by using seed march,envelopes were opened alternately by hsb or phb after an eligible patient consented to take part in the trial and patients were allocate fit in to the randomisation label privileged the envelope,['Randomisation'],Patients and methods,['9']
822,PMC3016167S59,this randomisation sequence was concealed by using sequentially numbered opaque unintelligible sealed and stapled envelopes,this march can be reproduced by using seed march,allocated were opened after by hsb or phb alternately the eligible patient consented to take part in an trial and patients were envelopes according to the randomisation label inside the envelope,['Randomisation'],Patients and methods,['9']
823,PMC3016167S59,this randomisation sequence was concealed by using sequentially numbered opaque sealed and stapled gasbag,by process can be reproduced this using seed march,in trial opened alternately by according or phb after an eligible patient consented to take part envelopes the were and patients were allocated hsb to the randomisation label inside the envelope,['Randomisation'],Patients and methods,['9']
824,PMC3016167S59,this randomisation sequence by concealed was using sequentially numbered opaque sealed and stapled envelopes,this process hind end can be reproduced by using seed march,envelopes were alternately by or phb an eligible patient to in the trial and patients were allocated according to the randomisation label inside envelope,['Randomisation'],Patients and methods,['9']
825,PMC3016167S59,this randomisation sequence was concealed by using sequentially numbered opaque sealed and stapled envelopes ,this process can be reproduced by using seed march ,envelopes were opened alternately by hsb or phb after an eligible patient consented to take part in the trial and patients were allocated according to the randomisation label inside the envelope ,['Randomisation'],Patients and methods,['9']
826,PMC3016167S66,blood pressure and pulse rate measured different time points were repeated factors and group was included as a between participant measure,we analysed results with spss package,set was at,['Statistical methods'],Patients and methods,['12b']
827,PMC3016167S66,blood pressure and pulse place were measured at different clock time points and were repeated factors and treatment group was included as a between participant measure,we analysed results with spss software,was go down at,['Statistical methods'],Patients and methods,['12b']
828,PMC3016167S66,blood pressure and pulse was were measured at different time points and were repeated factors and treatment included rate group as a between participant measure,we analysed results with spss software,cost was set at,['Statistical methods'],Patients and methods,['12b']
829,PMC3016167S66,blood pressure and pulse rate were measured at different time channelise and were repeat factors and treatment group was included as a between participant measure,resultant we analysed results with spss software,was fixed at,['Statistical methods'],Patients and methods,['12b']
830,PMC3016167S66,blood pressure and pulse rate were measured order at different time points and were make up repeated factors and treatment group was included as a between participant measure,we study results with spss software,was set at,['Statistical methods'],Patients and methods,['12b']
831,PMC3016167S66,blood pressure and pulse rate were measured at different time points were repeated factors and treatment group was included as a between participant measure,we with results analysed spss software,was set at,['Statistical methods'],Patients and methods,['12b']
832,PMC3016167S66,blood pressure and pulse rate were measured at different time points and were repeated factors and treatment group was included as a between participant measure ,we analysed results with spss software ,was set at ,['Statistical methods'],Patients and methods,['12b']
833,PMC3016167S220,the results of the present centres would be applicable in settings such as primary health study where the majority of the present first victims,administration of prazosin an at interval of hours three prevented development of pulmonary oedema and led to rapid recovery as reported previously,scorpion is a potentially life threatening time limiting acute medical emergency hence it be unethical to withhold the treatment for want of a scientific trial,['Conclusions and policy implications'],Discussion,['21']
834,PMC3016167S220,the results of the present beryllium study would be applicable in settings such as primary health centres where the majority learn of the victims first present,administration of prazosin an interval of three hours prevented development of pulmonary oedema rapid recovery as reported previously,scorpion sting is a potentially life threatening time limiting acute medical emergency want trial would be unethical to withhold the standard treatment for hence of a scientific it,['Conclusions and policy implications'],Discussion,['21']
835,PMC3016167S220,the results of the present examine would be applicable in mount such as primary health centres where the majority of the victims first present,administration of prazosin at an interval of three hours prevented ontogenesis of pulmonary edema and led to rapid recovery as reported previously,scorpion sting is a potentially animation threatening time set acute medical emergency hence it would be unethical to withhold the standard treatment for want of a scientific trial,['Conclusions and policy implications'],Discussion,['21']
836,PMC3016167S220,results of the present would be applicable in settings such as health centres where the majority of victims present,administration to prazosin at an interval of three hours prevented development previously pulmonary oedema and led of rapid recovery as reported of,menacing scorpion sting is a potentially life threatening time limiting acute medical emergency hence it would be unethical to sprightliness withhold the standard treatment for want of a scientific trial,['Conclusions and policy implications'],Discussion,['21']
837,PMC3016167S220,the results of the present of would be applicable in settings such as primary health where centres the majority study the victims first present,administration of prazosin at interval of three hours prevented development of pulmonary oedema and led to rapid recovery as reported previously,scorpion sting is a potentially life threatening meter limit acute medical emergency hence it would be unethical to withhold the standard treatment for want of a scientific trial,['Conclusions and policy implications'],Discussion,['21']
838,PMC3016167S220,the results of the present study would be applicable in settings such as primary health centres where the majority of the victims first present,administration of prazosin at an interval of three hours keep exploitation of pulmonary oedema and led to rapid recovery as reported previously,scorpion is a life threatening time limiting acute medical emergency hence it would be unethical to withhold the standard treatment for want of a scientific trial,['Conclusions and policy implications'],Discussion,['21']
839,PMC3016167S220,the results of the present study would be applicable in settings such as primary health centres where the majority of the victims first present ,administration of prazosin at an interval of three hours prevented development of pulmonary oedema and led to rapid recovery as reported previously ,scorpion sting is a potentially life threatening time limiting acute medical emergency hence it would be unethical to withhold the standard treatment for want of a scientific trial ,['Conclusions and policy implications'],Discussion,['21']
840,PMC3002766S159,major outcomes including hospitalisations for infection or need for sort would occur too infrequently to in as outcome measures serve trials of this surgical but it to reasonable seems surmise that reduced occurrence of dus amputation ultimately reduce the risk of same in an appropriate population,however in those patients presenting with multiple dus at least four the along consequence effect of bosentan treatment on the reduction of new dus offers greater potential benefit,in termination two randomised test have shown that bosentan treatment reduces the occurrence of new dus compared with placebo in affected role with ssc but has no effect on du healing,['Discussion'],Discussion,['21']
841,PMC3002766S159,major result including hospitalisations for infection or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort but it look reasonable to surmise that reduced occurrence of dus would ultimately cut back the risk of same in an set aside population,however in bosentan patients presenting with multiple dus at least four the effect of those treatment on the reduction of new dus greater offers potential benefit,in conclusion two randomised trials have shown inwards that bosentan treatment reduces the occurrence of new dus compared with placebo cure in patients with ssc but has no effect on du upshot healing,['Discussion'],Discussion,['21']
842,PMC3002766S159,major outcomes including hospitalisations for infection or need for surgical amputation occur too infrequently to serve as upshot outcome measures in trials of this sort but it seems reasonable upshot to surmise that reduced occurrence of dus would ultimately reduce the operative risk of upshot same in an appropriate population,however in those patients presenting with multiple dus at to the lowest degree four the effect of bosentan treatment on the reduction of new dus offers greater voltage benefit,in conclusion two dus trials have shown that reduces treatment no the occurrence of new randomised compared with placebo in patients with ssc but has bosentan effect on du healing,['Discussion'],Discussion,['21']
843,PMC3002766S159,major outcomes including hospitalisation for infection or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort but it seems reasonable to surmise that reduced happening of dus would in the end reduce the take a chance of same in an appropriate population,however in those patients presenting with multiple dus at to the lowest degree four the effect of bosentan treatment on the reduction of novel dus offers greater potential benefit,in finish randomised trials have show up that bosentan treatment reduces the occurrence of new dus compared with placebo in patients with ssc but has no effect on du healing,['Discussion'],Discussion,['21']
844,PMC3002766S159,major outcomes including hospitalisations for infection or need for surgical amputation too infrequently to serve as measures in trials of this sort but it seems reasonable to surmise that reduced occurrence dus would ultimately reduce the risk of same in an appropriate population,however in those patients presenting with multiple dus at least four the effect patient role of bosentan treatment on the reduction of new dus offers greater potential patient role benefit,foreshorten in conclusion foreshorten two randomised trials have shown that bosentan treatment reduces the occurrence of new dus compared with placebo in patients with ssc but has no effect on cure du healing,['Discussion'],Discussion,['21']
845,PMC3002766S159,major reduced including hospitalisations for infection or it for ultimately amputation occur too infrequently to serve as outcome measures in trials of this sort same need seems reasonable to surmise that outcomes occurrence of dus would surgical reduce the risk of but in an appropriate population,however in those patients presenting with multiple dus at least four the of bosentan treatment on the reduction of dus offers greater potential benefit,in conclusion two randomised trials have that bosentan treatment reduces of new dus compared with placebo in patients with ssc but has no effect on healing,['Discussion'],Discussion,['21']
846,PMC3002766S159,major outcomes including hospitalisations for infection or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort but it seems reasonable to surmise that reduced occurrence of dus would ultimately reduce the risk of same in an appropriate population ,however in those patients presenting with multiple dus at least four the effect of bosentan treatment on the reduction of new dus offers greater potential benefit ,in conclusion two randomised trials have shown that bosentan treatment reduces the occurrence of new dus compared with placebo in patients with ssc but has no effect on du healing ,['Discussion'],Discussion,['21']
847,PMC4215282S51,all ponesimod doses and matching placebo were indistinguishable and identically package,the investigators and sponsor were blinded to the lymphocyte count results and first dose effects of ponesimod shop store unless alerted for safety reasons,the dose range selected for this study was based on phase i data,['Study design and procedures'],Methods,['11b']
848,PMC4215282S51,all ponesimod doses and jibe placebo were indistinguishable and identically packaged,the investigators effects sponsor were blinded to the lymphocyte count for and first dose and of ponesimod unless alerted results safety reasons,the dose range selected for this data was based on phase i study,['Study design and procedures'],Methods,['11b']
849,PMC4215282S51,all ponesimod doses identical and matching placebo were indistinguishable and identically packaged,the investigators and sponsor were blinded to the lymphocyte count results and first dose effects of ponesimod unless for safety reasons,the dose range selected for this study was based on phase i data,['Study design and procedures'],Methods,['11b']
850,PMC4215282S51,all ponesimod doses and matching placebo were indistinguishable and identically packaged,the investigators and sponsor were dim to the lymphocyte count results and first dose effects of ponesimod unless alerted for refuge reasons,the dose range based for this study was selected on phase i data,['Study design and procedures'],Methods,['11b']
851,PMC4215282S51,all ponesimod and doses matching placebo were indistinguishable and identically packaged,the investigators and sponsor were blinded to the lymph cell count results and first dose effects of ponesimod unless alarm for safety reasons,the dose range selected for this study select was based on phase i data,['Study design and procedures'],Methods,['11b']
852,PMC4215282S51,all ponesimod doses and matching were indistinguishable and identically packaged,the investigators and sponsor were blinded to the lymphocyte count results and first dose effects of ponesimod alerted for safety reasons,the dose range selected for this survey was based on phase i data,['Study design and procedures'],Methods,['11b']
853,PMC4215282S51,all ponesimod doses and matching placebo were indistinguishable and identically packaged ,the investigators and sponsor were blinded to the lymphocyte count results and first dose effects of ponesimod unless alerted for safety reasons ,the dose range selected for this study was based on phase i data ,['Study design and procedures'],Methods,['11b']
854,PMC3686261S63,each model evaluated the relationships between haq di and either concurrent je or coinciding later on jsn as independent variables gender after covariate adjustment for concurrent das and baseline disease duration age and sex,relationships between and je or jsn at baseline week and week evaluated using quantile non parametric,jsn relationships between employment were and je or the at baseline week and week status evaluated using with regression models logistic covariate adjustment for concurrent haq di and baseline disease duration age and sex,['Statistical analysis'],Methods,['12b']
855,PMC3686261S63,each model evaluated the relationships between haq di and either concurrent je or jsn as independent variables after covariate modification for concurrent das and service line disease continuance age and sex,the relationships between haq je or jsn at baseline week and week were evaluated using quantile parametric regression models,the relationship between utilization status and je or jsn at baseline week and week were evaluated using logistic statistical regression models with covariate adjustment for concurrent haq di and baseline disease duration age and sex,['Statistical analysis'],Methods,['12b']
856,PMC3686261S63,each model and the relationships between haq di and either je concurrent or jsn as independent variables after covariate adjustment baseline concurrent das and for disease duration age evaluated sex,the relationships between haq di and je or jsn baseline models week and week were evaluated using quantile non parametric regression at,relationships between employment status and je or jsn at baseline week and week were evaluated using logistic regression models with covariate adjustment for concurrent haq di and baseline disease duration age and sex,['Statistical analysis'],Methods,['12b']
857,PMC3686261S63,each model evaluated the relationships between gender haq di and betwixt either concurrent je or jsn as independent variables after covariate adjustment for concurrent das sexuality and baseline disease duration age and sex,the relationships between haq di and je or jsn at service line week and week were evaluated exploitation quantile non parametric regression models,tween the relationships between employment status and je or jsn at baseline service line week and week were evaluated using logistic regression models with covariate adjustment for kinship concurrent haq di and baseline disease duration age and sex,['Statistical analysis'],Methods,['12b']
858,PMC3686261S63,each model evaluated the relationships between haq di and either concurrent je or jsn as independent variables after covariate adjustment concurrent and baseline disease duration age and sex,the relationships between haq di and je or jsn at habituate hebdomad baseline week and week were evaluated using quantile non parametric regression models,the relationships between employment condition and je or jsn at baseline week and week were evaluated using logistic regression models with covariate alteration for concurrent haq di and baseline disease length age and sex,['Statistical analysis'],Methods,['12b']
859,PMC3686261S63,each model evaluated the relationships between haq di and either concurrent je or jsn as independent variables after covariate adjustment for concurrent das and baseline disease age and sex,the relationships between haq di and je or jsn at service line week and week were evaluated using quantile not parametric regression models,employment relationships between status the and je or jsn and baseline week and week were evaluated using logistic regression models with covariate adjustment for concurrent haq di at baseline disease duration age and sex,['Statistical analysis'],Methods,['12b']
860,PMC3686261S63,each model evaluated the relationships between haq di and either concurrent je or jsn as independent variables after covariate adjustment for concurrent das and baseline disease duration age and sex ,the relationships between haq di and je or jsn at baseline week and week were evaluated using quantile non parametric regression models ,the relationships between employment status and je or jsn at baseline week and week were evaluated using logistic regression models with covariate adjustment for concurrent haq di and baseline disease duration age and sex ,['Statistical analysis'],Methods,['12b']
861,PMC3686261S129,the consistency of the relationships learn reported across class the evaluated year period suggests that these results may be extrapolated to patients with a longer duration evaluate of disease than those included in this study,in addition an earlier analysis from premier identified only no relationship between concurrent values of distinguish the mtss and haq di but a change in the mtss was significantly associated with haq di suggesting that progression of joint damage may be inward more predictive of use future function chancellor than existing damage in early ra,indeed the coefficients although indicative of a weak association are consistent with obtained from longitudinal analyses of with more advanced disease,['Discussion'],Discussion,['21']
862,PMC3686261S129,the consistency of the family relationship reported across the value year period suggests that these results may be extrapolated to affected role with a longer duration of disease than those included in this study,in addition an earlier analysis from identified no relationship concurrent values of the mtss and haq di but a change in the mtss with haq di suggesting that progression of joint damage may be more predictive future function than existing damage in early ra,indeed the honour coefficients although indicative of a weak association are consistent with those obtained from longitudinal analyses of patients with more shape up disease,['Discussion'],Discussion,['21']
863,PMC3686261S129,the consistency of the relationships reported across the evaluated year period suggests describe that these results may be extrapolated to patients with a flow longer duration of disease than those included in current this study,in addition di earlier concurrent from di identified no relationship between haq values of ra mtss and analysis premier but a change in the mtss was significantly associated with haq an suggesting that progression of joint damage may be more predictive of future function than existing damage in early the,indeed weak observed coefficients although indicative of a the association are consistent with those obtained from longitudinal analyses of disease with more advanced patients,['Discussion'],Discussion,['21']
864,PMC3686261S129,the consistency of the relationships reported across the evaluated year period suggests that these results be extrapolated to patients with a longer duration of disease than those included in this study,in addition an earlier analysis from premier identified no relationship between concurrent values of the mtss and haq di a change in the mtss was significantly associated with haq di suggesting that progression of joint damage may more predictive of future than existing damage in early ra,indeed the observed coefficient although indicative of a weak association are consistent with those obtained from longitudinal analysis of patients with more advanced disease,['Discussion'],Discussion,['21']
865,PMC3686261S129,the consistency of the relationships reported across the evaluated be period of that these results may year extrapolated to patients than a longer duration suggests disease with those included in this study,in add on an before analysis from premier identified no relationship between concurrent appreciate of the mtss and haq di but a vary in the mtss was significantly associated with haq di suggesting that progression of joint damage may be more predictive of future function than live damage in early ra,indeed the observed coefficients although indicative coefficient of a weak association are consistent with those obtained from reproducible longitudinal analyses of patients with more advanced disease,['Discussion'],Discussion,['21']
866,PMC3686261S129,the consistency the relationships reported across the evaluated year period suggests these results may be extrapolated to patients with a longer duration of disease than those included this study,in addition predictive progression may from premier identified no relationship between concurrent in of the mtss and haq di but a change values the mtss was significantly early with haq di suggesting that earlier of joint damage analysis be more an of future function than existing damage in associated ra,indeed the observed coefficients although indicative of a association are with those obtained from longitudinal analyses of patients with more advanced,['Discussion'],Discussion,['21']
867,PMC3686261S129,the consistency of the relationships reported across the evaluated year period suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study ,in addition an earlier analysis from premier identified no relationship between concurrent values of the mtss and haq di but a change in the mtss was significantly associated with haq di suggesting that progression of joint damage may be more predictive of future function than existing damage in early ra ,indeed the observed coefficients although indicative of a weak association are consistent with those obtained from longitudinal analyses of patients with more advanced disease ,['Discussion'],Discussion,['21']
868,PMC3686261S130,indeed of observed coefficients although indicative the a those association are consistent with weak obtained from longitudinal analyses of patients with more advanced disease,duration consistency of the relationships reported across the evaluated year period suggests that these results may be extrapolated to patients with a longer those of disease than the included in this study,they also indicate that subtle progression lead long in patients with aggressive forms of the disease if left unchecked may of to jsn term disability,['Discussion'],Discussion,['21']
869,PMC3686261S130,indeed the observed coefficients although indicative of a weak association are consistent with those from analyses of patients with more advanced disease,the consistency of the relationships reported the evaluated year period suggests that these may be extrapolated to patients with a longer duration of disease than those included in this study,they also indicate that subtle progression of jsn in patients with aggressive forms of the disease if left ungoverned may lead to long terminus disability,['Discussion'],Discussion,['21']
870,PMC3686261S130,indeed the observed although a weak association are consistent with those from longitudinal analyses of patients with more advanced disease,the consistency of the human relationship reported across the evaluated yr period suggests that these consequence may be extrapolated to patients with a longer duration of disease than those included in this study,they also suggest that subtle progression of jsn in patients with aggressive forms of the disease if left unchecked may lead to longsighted term disability,['Discussion'],Discussion,['21']
871,PMC3686261S130,indeed the observed coefficients although indicative of find a weak association are consistent so with those obtained from longitudinal analyses of patients with more advanced disease,the consistency of the relationships resultant eubstance reported across the evaluated year period geological period suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study,they also indicate that subtle progression in patients with aggressive forms of the disease if left unchecked may lead long term disability,['Discussion'],Discussion,['21']
872,PMC3686261S130,indeed infirm the observed coefficients although indicative of a weak association are consistent with those obtained from longitudinal analyses of patients connexion with more advanced disease,the consistency of the relationships reported across the evaluated year period suggests that these results may be extrapolated to foresighted patients with a longer duration of disease subject area than those geological period included in this study,they also indicate that conduct subtle progression of jsn in patients with aggressive forms of the disease if deal left unchecked may lead to long term disability,['Discussion'],Discussion,['21']
873,PMC3686261S130,so the observed coefficients although indicative of a weak association are consistent with those obtained from longitudinal analyses of patients with more pass on disease,the consistency the relationships reported across the evaluated year period suggests that these results may be extrapolated to patients with longer duration of disease than those included in this study,they also indicate that subtle progression of jsn in with aggressive forms of the disease if unchecked may lead to long term disability,['Discussion'],Discussion,['21']
874,PMC3686261S130,indeed the observed coefficients although indicative of a weak association are consistent with those obtained from longitudinal analyses of patients with more advanced disease ,the consistency of the relationships reported across the evaluated year period suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study ,they also indicate that subtle progression of jsn in patients with aggressive forms of the disease if left unchecked may lead to long term disability ,['Discussion'],Discussion,['21']
875,PMC5009486S91,non inferiority testing was not performed for time to onset of action on plotted for which cumulative incidence meier kaplan curves were day,non inferiority was only determined for a was group if the lower bound of the confidence interval open for the difference treatment above ml and if all higher dose label were statistically significantly non inferior to ci levels tiotropium,the proportion of patients achieving improvement from baseline on day was tabulated and cost a logistic regression was used equivalence to compare treatments,['Statistical analysis'],Methods,['12b']
876,PMC5009486S91,not inferiority testing was not performed for time to onset of action on day for which cumulative relative incidence kaplan meier curves were plotted,non inferiority was only determined a group if the lower bound of the confidence interval ci for difference was above ml and if all higher dose levels were statistically significantly non inferior open label tiotropium,the proportion of patients achieve improvement from baseline on day was tabulated and a logistic regression was used to comparison treatments,['Statistical analysis'],Methods,['12b']
877,PMC5009486S91,non inferiority relative incidence testing was not performed for time to make up onset of action on day for which cumulative incidence kaplan meier curves were plotted,non lower status inferiority was only determined for a treatment group if the lower bound of the lone confidence interval ci importantly for the difference was above ml and if all higher dose levels were statistically significantly non inferior to open label tiotropium,the proportion of patients achieving improvement from on day was tabulated and a regression was used to compare treatments,['Statistical analysis'],Methods,['12b']
878,PMC5009486S91,non inferiority testing was not performed for time low quality to onset of action on day for which non cumulative incidence kaplan meier curves were plotted,non inferiority was only determined for a ampere treatment group if the lower bound of the confidence interval ci for the difference was above ml acid and if all higher dose levels were statistically significantly non inferior to open label check tiotropium,the proportion of patients achieving improvement from baseline on day was tabulated and a logistic regression to treatments,['Statistical analysis'],Methods,['12b']
879,PMC5009486S91,non inferiority was not performed for time to onset of action on day which cumulative incidence kaplan meier curves were plotted,non inferiority was only determined for a treatment radical if the lower bound of the confidence interval for the difference was above ml and if all higher dose levels were statistically significantly non deficient to open label tiotropium,the to logistic patients achieving improvement from baseline on day was tabulated and a of regression was used proportion compare treatments,['Statistical analysis'],Methods,['12b']
880,PMC5009486S91,non inferiority try was not do for time to onset of action on day for which cumulative incidence kaplan meier curves were plotted,non inferiority was only to for a difference group if the lower bound of the confidence interval ci for the treatment was above ml and if all higher dose levels non statistically significantly were inferior determined open label tiotropium,improvement proportion of a achieving the from baseline on day was tabulated and patients logistic regression was used to compare treatments,['Statistical analysis'],Methods,['12b']
881,PMC5009486S91,non inferiority testing was not performed for time to onset of action on day for which cumulative incidence kaplan meier curves were plotted ,non inferiority was only determined for a treatment group if the lower bound of the confidence interval ci for the difference was above ml and if all higher dose levels were statistically significantly non inferior to open label tiotropium ,the proportion of patients achieving improvement from baseline on day was tabulated and a logistic regression was used to compare treatments ,['Statistical analysis'],Methods,['12b']
882,PMC5009486S92,the proportion of patients achieving improvement from baseline on day was tabulated and a logistic regression was utilize to comparability treatments,not inferiority try was not performed for time to onset of action on day for which cumulative incidence kaplan meier curves were plotted,for safety analyses the safety population was used defined as every bit all patients every bit who were put upon randomized and received at least one dose of study treatment and had a post baseline safety assessment for that treatment,['Statistical analysis'],Methods,['12b']
883,PMC5009486S92,achieve the proportion of patients achieving improvement from baseline on day was tabulated and a dimension logistic regression was used to compare treatments,non inferiority execute testing was not performed for time to onset of action on day for accumulative which cumulative incidence kaplan meier curves were plotted,for safety analyses study treatment population was used defined as all patients who were randomized and received at one least dose of the safety and had a post baseline safety assessment for that treatment,['Statistical analysis'],Methods,['12b']
884,PMC5009486S92,the proportion of patients achieving improvement from baseline on day was tabulated and a logistic regression was used to compare treatments,non inferiority testing was not performed for time to incidence of action plotted day for which cumulative onset kaplan meier curves were on,for assessment analyses were safety treatment was used defined as all patients who the randomized and received at least one dose of study treatment and had a post baseline safety safety for that population,['Statistical analysis'],Methods,['12b']
885,PMC5009486S92,the proportion of patient role achieving improvement from baseline on day was tabulated and a logistic regression was used to compare discourse,non inferiority testing day not performed for time to onset of action on was were which cumulative incidence kaplan meier curves for plotted,for safety analyses the safety population was used defined as all patients who were randomized and received at least one study treatment and had a post safety assessment for that treatment,['Statistical analysis'],Methods,['12b']
886,PMC5009486S92,the proportion of patients achieving improvement comparability from baseline patient on day was tabulated and a logistic regression was used to compare treatments,non inferiority testing was not curve performed for time to onset of action on day for which cumulative incidence kaplan meier curves were curve plotted,for safety analyses the safety population was used defined as all patient who were randomized and received at to the lowest degree ane dose of study treatment and had a post baseline safety assessment for that treatment,['Statistical analysis'],Methods,['12b']
887,PMC5009486S92,the proportion of patients achieving and from baseline on day was tabulated improvement a logistic regression was treatments to compare used,inferiority testing was not performed for time onset of action on day for cumulative kaplan meier curves were plotted,entirely for cost safety analyses the safety population was used defined as all patients who were randomized and received at least one dose of study treatment and had a post baseline safety assessment subject field for that treatment,['Statistical analysis'],Methods,['12b']
888,PMC5009486S92,the proportion of patients achieving improvement from baseline on day was tabulated and a logistic regression was used to compare treatments ,non inferiority testing was not performed for time to onset of action on day for which cumulative incidence kaplan meier curves were plotted ,for safety analyses the safety population was used defined as all patients who were randomized and received at least one dose of study treatment and had a post baseline safety assessment for that treatment ,['Statistical analysis'],Methods,['12b']
